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ABSTRACT OF THESIS
Understanding the pathways by which endogenous cell death occurs in tumours may be of
considerable value when identifying potential therapies. In glioblastoma, two main types of
cell death are observed, apoptosis and necrosis. Although the regulatory mechanisms leading
to necrotic and apoptotic morphologies are thought to vary widely, their close association in
glioblastoma suggests they may share some regulatory function. High levels of Fas (APO-1),
HIF-la and PARP found within perinecrotic tissue in vivo suggests regulatory factors do
exist. The presence of these regulatory factors, sub-lethal stress and a high apoptotic index
suggests the p53 pathway may be involved in the cell death response around these areas. In
order to investigate cell death regulatory factors in vitro, particularly those relating to the p53
pathway, the glioma spheroid system was utilised. Glioma spheroids are known reproduce
some of the regional heterogeneity found in vivo and they form areas of necrosis as the
spheroids become larger and the central core of cells becomes metabolically compromised.
Using spheroids derived from four glioma cell lines, the aims of this project were (i) to fully
characterise the glioma spheroid system for the four glioma cell lines, U87, U373, MOG-G-
CCM and A172 and to establish that the system adequately reflects many of the features
found in glioblastoma cell populations in vivo\ (ii) to define the exact time point in spheroid
growth when central cell death occurs and to identify the modes of cell death present (iii) to
establish which p53-related proteins are associated with areas of cell death within stressed
glioblastoma cell populations and to determine any correlations between this distribution and
the genetic status of the cell lines; and finally, (iv) to ascertain whether modulation of the
P53 status of the cells has an effect on the development of cell death and the expression of
p53-related proteins within glioma spheroid cultures.
Regions of proliferation, death and differentiation were first assessed using a variety of
immunohistochemical and microscopical techniques. Spheroid growth and apoptotic index
were also quantitatively recorded. Onset of central cell death was seen to occur over week 3
and these spheroids were examined using electron microscopy to establish the primary mode
of cell death (apoptosis or necrosis). HIF-la expression was used as a marker to determine
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the metabolic status of spheroid central regions at this time point. The P53 genotype of the
cell lines was then determined and the reactivity of p53, Bax, p21 and MDM2 in monolayer
cultures of the 4 lines was assessed following exposure to hypoxia and free radical stress.
Perinecrotic expression of p53, Bax, p21 and MDM2 was recorded in both week 3 spheroid
cultures and in glioblastoma biopsy material. The cell lines were transfected with wild-type
and dominant negative P53 transcripts to investigate the effect of increasing and decreasing
levels of endogenous p53 on cell death susceptibility within 3-dimensional spheroid cultures.
Cross-sections of large glioma spheroids appeared highly representative of GBM tissue,
modeling the span from blood vessels to nutritionally compromised, necrotic tissue distinct
from the vasculature. The primary cell death morphology observed was necrosis, followed by
increases in perinecrotic apoptotic index. Increases in HIF-la expression coincided with the
onset of necrosis. HIF-la, p53 and p21 accumulation were associated with U87 and A172
monolayer cultures (p53 wild-type), but not U373 and MOG-G-CCM monolayer cultures
(.P53 mutant), following exposure to oxidative stress. No increases in p53, Bax and p21
expression were found within perinecrotic tissue in spheroid cultures derived from any of the
cell lines. A 60kDa MDM2 isoform was found to be upregulated within perinecrotic tissue in
both spheroids and in 80% of biopsy cases irrespective of P53 status. The addition of a wild-
type P53 transcript to U87 cells did not effect cell death susceptibility within U87 spheroids.
U373 cells transfected with wild-type P53 died 3 days post transfection. Cell death
susceptibility was not altered in either U87 and U373 spheroids following transfection with
dominant negative P53.
In conclusion, in large 3-dimensional glioma spheroid cultures, necrosis is the primary cell
death event, followed by increases in perinecrotic apoptotic index. Although increases in
p53-related expression are observed in P53 wild-type lines in response to oxidative stresses,
p53, Bax and p21 accumulation do not appear to be important for the regulation of cell death
in spheroid cultures, irrespective of the P53 status of the cell lines. Although the TGdgene
appears to be essentially redundant within perinecrotic tissue, high levels of 60kDa MDM2
may associate with other cell death regulatory factors thus significantly influencing cell death
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The prognosis for patients suffering from highly malignant brain tumours such as
glioblastoma multiforme (termed GBM, WHO grade IV) is uniformly fatal with a mean
survival time for patients with GBM of 8 months (Whittle, 1996). Because the search for
an effective therapy remains elusive, understanding the molecular basis of gliomas, to
identify novel therapeutic strategies has become of utmost importance. Because large
increases in tumour volume and subsequent death of eloquent brain tissue occur in such a
short period of time, many novel strategies are being designed around increasing levels of
cell loss within tumour cell populations.
Cell loss in tumours may occur due to apoptosis or necrosis (Steel, 1977). Apoptosis is a
process that often requires new gene transcription and the triggering of complex
regulatory pathways (Wyllie, 1995). As a result, these pathways have begun to be
thoroughly researched in recent years as potential therapeutic targets. In contrast, necrosis
is sudden and accidental cell death brought on by a large stimulus sufficient to kill the cell
and generate an inflammatory response (Trump et al., 1997). Necrosis is generally
regarded as an unregulated process, which, in contrast to apoptosis, is not under genetic
control. However, necrosis is a poorly understood process and it is possible that there are
regulatory mechanisms involved, perhaps separate from those involved in apoptosis
(Clarke, 1998).
In the diffuse astrocytoma group of tumours, apoptotic index increases with tumour grade,
thus glioblastomas have the highest apoptotic index. Necrosis is only associated with high
grade tumours and is a diagnostic feature to allow the categorisation of an astrocytoma as
glioblastoma multiforme (Alvord, 1992; Kleihues et al., 1993). It has been suggested that
there are two types of necrosis, ischaemic necrosis with an infarct-like pattern and smaller
areas of necrosis surrounded by pseudopallisading layers of tumour cells (Kleihues et al.,
2000). It is unclear whether these two types of necrosis are linked or whether they arise
independently as a result of different pro-death signals. Understanding endogenous cell
death in glioblastoma is important as it could elucidate specific pathways and target
molecules that are switched on when a tumour cell is stressed.
Susceptibility to cell death within normal and tumour cell populations is often decided by
a complex series of pathways central to which lies the p53 protein (Vogelstein et al.,
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2000). p53 up-regulates the expression of proteins such as p21, which induces cell cycle
arrest, and pro-apoptotic members of the Bel family such as Bax (Wylie, 1995). P53
mutations are prevalent in secondary glioblastomas i.e. those arising from a lower grade
glioma (Nagane et al., 1997). Another protein called MDM2 binds to and inactivates the
p53 protein. Upregulation of this protein can result in abrogation of p53-mediated cell
death. Abnormal MDM2 over-expression is common in primary tumours (Yu et al., 2000;
He et al., 1994). The constant acquisition of mutations picked up throughout the life span
of each individual tumour (Rasheed et al., 1999; Collins et al., 1999), suggests that cell
death associated with areas of necrosis in GBM most likely occurs via assorted pathways
that have retained some residual function. In many cell types, p53 has been implicated in
stress-induced cell death involving various mediators such as the activation of
intracellular reactive oxygen species, Fas (CD95) and HIF-la (Chandel et al., 2000;
Edwards et al., 2000; Vogt et al., 1998; An et al., 1998). Fas and HIF-la have been found
to be increased within perinecrotic tissue in GBM (Tachibana et al., 1996; Zagzag et al.,
2000). Although this is the case, it remains unclear as to whether areas of cell death,
which are pathologically similar in most glioblastomas regardless of progression, occur as
a result of a p53 related mechanism or whether other pathways are involved.
A number of in vitro and in vivo models have been developed to study the characteristics
of glial tumour cell growth (Bernstein et al., 1987; Geise et al., 1995; Schor et al., 1982;
Bjerkvig et al., 1986). Monolayer and cell suspension systems are of great value when
assessing detailed cell function and to study the regulation of apoptosis, but they do not
reconstruct the cellular microenvironments present within a tumour cell mass and there
are no simulated nutrient gradients. In addition, many in vitro models are limited in the
study of cell death in that they do not model necrosis. The spheroid system for cell culture
is a three-dimensional model which creates areas of proliferation, differentiation and cell
death within a tumour cell mass (Kunz-Schughart et al., 1998; Tamaki et al., 1997;
Sutherland et al., 1988). These areas can be studied individually when the spheroid
becomes larger and a nutrient gradient forms across the radius of the spheroid. It is the
intention to utilise this system to investigate the pathogenesis and regulation of cell death
within hypoxic and nutritionally-deprived tumour cell populations.
Four factors have to be taken into consideration when identifying potential candidates in
the search for target genes and pathways activated around areas of endogenous cell death
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in glioblastoma. Firstly, the typical characteristics of the diffuse astrocytoma group of
tumours should be fully understood. These include general patterns of growth, death,
differentiation, invasion and progression. Secondly, the morphology of the cells
associated with regions of cell death need to be taken into consideration. The existence of
apoptotic morphologies suggests that regulatory molecules are involved. In contrast, the
presence of necrosis implies that fewer regulatory mechanisms are involved. Thirdly, the
type and intensity of insult applied to the tissue can result in different cell death pathways
being activated. A broad knowledge of the molecules and pathways associated with
necrotic and apoptotic cell death, in response to a wide variety of cell stresses, such as
hypoxia and nutrient deprivation, is therefore vital. And lastly, the genetic background of
the tumour has to be established. Mutations occurring in specific cell death pathways may
alter the expression of certain proteins around and within areas of cell stress. The
following four sections of this project are therefore dedicated to these issues (1.2-1.5),
followed by a review of the literature on 3-dimentional culture systems (1.6), by which the
evolution of areas of cell death in glioblastoma will be studied.
4
1.2. The diffuse astrocytomas
1.2.1. Introduction to the diffuse astrocytoma group
This study focuses mainly on the most malignant of the diffuse astrocytoma group,
glioblastoma multiforme. However, it is important to fully understand the diffuse
astrocytoma group as a whole because these tumours are related not only in terms of their
glial status, but also by their genetic progression and overall biological behaviour. Diffuse
astrocytic tumours share the following characteristics: (i) they may arise at any site in the
central nervous sytem (CNS), preferentially in the cerebral hemispheres; (ii) they usually
manifest clinically in adults; (iii) they possess a wide range of histopathological features;
(iv) they show diffuse infiltration of adjacent and distant brain structures; (v) they have a
tendency to progress to a more malignant phenotype.
1.2.2. Incidence
Diffusely infiltrating astrocytomas are the most frequent intracranial neoplasms and
account for more than 60% of all primary brain tumours. Approximately 6 new cases per
100,000 are diagnosed each year. Glioblastoma multiforme is the most common tumour
type within the diffuse astrocytoma group and accounts for approximately 12-15% of all
intracranial neoplasms and 50-60% of all astrocytic tumours. In most developed countries
2-3 new cases per 100,000 population are diagnosed each year (Kleihues, 2000).
1.2.3. Localization of diffuse astrocytomas
Diffuse astrocytomas most commonly occur in the cerebral hemispheres, in particular in
the fronto temporal and parietal regions. Infiltrative spread is a common feature of all
diffuse astrocytic tumours (Burger et al., 1988). However, it is glioblastomas, the most
malignant of the diffuse astrocytoma group, that are renown for their rapid invasion into
neighbouring brain structures. Tumour infiltration occurs most often in the cerebral
hemispheres and tumour infiltration often extends into the contralateral hemisphere
creating the image of a bilateral symmetrical lesion ('butterfly glioma'). Similarly, rapid
spread is observed in the internal capsule, fornix, anterior commisure and optic radiation.
Increased intracranial pressure resulting from the fast growth of these tumours is the
greatest threat to survival resulting in the sudden onset of symptoms such as headache and
personality changes. Although diffuse astrocytomas are highly invasive they tend not to
metastasise and do not invade the subarachnoid space, cerebrospinal fluid or vessel lumen
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(Giordana et al., 1995). In addition, haematogenous spread to extraneural tissue is very
rare in patients that have not received neurosurgical intervention (Hoffman et al., 1985).
1.2.4. Histological grading of diffuse astrocytomas
The length of the patients history and chance of a long, recurrence-free survival are
closely associated with the intrinsic biology of the neoplasm. Significant indicators of
anaplasia in gliomas include nuclear atypia (coarse nuclear chromatin, nuclear
pleomorphism, multinucleation and pseudoinclusions), mitotic activity, cellularity,
vascular proliferation and necrosis. These histological characteristics have been used by
the World Health Organisation (WHO) to produce a grading scheme for the diffuse
astrocytoma group. As a general rule, grading is based on areas showing the highest
degree of anaplasia, on the assumption that this tumour cell population eventually
determines the course of the disease. WHO grade I astrocytomas (eg pilocytic
astrocytomas) are the least malignant of the astrocytoma group. These tumours rarely
possess any of the above described histological criteria and are biologically distinct
clinicopathological entities. WHO grade II astrocytomas consist of astrocytomas which
have no histological criteria, and low-grade diffuse astrocytomas which exhibit nuclear
atypia. WHO grade III astrocytomas are designated anaplastic astrocytomas and these
tumours possess 2 histological criteria, nuclear atypia and mitotic activity. WHO grade VI
astrocytic tumours are designated glioblastoma multiforme and are identified by the
presence of three out of four histological criteria. These include the presence of; (I)
nuclear atypia (II) microvascular proliferation, (III) high mitotic activity and/or (IV) the
presence of necrosis (Daumas-Duport et al., 1988).
1.2.5. Histological evaluation of glioblastoma multiforme
The level of intra- and inter-tumoural heterogeneity is almost endless in glioblastoma.
However, some tissue patterns are more commonly observed than others. Poorly
differentiated, round, fusiform and pleomorphic cells are very common in GBM, although
more differentiated neoplastic cells, such as gemistocytes and fibrillary astrocytes, are
also often observed (Burger, 1989). Areas containing recognisable astrocyte
differentiation and highly anaplastic cells are often observed side by side within the same
tumour. Although fibrillary and poorly differentiated morphologies are most prevalent,
other tissue patterns such as the presence of giant, sarcoma-like and epithelial-like cancer
cells are also common.
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Although glioblastomas are derived from glial tissue, GFAP (glial fibrillary acid protein)
expression is very variable between tumours. Well differentiated, astrocyte-like cells are
generally positive for GFAP and small undifferentiated cells tend to be negative or stain
weakly. Although large portions of a GBM may lack GFAP expression, usually
occasional cells are found to be positive after extensive examination.
In addition to the presence of highly anaplastic cells, the presence of microvascular
proliferations are typical of GBMs. These are mitotically active endothelial cells recruited
by the glioma cells to encourage vascularization of poorly oxygenated areas of the
tumour (Nagashima et al., 1987). VEGF (vascular endothelial growth factor) is the most
important regulator of vascular functions in glioma-induced angiogenesis and acts
specifically on endothelial cells and vascular permeability in vivo (Cheng et al., 1996).
VEGF is hypoxia-inducible and is often found within areas of perinecrotic tumour cells
(Plate et al., 1992).
A high proliferative index is also a feature of GBM. The Ki67 index (labels cells in Gl, S,
G2 and M phase) shows great regional variation and average values are around the 15-
20% mark (Gerdes et al., 1983; Deckert et al., 1989). Small undifferentiated cells
generally show high higher proliferative indices than better differentiated neoplastic
astrocytes and gemistocytes (Watanabe K., 1997).
It has been suggested that two major types of necrosis can be distinguished in GBM. The
first type consists of huge areas of destroyed tumour tissue, which may comprise more
than 80% of the total tumour mass. These appear as yellowy -white coaggulated masses
that often contain some remnants of the vasculature (Burger et al., 1983). The second type
of necrosis observed is that of small necrotic foci surrounded by layers of
pseudopallisading small, fusiform glioma cells (Lantos et al., 1996). Necrosis in GBM
will be discussed at length in section 1.4.2.
1.2.6. Primary and secondary glioblastoma
Glioblastomas can be split into two categories by their clinical duration (Scherer, 1940).
Secondary glioblastomas can arise from a low grade diffuse or anaplastic astrocytoma and
can develop over months or years. Low-grade diffuse astrocytomas frequently develop
recurrent lesions with the second biopsy often showing histopathological evidence of
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increased nuclear atypia, hyperchromasia, mitotic activity and in some cases vascular
proliferation and /or necrosis, i.e. features of the glioblastoma. The acquisition of these
anaplastic features, though an inherent property of diffuse astrocytomas, is largely
unpredictable in terms of both clinical and histological outcomes. While some
astrocytomas show no change in histological grade over more than 10 years following the
first resection, others show a rapid transition to malignancy within 1-2 years. This type of
tumour usually effects younger adults (aged 30-45 years). Primary GBMs have a short
clinical history (usually of less than six months) and do not have any clinical or
histopathological evidence of a precursor lesion. They normally occur in older adults
(around 55 years).
Histologically the two tumour types are very similar with respect to the highly
heterogeneous nature of the tissue. However, secondary GBMs are generally found to
have a greater number of the better differentiated fibrillary morphologies and primary
GBMs show a prevalence of the more monotonous, small, largely GFAP negative cells
that congregate at high density.
1.2.7. Genetic progression of the diffuse astrocytomas
Extensive studies examining the molecular genetics of the diffuse astrocytoma group have
revealed the presence of huge numbers of genetic abnormalities. Loss or mutation of the
P53 gene has been detected in many types of glioma and represents an early genetic event
in a subset of astrocytomas. P53 is a tumour suppressor gene which, in normal cells,
activates either cell cycle arrest or apoptosis (programmed cell death) in response to stress
(Watanabe et al., 1996) (see section 1.4 for review). Allelic loss of chromosome 17p and
P53 mutations are observed in approximately one-third of all three grades of adult
astrocytomas, suggesting that inactivation of P53 is important in the formation of grade II
tumours. In addition, high-grade astrocytomas with homogenous P53 mutations can
evolve clonally from subpopulations of similarly mutated cells present in tumours that are
initially low grade. An important consequence of the loss of wild-type P53 activity is
increased genomic instability, which appears to accelerate neoplastic progression. Thus,
P53 appears to play a role in both the formation of low grade disease and in the
progression towards secondary glioblastoma. P53 mutations occur in approximately 60-
70% of secondary tumours. In contrast, P53 mutations are rare (approximately 10%) in
primary glioblastomas. This theory is supported by the observation that younger
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astrocytoma patients not only had higher incidences of P53 mutations but also survived
longer than those without mutations. Therefore, glioblastomas evolve by one of at least
two distinct pathways: one that requires P53 inactivation and one that does not. The P53
pathway and glioblastoma will be discussed in detail later in the project (1.5.). Other
combinations of mutagenic events commonly occur during astrocytoma progression such
as RB (retinoblastoma protein) alterations (-25%), PDGFR (platlet derived growth factor)
amplification (-10%) and the loss of expression of DCC (deleted in colorectal cancer
gene, -50%) (Kleihues et al., 2000; Collins, 1999).
Primary GBMs most commonly fall into the group of glioblastomas that do not require
P53 mutations to evolve. One of the most common genetic abnormalities is the
overexpression and/or mutation of the epidermal growth factor receptor gene (EGFR).
EGFR is a transmembrane receptor responsible for sensing extrecellular ligands, EGFR
and transforming growth factor beta (TGF-P). EGFR mitogenisis appears to encompass
many pro-proliferative systems including ligand-driven dimerization of receptor
monomers and tyrosine kinase activation. Overexpression of the EGFR gene in cancerous
cells results in abnormally high numbers of the EGFR receptors being expressed on the
cell surface. This can often occur in conjuction with the generation of an abnormal
receptor resulting in a mutant transcript that is constitutively activated (Nishikawa et al.,
1994). EGFR amplification and/or overexpression occurs in approximately 60% of
primary GBM s and only 5% of secondary tumours (Lang et al., 1994). Another common
finding in primary tumours is the loss of specific alleles known to encode for the tumour
suppressor PTEN (-30%) (Bostrom et al., 1998). PTEN expression inhibits the
proliferation of glioma cells by inducing G1 arrest and elicits astrocytic differentiation.
Inactivation of PTEN therefore plays an important role in the enhancement of unregulated
growth of undifferentiated glioma cells (Adachi et al., 1999). CDKN2A mutations are also
common in primary tumours (Ueki et al., 1996). This locus encodes for pl6 and pl4 ARF
proteins which are important for regulating both cell cycle control and apoptosis
respectively (Stewart et al., 2001). P14ARF helps govern levels of intracellular p53 by
regulating the movement of the MDM2 protein. The implications of the latter will also be
discussed at length later in the project (1.4.7. and 1.5.3.)
It is therefore clear that in glioblastoma, in terms of primary and secondary tumours,
different sets of mutations can result in phenotypically similar endpoints. These
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progressive events can lead to disruption of both proliferative and cell death regulatory
pathways.
1.2.8. Current therapeutic strategies for glioblastoma
Glioblastomas are essentially incurable and current treatments are limited to marginally
increasing quantity and quality of life. The management of glioblastoma is based on a
combination of surgery, radiation therapy and chemotherapy (Prados & Levin, 2000).
Surgery is usually initially performed to debulk the tumour, followed by involved-field
radiation (cumulative dose of up to 60Gy). Unfortunately, due to the diffusely infiltrative
nature of glioblastomas and the intrinsic resistance of many gliomas to irradiation induced
cytotoxicity, the combination of these two treatments usually only adds 2-3 months onto
the overall prognosis. Chemotherapy is generally used selectively on recurrent tumours.
The most commonly used chemotherapy drugs are alkylating agents, particularly
nitrosoureas (Jeremic B et al., 1992; Levin V et al., 1990). These have been commonly
used as single agents or in combination with other drugs such as procarbazine or
etoposide. At present, response rates to chemotherapy are rather limited, with only 20-
30% of tumours responding at all to chemotherapy and even then the prognosis is only
lengthened by 2-3months (Stewart, 1989).
1.2.9. Recent advances in glioblastoma therapy
At a clinical level, improvements in the delivery of the above mentioned
chemotherapeutic drugs combined with different therapeutic schedules (eg chemotherapy
before surgery) are currently being tested and have been shown to improve prognosis in
some patients (Prados & Levin, 2000). In addition, new chemotherapeutic drugs, such as
temozolomide have been shown to be more effective in infiltrating the blood brain barrier
and have shown progression free survival after 6 months (Yung et al., 1998). The
effectiveness of alkylating agents can been further enhanced by the use of O6-
benzylguanine, which inactivates O6 alkylguanine-DNA alkyltranferase (AGT) reducing
tumour cell survival after DNA damage (Wedge et al., 1996). AGT is involved in the
repair of alkylator based DNA crosslinks.
Much recent research has focused on immunotherapeutic strategies for glioma. Antibody-
targeted immunotherapy involves the targeting of tumour cells with antibodies conjugated
to radioisotopes or toxins. However, this relies heavily on the tumours cells expressing the
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same specific markers. Transferin and EGFR receptors are preferentially expressed on
tumour cells and immunotherapies targeting these have been tested on gliomas in nude
mice with very mixed results (Laske D et al., 1994; Wikstrand et al., 1998). Cytokine-
based immunotherapy (eg IL2) and the use of interferons (eg IFN-y) have also showed
promise as prospective therapeutic agents. Although when used on their own there is little
tumour regression, it is thought they may enhance the activity of some other anti-
tumourgenic drugs by stimulating direct immune responses against cancerous cells
(Gansbacher et al., 1990). TNF-a is another prospective therapeutic agent and has been
shown to induce death in some tumour types. It has a range of functions in the immune
system including stimulating T cell growth and enhancing the cytotoxicity of monocytes .
Unfortunately, cultured glioma cells are usually resistant to TNF-a, and clinical trials
studying the therapeutic efficacy of TNF-a have been disappointing (Weller et al., 1994).
As a consequence of the limited success of the above strategies, a considerable amount of
research has focused on combating the resistance of glioma cells to various cytotoxic
agents and to the actions of immune cells. The phenotype of resistance is thought to
depend on the pattern of genes expressed, and most importantly, those responsible for cell
cycle arrest and apoptosis. For this reason, considerable time and effort has been put into
investigating systems regulating cell death that could potentially be employed to
overcome these problems. Currently, great hope is placed on the ability of death ligands
(namely TRAIL and CD95) to induce cell death in tumour cells without damaging healthy
tissue. The mechanisms behind this approach and other experimental treatments aimed at
targeting apoptotic pathways will be discussed later in the project (1.5.5.). However, it is
also possible that by investigating the pathogenesis and regulation of endogenous tumour
cell death, which is particularly abundant in glioblastoma, specific molecules/pathways




1.3. The pathology of cell death in glioblastoma
1.3.1. General introduction to cell death
In the last 30 years, the two fundamentally different forms of cell death, apoptosis and
necrosis, have been defined in terms of their morphology, biochemistry and incidence.
The realisation that one of the two processes, apoptosis, has the theoretical potential to be
influenced to produce a desired outcome in clinical problems such as cancer and
neurodegenerative disease, is of particular interest to scientists and clinicians alike. Most
tumour types exhibit some level of endogenous cell death, whether it be low levels of
apoptosis as observed in astrocytomas or high levels of apoptosis and necrosis seen in the
more malignant glioblastoma group. It is possible that this intrinsic cell death may help
find the key to identifying key regulatory pathways involved in these systems, which
could potentially be targeted therapeutically. Because different modalities of cell death,
such as apoptosis and necrosis, can be activated as a result of different regulatory
mechanisms, understanding the morphology and incidence of specific cell death types is
vital. The following is a summary of the key morphological changes associated with
apoptosis and necrosis and their distribution within glioblastoma tissue.
1.3.2. Pathology of apoptosis and necrosis
Apoptosis was first seen to be discrete from necrotic cell death by an individual series of
morphological changes (Kerr, 1971; Wylie,1981). The living cell begins with segregating
chromatin into condensed masses that cling to the inside of the nuclear envelope. The
nucleus then fragments into several discrete fragments usually bound by a double
membrane. Cytoplasmic changes also occur at this time and cytoskeletal elements, such as
smooth ER, aggregate parallel to the cell surface. Eventually, in cells with abundant
cytoplasm, extensive surface blebs form and these separate out into membrane bound
apoptotic bodies of varying size which are engulfed or phagocytosed by adjacent cells or
macrophages.
Apoptosis occurs in many circumstances, both in normal tissue and in cancer. Because it
does not stimulate an inflammatory response, in normal tissue it is used by organisms to
break down unwanted cells in a slow and controlled manner without causing undue harm
to surrounding tissue (Cummings et al., 1997). In cancer it is thought to be stimulated by
low level stress caused by oxidative stress, nutrient deprivation and growth factor
withdrawal (Bellamy., 1995; Graeber et al., 1996; Shiffer et al., 1995). Because a complex
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series of pathways are involved in regulating apoptosis. If abnormal alterations or
mutations occur in these pathways, the malignant potential of a cell is enhanced because
the ability of the cell to apoptose is reduced (Wyllie, 1997).
Necrosis, in contrast to apoptosis, is thought of as an accidental passive process. This
results in the progressive breakdown of ordered cell structure and function after
irreversible damage caused by a major environmental change such as severe ischemia,
chemical trauma or extremes of temperature. Necrosis has no role in normal tissue
physiology or development but is a common phenomenon when tissue is severely
mechanically damaged, diseased or highly malignant (Trump et al., 1997).
Unlike apoptosis, the necrotic cell is already dead when morphological changes are seen
to occur. These changes begin with the breakdown of cytoplasmic components. Initially,
irregularities form in the cytoskeleton, intramatrical granules are lost from mitochondria,
the plasma membrane begins to bleb and the ER and golgi elements become dilated.
Following this, the cell membrane begins to lose its integrity, the mitochondria become
swollen and the cytoskeleton and ER fragment. The cell membrane then completely
breaks apart, spilling the contents of the cell into the extracellular space. The cell contents,
particularly mitochondrial proteins, can induce an inflammatory reaction. Following this,
the nucleus, which by this stage contains condensed chromatin, breaks down (Trump &
Berezesky, 1998; Phelps et al., 1989). The mechanisms thought to be responsible for this
series of events are not thought to be controlled by a complex series of pathways as with
the apoptotic response. Because the stress is usually so great, membranous/cytoplasmic
changes occur first, preceeding nuclear damage. In apoptosis, changes to the nuclear
morphology are one of the first to occur because the cell has made a 'decision' to
apoptose as a result of a series of extra- or intranuclear molecular signals.
1.3.3. Methods of detecting apoptotic and necrotic cells
Because of the recent interest in apoptosis as a target for anticancer therapies, scientists
have spent considerable time designing ways to detect apoptotic cells. The four most
popular ways of detection are currently electron microscopy, high resolution light
microscopy, the TUNEL assay and Annexin V labelling. High resolution light microscopy
using slides stained with haematoxylin and eosin (H&E) is the simplest way of identifying
and counting apoptotic figures. However, because considerable cell shrinkage occurs in
13
the apoptotic process, apoptotic cells are sometimes difficult to detect compared to other
methods. Electron microscopy (EM) is easily the best way for morphologically identifying
apoptotic figures. However, EM is time consuming, expensive and only relatively small
areas of tissue can be examined. To make the detection process easier, more complex
assays have been designed to label apoptotic cells. One such assay is the TUNEL (TdT-
mediated dUTP-X nick end labelling) labelling system. One of the hallmarks of apoptosis
is DNA degradation. As a result, many nicks (both single and double standed) appear in
the DNA exposing free 3'-OH termini. The TUNEL assay involves using the enzyme
terminal deoynucleotidyl transferase (TdT) to label free 3'-OH termini with modified
nucleotides. These nucleotides are conjugated to biotin or fluorescein as a secondary
detection system. The cells can then be examined using either light/fluorescence
microscopy or flow cytometry. Unfortunately, the TUNEL method has previously been
shown to lack specificity, in that it may label necrotic as well as apoptotic cells (Grasl-
Kraupp et al., 1995). In addition, other studies have shown that it may also label actively
transcribing nuclei (Kockx et al., 2000).
Another trademark of apoptosis, preceding that of DNA degradation, is the translocation
of phosphotidylserine (PS) from the interior side of the plasma membrane to the outer
leaflet. It was discovered that a Ca2+ dependent phospholipid-binding protein, named
Annexin-V, had a high affinity for PS. The Annexin-V protein, which is normally
conjugated to a fluorescent marker, was therefore developed as a marker for apoptotic
cells. Because necrotic cells also expose PS with a loss of membrane integrity, apoptotic
cells are differentiated by the addition of propidium iodide (PI) which is incorporated into
the nucleus of necrotic cells thus distinguishing them from the PI negative, apoptotic cells.
The cells can then be examined using fluorescence microscopy or flow cytometry. There
are two main problems surrounding this method. Firstly, fresh tissue has to be used for the
labelling process. Fixed cells have permeabilized cell membranes and thus allow the
entrance of both Annexin-V and PI into healthy cells. Secondly, a single cell suspension
has to be used. This is particularly awkward when using tissue biopsies or three-
dimentional cell culture systems. Aggressive disaggregation protocols could unwittingly
permeabilize the cell membranes of healthy cell populations. It is therefore clear that a
combination of detection systems has to be used when analysing cells/tissue for apoptotic
indices. In monolayer cultures, a combination of H&E counts and Annexin V flow
cytometry is possibly the best way to measure apoptotic indices, whereas when using
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fixed, paraffin embedded material, a combination of TUNEL labelling and H&E apoptotic
counts may be more appropriate.
The only guaranteed way of identifying individual necrotic cells is by using electron
microscopy. This is because the necrotic process usually encompasses more than one cell
making it difficult to distinguish individual cells from a necrosing cell population. In
addition, necrotic cells often become swollen and burst thus rendering the outline of such
cells difficult to see using conventional light microscopy. The resolution of the electron
microscope is high enough to identify the outlines of such cells. Theoretically Annexin V
labelling is also a possibility for the measurement of necrotic cells. However, necrotic
cells rarely retain an intact morphology for long enough for proper flow cytometric
analysis. Because of these difficulties, necrosis tends to be measured by the area of tissue
lost in tissue biopsies and three-dimentional cultures systems, and by cell viability assays
(such as the MTT assay) in monolayer culture systems.
1.3.4. Distribution of apoptosis and necrosis in the diffuse astrocytoma group
Although high grade diffuse astrocytomas, such as GBMs, are highly heterogeneous
tumours, specific patterns of apoptosis and necrosis, can be distinguished both between
different tumours and within individual tumour cell populations.
Apoptotic indices in astrocytic tumours have been found to increase with increased
anaplasia and is therefore indicative of a poor prognostic outcome. This general pattern of
apoptotic indices in a broad spectrum of different brain tumour types of various grades has
been observed in many previous studies (Tew, 1999; Kordek et al., 1996; Migheli et al.,
1994; Patsouris et al., 1996; Wharton et al., 1998). To quote one example, in a series of
astrocytomas, Ellison et al found that apoptotic indices increased across a spectrum of
astrocytic tumours from grade II to grade IV. In addition, there was a strong correlation
between growth fraction (cells labelled with Ki67 antibody) and apoptotic index (Ellison
et al., 1995). In normal tissues, cell proliferation, which may be sustained by growth
factors, is usually inversely correlated with apoptosis which is the natural response of
some tissues to withdrawal of these factors (Kerr et al., 1994).
The presence of necrosis is a defining feature of a glioblastoma multiforme (Kleihues et
al., 2000). Generally, two distinct types of necrosis are observed in GBM; large ischaemic
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areas of necrosis and smaller foci of necrosis surrounded by pseudopallisading tumour
cells. The large areas of geographic necrosis in GBM are thought to arise due to
insufficient blood supply and as a result have been termed ischemic in type. These are
most common in primary (de novo) tumours (Kleihues et al., 2000). Poorly differentiated,
highly anaplastic cells generally have a high proliferative index resulting in areas of
hypercellularity with high energy requirements. As a consequence, cells distant from the
tumour vasculature are more susceptible to necrosis due to acute hypoxia and nutrient
deprivation. The perinecrotic cells situated at the periphery of this type of necrotic tissue
often exhibit Fas expression (Tachibana et al., 1994). Fas is a member of the cell death
receptor family and is associated with an apoptotic response (Waring & Miillbacher,
1999).
Smaller, irregularly shaped, band like, necrotic foci are common in both primary and
secondary tumours. These are generally surrounded by radially orientated, densely
packed, fusiform tumour cells in a 'pseudopallisading' pattern which often exhibit a high
apoptotic index (Lantos et al., 1996). These regions also often contain regions of high
VEGF expression which is thought to be induced in response to hypoxia (Plate et al.,
1992). Also thought to be induced in response to hypoxia within pseudopallisading cell
populations is the HIF-la protein. In a study by Zagzag et al.(2000), 100% of all GBMs
(n=12) tested exhibited high levels of HIF-la around such areas. The combination of
VEGF expression, HIF-la expression and the appearance of apoptotic figures suggests a
less acute stress than with the ischemic necrosis resulting in the activation of specific
pathways to activate both apoptosis and neovascularisation.
It is unknown whether these two types of necrosis are related. The fact that patterns of
VEGF and Fas expression are usually specific to each of the above types of necrosis,
suggests that this is unlikely. However, the general consensus in the literature is that the
small foci of necrosis eventually become enlarged, forming the huge ischaemic type areas
of necrosis (Lantos et al., 1996; Kleihues et al., 2000). Regardless of the type of necrosis
that eventually evolves, the mode of cell death that occurs first, necrosis or apoptosis,
remains an unanswered question that could have implications in our knowledge of brain
tumour biology. There are two possible theories that can describe the events that occur
preceding the appearance of necrotic tissue. Firstly, small clusters of apoptotic cells may
form first within areas of cell stress. As this stress becomes greater, necrotic cells become
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interspersed within these foci. As these areas expand, pseudopallisading morphologies
arise containing scattered apoptotic figures containing a central core of necrosis. Large
areas of ischaemic necrosis eventually arise when the central necrotic core becomes
extremely large. A second theory is that necrosis is the first event to occur due to the high
energy requirements of the surrounding tissue and the fast growth of the invasive tumour
cell mass into normal brain. Vascular thrombosis may also contribute to a sudden onset of
necrosis without an initial onset of apoptosis. The existence of these small foci of necrosis
may encourage the onset of apoptosis as a secondary response due to sub-lethal levels of
hypoxia or pro-apoptotic signals from the central core of necrotic cells. Again, this may
lead to the eventual creation of large areas of ischaemic tissue. Elucidation of the primary
morphological changes occurring within these areas of cell death is important as it may
implicate specific target molecules activated when glioblastoma tumour cells are under
stress.
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1.4. Regulation of cell death
1.4.1.General introduction to cell death regulation
To identify likely pro-death candidates/pathways that are associated within and around
regions of necrosis in glioblastoma, the complexity of the pathways involved in a normal
cell death response must first be understood. It has generally been assumed that stresses
such as hypoxia and nutrient deprivation activate an unregulated necrotic mode of death
when the stress is too great and too acute to activate the more regulated series of events
that is associated with apoptosis. However, recent evidence suggests that there may be
some overlap between the two processes. This may be of particular relevance to
glioblastoma where necrosis and apoptosis are seen within close proximity to each other.
The following is a review of the key regulatory changes that are associated with both
apoptosis and necrosis in response to cell stress in normal tissue. Also discussed is a
summary of key pathological and regulatory events that indicate these processes may not
be entirely separate cell death entities.
1.4.2. The regulation of apoptosis
From a developmental perspective, apoptosis is a common occurrence programmed into
the genetic make-up of an organism to remove excess cells from in organs, vessels and
epithelia as they grow and differentiate (Meier et al., 2000). In certain pathological states,
apoptosis can also remove damaged tissue in order to reduce inflammation, infection and
abnormal cellular proliferation (Wyllie, 1997a). Although there are differences in the
regulatory pathways responsible for activating apoptotic cell death under these
circumstances, there are also many universal regulatory molecules that are involved in
both. It is likely that although aberrations in apoptotic pathways are present in many
glioma cells, some similar molecular strategies may be employed with glioblastoma cell
populations in response to endogenous stress.
Injury to DNA, injury to cell membranes, mitochondrial damage and cytotoxic T
lymphocyte killing can all stimulate an apoptotic response in human cells (Wyllie,
1997A). Direct damage to DNA can initiate apoptosis by a powerful, early activated
mechanism dependent on the nuclear protein p53 via the checkpoint sensors ATM (ataxia
telengiectasia mutated), ATR (ataxia telengiectasia Rad-3 related) and DNA-PKs (the
catalytic subunit of DNA-dependent kinase). The main role of p53 is in the decision
making process in which the cell is directed towards the completion of repair or apoptosis.
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This mechanism is critical in the cellular response to double stranded DNA breaks (eg.
damage inflicted by ionizing radiation), the generation of nucleotide dimers (eg. damage
inflicted by UV light) and other DNA damaging agents (such as drugs that cause DNA
alkylation) (Smith et al., 1999; Smith & Jackson, 1999; Hoekstra, 1997).
Injury to the cell membrane can result in the activation of acid sphingomylinase which
generates the second messenger ceramide from membrane lipids (Figure 1). Ceramide can
alter cellular susceptibility to apoptosis via MAP/JUN kinase signalling pathways
(Sawada et al., 2001; Basu & Kolesnick, 1998). Active p53 protein has also been shown
to regulate ceramide formation by neutral sphingomyelinase during periods of oxidative
stress. Both the production of reactive oxygen species (ROS) from the mitochondria and
upregulation of hypoxia-inducible factor la (HIF-la) are capable of stabilising the p53
protein under these circumstances (An et al., 1998; Carmeliet et al., 1998; Chandel et al.,
2000; Graeber et al., 1996). Similar pathways are thought to be activated when cells are
exposed to glucose deprivation (Moley & Mueckler, 2000) and growth factor withdrawal
(Asschert et al., 1998). Direct damage to the mitochondria can lead to the depolarisation
of the mitochondrial membrane and the release of certain pro-apoptotic factors such as
cytochrome C (Kroemer, 1997). Finally, T cell killing (by cytotoxic T lymphocytes, T
helper cells, natural killer cells) works by releasing factors such as TNFs (tumour necrosis
factor) and Fas/CD95 ligand which activate cell surface receptors resulting in the
activation of pro-apoptotic pathways inside the target cell (Waring and Miillbacher, 1999;
Krammer, 2000). Cytotoxic T cells also release granules, such as perforin which increase
the permeability of the target cell membrane, and various proteases including Granzyme B
(Greenberg, 1996).
The above insults culminate in the activation of a family of proteases called caspases
(Figure 1). All known caspases possess an active cysteine which can cleave substrates
after aspartic acid residues. Caspases are responsible for cleaving specific target proteins
(eg. nuclear lamins and cytoskeletal proteins such as fodrin and gelsolin) resulting in the
characteristic morphology of nuclear fragmentation and cell membrane blebbing (Wyllie,
1997). Approximately 14 caspases have been identified thus far, some of which are
involved in the inflammatory response, and others that act as initiator and effector
caspases as part of the apoptotic response (Yuan, 2000). Caspases are synthesized as
enzymatically inert zymogens. They are composed of 3 domains, the N-terminal domain
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(pro-domain), and the p20 and plO domains, which are found in the mature enzyme. The
mature enzyme forms a tetramer containing two p20/pl0 heterodimers and two active
sites. Most caspases are activated by proteolytic cleavage of the zymogen between the p20
and plO domains at Asp-X sites. Thus, the easiest way of activating a caspase is by
exposing it to another activated caspase resulting in a 'caspase cascade'. This strategy is
employed by the 3 effector caspases, caspases 3, 6 and 7. These effector caspases are
activated by initiator caspases and usually possess short pro-domains. Once activated,
effector caspases are responsible for cleaving the specific cellular target proteins
mentioned above. Initiator caspases have long pro-domains as they are not activated by
other caspases but by complex combinations of other pro-apoptotic proteins (Earnshaw et
al., 1999).
Two important initiator caspases involved in the apoptotic response are caspases 8 and 9.
Caspase 8 is the key initiator caspase in the death-receptor superfamily. Upon ligand
binding, caspase 8 is recruited by receptors such as Fas (Apo-l/CD95) to form membrane
bound signalling complexes with other caspase 8 molecules and various adapter proteins.
The caspase 8 molecules can then mutually cleave and activate each other. Caspase 9 has
an even more complex mode of activation. The key requirement for caspase 9 activation is
its association with a protein cofactor, Apaf-1. Apaf-1 becomes associated with caspase 9
when it is activated by cytochrome c. Cytochrome c is released into the cytosol from the
mitochondria through pore-forming, Bcl-2 family homodimers such as Bax. The entire
complex containing cytochrome c, Apaf-1 and the activated caspase 9 molecule is known
as the apoptosome (Hengartner, 2000).
Caspases are regulated by a family of proteins called inhibitors-of-apoptosis (IAP)
proteins (Miller, 1999). These are thought to provide a dampner on the very final step of
caspase induction should an apoptotic fate not be required. Recent evidence has been
shown that LAPs can be inhibited by signals from the mitochondria to allow full activation
of the apoptotic machinery. Two of these inhibitors of IAPs have been named Smac (for
second mitochondria-derived activator of Caspases) and DIABLO (for direct IAP-binding
protein with low pi) (Du et al., 2000; Verhagen et al., 2000).
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1.4.3. The p53 protein
Mediation of the apoptotic response from the initial insult to caspase activation occurs
through a complex series of molecular events (Figure 1). A protein often central to this
sequence of events is the p53 protein. p53 is partly responsible for mediating the apoptotic
signal, in all of the described modes of injury described above.
The P53 gene is situated on chromosome 17p. When transactivated, the resulting protein
is modular, containing several regions with distinct functions that interact to integrate
various stimuli from a range of cellular stresses to protect against adverse cellular activity.
The p53 protein is essentially a transcription factor, capable of regulating a range of
downstream genes including those directly responsible for cell cycle arrest, DNA repair
and apoptosis (Prives & Hall, 1999). Because many types of tissue are ultimately reliant
on this proteins ability to perform these functions, a lack of p53 function is thought to be
directly responsible for the malignant progression of many tumours.
The core of the p53 protein is a region which folds in such a way as to form a domain
which can interact with DNA in a sequence specific manner (el-Deiry et al., 1992). The
binding of DNA in normal cells is optimal when the p53 protein is in a tetrameric state,
that is when 4 separate p53 molecules interact via the tetramerization domain (Jeffrey et
al., 1995). The C terminal domain of the protein forms a region thought to contain key
regulatory properties associated with post-translational modification of the p53 protein.
Acetylation, phophorylation and O-glycosylation and RNA binding have all been reported
to occur in this region although the significance of all of these occurrences remains
unclear. One theory is that this region regulates the conversion of a 'latent' p53 molecule
to one that is active for DNA binding (Hupp & Lane., 1994). Another theory suggests that
the C terminus somehow regulates the DNA binding capabilties of the p53 protein on
longer DNA molecules (Bayle et al., 1995). Between the DNA binding domain and the N-
terminus lies the SH3 domain. This region can interact with with signal transduction
molecules that contain a SH3 domain including the c-abl oncogene (Yuan et al., 1996).
The N-terminus allows the p53 protein to recruit the transcriptional machinery required
for transcribing the new mRNA of specific target genes and is also involved in the self-
regulation of the p53 molecule (Kubbutat et al., 1997).
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1.4.4. p53 and apoptosis
Probably the best documented cases of p53 mediated activation of apoptosis are those
involving the Bcl-2 family of proteins. Although these proteins share a combination of
similar domains, Bcl-2 family members can be either pro-survival (eg Bcl-2, Bcl-X) or
pro-apoptotic (eg Bax, Bad, Bid, Bak). It is thought the Bax protein, a pro-apoptotic
member of the Bcl-2 family, can homodimerize on the outer membrane of the
mitochondria to form pores allowing the release of cytochrome c from the intermembrane
space. Cytochrome c then appears to mediate the activation of initiator caspase 9, which
triggers a caspase release resulting in apoptosis. The proteins smac and DIABLO are also
released at this time, which inactivate inhibitors-of-apoptosis proteins (Du et al., 2000;
Verhagen et al., 2000). The Bcl-2 protein, a pro-survival member of the Bcl-2 family can
heterodimerize with Bax preventing cytochrome c release. Wild-type p53 protein can
transactivate the Bax promoter, boosting levels of mitochondrial Bax to increase the
likelehood of Bax homodimer formation (Reviewed in Kroemer, 1997; Adams & Cory.,
1998). The relative contribution of Bax to p53-mediated apoptosis appears to be cell-type
dependent. For example, Bax is not required for radiation induced, p53-dependent
apoptosis in thymocytes (Knudson et al., 1995) but Bax-deficient fibroblasts appear to be
compromised in DNA-damage induced apoptosis (Schmitt et al., 1999). It is also thought
that p53 is responsible for regulating levels of the pro-apoptotic Bcl-2 family member
Bad. Bad heterodimerizes with the Bcl-2 protein, thus allowing more free Bax molecules
to homodimerize resulting in subsequent caspase activation (Chao & Korsmeyer., 1998).
Other Bcl-2 family members have more ambiguous functions such as Bag-1. Bag-1 is a
heat shock (Hsp70)-binding protein that can collaborate with Bcl-2 in suppressing
apoptosis after growth factor withdrawal, but can slow proliferation when over-expressed
(Roth et al., 2000).
Although ligand binding stimulates an apoptotic response via members of the death-
receptor family, transcription of the death receptor Fas is induced by p53 through a p53
responsive element (Figure 1). Fas ligand/Fas receptor binding serves many crucial
physiological functions including tumour cell killing, lymphocyte culling and establishing
zones of immune privilege (Waring and Mullbacher., 1999; Krammer, 2000). Fas has also
been implicated in the cellular response to hypoxia (Kwon et al., 2001). The increased
production of the Fas receptor increases susceptibility of the target cell to apoptosis via
the Fas (CD95) ligand. Binding of the Fas ligand to the Fas receptor leads to the formation
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of a submembrane death inducing signalling complex (DISC). FADD (Fas-associated
death domain protein, also known as Mortl) instantly binds to the Fas receptor after
ligand engagement and then recruits DED- containing procaspase 8 (also known as
FLICE). Caspase 8 is then activated into the cytoplasm to initiate the caspase cascade
(Kischkel et al., 1995). p53 can also stimulate the expression of another death receptor,
KILLER/DR5. Like the Fas receptor, when KILLER/DR5 binds to the extracellular
signaling molecule FRAIL, a signaling cascade is activated that results in caspase
activation (Wu et al, 1997). Elaborate molecular control mechanisms have been found to
exist to prevent either inappropriate or inadequate cell killing within the TNF-receptor
super family. Decoy receptors exist that lack the 'death domain'and can prevent
engagment of the apoptotic pathway (Rasper et al., 1998). Also, recruitment of caspase 8
into the successfully ligated death receptor complex can be prevented by c-flip, a
catalytically incompetent pseudocaspase (Thome et al., 1997).
Mitochondrial Cell membrane DNA damage T cell killing
I \i I /
Cell cycle arrest Caspase activation
i
DEATH
Figure 1. p53 mediated apoptotic pathways
Other p53 mediated pro-apoptotic target molecules are currently being researched and
recently a group of PIGS (p53-induced genes) were identified that appear to increase
cellular oxidation. When oxidation was blocked, p53-mediated apoptosis was inhibited,
suggesting that p53 may activate apoptosis via cellular oxidation (Polyak et al., 1997).
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The advent of microarray technology has also allowed the identification of another p53
dependent newcomer called PERP. PERP is a four span plasma membrane protein with
similarity to the PMP-22/Gas3 family and is associated exclusively with the apoptotic
machinery (Attardi et al., 2000). p53 has also been shown to associate with the c-abl
protein tyrosine kinase that is distributed in the nucleus and the cytoplasm of proliferating
cells (Shaul, 2000). Although c-abl is thought to cause the dissociation of DNA repair
machinery during DNA repair, its other roles include the prevention of nuclear export and
subsequent degradation of p53 by MDM2 (Sionov et al., 1999).
1.4.5. p53 and cell cycle arrest
A critical mediator of the p53 response to cell damage is the CDK inhibitor p21. p21 is
transcriptionally regulated by p53 and can function as a dual specific inhibitor of cell
proliferation by two independent and functionally distinct mechanisms. Firstly, p21 is a
member of the Cip/Kip family of CDK (cyclin dependent kinase) inhibitors, a family that
includes p27 and p57 (Mainprize et al., 2001). Cip/Kip proteins bind to and inhibit
cyclin/cyclin dependent kinase complexes that are required for cell cycle progression.
Each Cip/Kip protein has distinct functional properties, attributable to structural
differences at their C-termini. This results in differing binding affinities of these proteins
to CyclinD/ cdk4&6 and CyclinE/cdk2 (Russo et al., 1996).
p21 also associates with the DNA replication factor PCNA (Waga et al., 1994). PCNA is
an auxiliary protein to certain DNA polymerases required for DNA synthesis. These
p21/PCNA complexes can block DNA replication but not PCNA-mediated DNA repair.
These p21/PCNA complexes also associate with the cyclin/cdk complexes suggesting that
p21 may help to coordinate CDK-dependent cell cycle progression together with
processes regulating DNA replication and /or repair (Li et al., 1994). Since the majority of
p21 is found in activated cyclin/cdk complexes in proliferating cells and is required for
proper assembly of cyclinD/cdk2 complexes, low levels of p21 may aid progression of the
cell cycle (Zhang et al., 1994)
GADD45 is another target for p53 function involved in growth arrest. It is one of a family
of genes called MyD that have been shown to interact with the stress responsive
MTK1/MEKK complex and the p21/PCNA/CDK complex, both of which actively inhibit
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cell cycle progression (Azam et al., 2001). p53 can also activate the 14-3-3 protein, 14-3-
3a, which has been shown to block the cell cycle at the S/G2 transition (Fu et al., 2000).
Not only does p53 have an active role in arresting the cells to allow repair to take place,
the p53 protein itself is thought to be directly involved in maintaining DNA integrity.
While cells are arrested for DNA repair, p53 can bind to and inactivate Rad51, a protein
involved in homologous recombination (Buchhop et al., 1997). p53 also interacts through
its C-terminal domain with the transcription repair TFIIH-associated factors ERCC2 and
ERCC3 (XPB and XPD), that are involved in strand-specific DNA repair (Wang et al.,
1996). A ribonucleotide reductase gene is also thought to be involved as a p53 dependent
cell cycle checkpoint for DNA damage. P53R2 is activated in response to DNA damage
and supplies urgent precursors (dNTPs) for DNA synthesis at the actual site of repair in
the nucleus (Tanaka et al., 2000).
1.4.6. p53 regulation
In normal mammalian cells, p53 is expressed at extremely low levels because the protein
is rapidly degraded following synthesis. The MDM2 (murine double minute-2) protein is
known as the key protein involved in the regulation and stability of the p53 protein
(Kubbutat et al., 1997). MDM2 interacts with p53 in undamaged cells and targets it for
ubiquitin-mediated degredation. MDM2 also binds to the p53 protein and inhibits the
ability of p53 to act as a transcription factor. The promoter of the MDM2 gene contains a
p53 binding site and is transcribed in a p53 dependent manner. This has led to a model in
which p53 up-regulates the MDM2 protein, therefore providing a negative feedback loop
for p53 activity (Wu et al., 1993). The control that MDM2 exerts over p53 is essential for
normal cell growth and the death of MDM2 deficient mice can only be rescued by the
simultaneous deletion the p53 gene (Montes de Oca Luna et al., 1995).
The pl4ARF protein indirectly influences levels of intracellular p53. This protein was
initially identified when researchers were examining the role of the CDKN2A locus. The
CDKN2A locus has been shown to encode a family of proteins called INK4. These
proteins (pl5, P16, pl8 and pl9) have been shown to inhibit various cyclin dependent
kinases that are important for cell cycle progression (Roussel, 1999). Alternative splicing
of the CDKN2A locus produces the pl4ARF protein. The pl4ARF protein is a nuclear
protein, which is localized specifically to the nucleolus. Here, it binds and sequesters
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MDM2, preventing MDM2-mediated export of p53 to the cytoplasm for degradation
(Kamijo et al., 1998). It has also been found that wild-type p53 can down-regulate
transcription from the pi4^^ promoter despite that fact that this promoter does not appear
to have p53 binding sites. Therefore, like the relationship between p53 and MDM2, the
relationship between p53 and pl4ARF produces an autoregulatory negative feedback loop
(Stott et al., 1998). The participation of pl4ARF in specific signalling pathways upstream
of p53 still however requires some elucidation.
Another factor that is thought to be involved in the regulation of p53 is a member of the
E2F family of transcription factors, E2F-1. The E2F-1 transcription factor is a regulator of
both cell cycle progression and apoptosis (Strachan et al., 2001). E2F-1 controls cell cycle
transit in part by regulating transcription of genes whose products are involved in DNA
synthesis. E2F-1 accomplishes this by binding DNA as a heterodimer with a Dp family
member (La Thangue, 1994; Lam et al., 1994). The ability of E2F-1 to regulate
transcription is in turn controlled by the retinoblastoma protein (Rb), which inhibits E2F-1
activity by binding to the C-terminal transactivation domain of E2F-1 (Dyson, 1998).
Phosphorylation of Rb by cyclin D-dependent kinase is a defining event of Gl/S
checkpoint progression because it results in the dissociation of Rb from the E2F-1/Dpl
complex thus allowing E2F-1 to activate transcription of target genes. The activation of
apoptosis is thought to be unique to E2F-1 among E2F family members and can occur via
multiple mechanisms including both p53 dependent and independent pathways. In terms
of its association with the p53 pathway, E2F-1 is able to transcriptionaly activate pl4ARF,
which, as described above, stabilizes p53 (Pierce et al., 1999) by increasing the
degradation of MDM2. Interestingly, MDM2 can bind to the C-terminal domain of the
E2F-1 protein and modulate E2F-1 transcriptional activity. Another way by which E2F-1
increases the pro-apoptotic function of p53 is by binding to the p53 protein directly
resulting in an increase in the half-life of the protein (Kowalik et al., 1998). E2F-1 can
also transcriptionally activate the p73 gene, the action of which is discussed below.
Finally, because of its association with perinecrotic tissue in glioblastoma, it is important
to mention the hypoxia inducible factor-1 (HIF-1) group of proteins. Following mild
hypoxic insult, HIF-1 a binds to HIF-1 P (to form the complex HIF-1) and genes are
activated that are important for cell survival. These include factors such as VEGF, nitric
oxide synthase, transferrin, endothelin-1, IGF-2 and many glucose transporters (Zhong et
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al., 1999). However, if very high levels of HIF-la are induced as a result of a large
hypoxic insult or in the presence of low level HIF-1 (3, HIF-la can bind to p53, increase
the half-life of the p53 molecule and promote p53 dependent apoptosis. Phosphorylated
HIF-la is thought to bind to HIF-ip and unphosphorylated HIF-la is thought to bind to
p53. HIF-la can also prevent MDM2 mediated degradation of p53 (Suzuki et al., 2001).
When HIF-la binds to p53 it can stimulate transcription of Bax and p21 genes and
suppresses Bcl-2 transcription (Carmeliet et al., 1998). These findings suggest that HIF-la
plays a vital role in hypoxia induced apoptosis in many systems. HIF-la dependent
induction of p53 has also been implicated in regions of glucose deprivation (Moley &
Mueckler., 2000). HIF-la was initially thought to be stimulated via PI(3)K
(phosphatidylinositol 3-kinase) and Akt kinase signalling pathways following hypoxic
insult (Zundel et al., 2000). However, recent evidence suggests that activation of the
PI(3)K/Akt pathway may be be activated concurrently with HIF-la and may not be
necessary for HIF induction (Arsham et al., 2002; Alvarez-Tejado et al., 2002).
1.4.7. p63 and p73
Most genes occur in families, and until recently p53 was thought to be an exception to this
rule. However, two new members of the p53 family have now been identified. Although
neither of these genes is examined in this study, it is important that their existence is
briefly mentioned. p73 is a putative tumour suppressor with considerable structural
homology to p53 and has a 63% similarity in the DNA binding region (Kaghad et al.,
1997). Like p53, p73 is able to induce cell cycle arrest by activating p21 and recently it
has been shown that p73 is a target of c-abl in response to DNA damaging agents (Davis
& Dowdy, 2001). However, p73 does not degrade after MDM2 binding and other p53-like
functions have not yet been identified. It was thought that p73 could play a role in the
pathogenesis of malignancies in a similar way to p53. However, although p73 is mapped
to lp36, a region frequently deleted in a variety of human cancers, several studies have
documented only rare mutations (Tsujimoto et al., 2000; Yokomizo et al., 1999). p63
(also known as p51) more closley resembles p73 than p53 and is also able to induce
growth arrest in a similar manner to p53. Although it is also maps to a chromosome
frequently deleted in some cancers (3q27-28), like p73, mutations in p63 appear to be rare
(Shimada et al., 1999). Findings by Celli et al found that knock out mice for p63 do not
develop cancers but have developmental problems, suggesting this p53 analogue may be
more important for development than the cellular response to stress (Celli et al., 1999).
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1.4.8. Molecular events leading to the onset of necrosis
Unlike apoptosis, cell death has already occurred when the characteristic necrotic
morphology is seen to occur. As a result, the short period of time preceding these changes,
when molecular changes arise, has been termed 'oncosis' by some researchers (Trump,
1997). However for consistency in this summary, the entire process from onset of the
insult until the cells exhibit a necrotic morphology, will be referred to as necrosis.
Necrosis has attracted less interest than apoptosis due its status as an uncontrolled and
accidental process.
Necrosis often follows a variety of injuries, such as toxins (eg. metabolic inhibitors such
as antimycin and ATPases) and ischemia. Because many of these interfere with ATP
synthesis, they destroy control of the interior environment of the cells by destroying
control at the plasma membrane (Bonventre, 1993). This loss of control usually occurs
because the balance between Na+ entry and Na+extrusion is lost.
Alternatively, direct damage to the cell membrane can also result in a necrotic outcome
and ATP loss. Cell membrane damage may occur as a result of mechanical damage,
modification of membrane lipids (eg. detergents), variations in pore/channel formation (eg
complement C5-9) and the influence of ionophores (such as sodium and calcium). Lack of
ATP and/or loss of cell membrane integrity means that control of cellular ion content,
again resulting from a balance between Na+ entry and active Na+ removal is lost. This in
turn results in a massive influx of water causing cell swelling and eventual rupture of the
cell membrane (Trump et al., 1998). The initiation of a necrotic response can also result in
a reduction of the mitochondrial membrane potential. It is thought that the change in
mitochondrial membrane transition (MPT) is a result of a combination of Ca2+ influx
(Bernardi & Petronelli, 1996), cytoskeletal alterations (Evtodienko et al., 1996) and
increasing levels of intracellular phospholipases (particularly phospholipase A2)
(Lemasters et al., 1999).
1.4.9. Similarities in the regulation of apoptosis and necrosis
Recently, much evidence has come to light suggesting that the definition of apoptosis
versus necrosis may not be so clearcut. Many researchers have found overlapping
molecules involved in both modalities of cell death. Others have found dead or dying cells
in situ exhibiting morphologies common to both processes.
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As previously discussed, during necrogenesis a sudden decrease in ATP occurs very
rapidly. This is not the case during apoptosis where ATP levels are maintained longer
during a 'reversible phase', that is, when the cell is able to revert back to a path of survival
(Trump et al., 1997). Indeed, some researchers have suggested that ATP levels can act as
a type of switch, determining either an apoptotic or necrotic fate (Eguchi et al., 1997).
During the 'reversible phase' the apoptotic cell shrinks implying the loss of ions such as
K+ and Cl~ . Because the necrotic process is ultimately more acute, no such shrinkage
occurs. However, the loss of K+ and Cl~ ions in the apoptotic process is thought to be due
to a massive increase in Ca2+ and stimulation of Ca2+ activated K+ channels. Interestingly,
huge increases in the level of intracellular calcium also plays a role in 'oncosis' the
process preceeding death of the cell by necrosis (Trump et al., 1997; Trump & Berezesky.,
1998; Clarke, 1998). Movement of intercellular calcium has increasingly been implicated
in various aspects of gene transcription and cytoskeletal function (Bootman et al., 2001).
These factors suggest that there may be a regulative aspect to necrotic cell death.
This idea has been supported by the identification of a regulatory enzyme upstream of
ATP depletion called Poly(ADP-ribose) polymerase (PARP). It is thought PARP can alter
the cells fate according to the intensity of an insult such a hypoxia or irradiation. During
low level stress, PARP acts as a DNA repair enzyme which is activated by single stranded
DNA damage. If the damage is too severe for proper repair of DNA, the enzyme can
catalyse the poly(ADP-ribosyl)ation of proteins, including histones. Because NAD is a
precurser in this reaction, NAD levels within the cell drop resulting in reduced ATP
production (D'Amours et al., 1999). This in turn results in cell death via the
oncotic/necrotic process. Because the apoptosis effector Caspase 3 has PARP as its major
substrate and cleaves the enzyme as soon as breaks becomes present on the DNA
backbone, PARP is thought to be involved in the regulation of both apoptosis and
necrosis. Recently, the presence of poly(ADP-ribose)groups within perinecrotic cells in
glioblastoma was discovered (Wharton et al., 2000). The involvement of the PARP
enzyme in necrogenesis again supports the idea that regulative elements are present.
Further evidence for an element of regulation in necrotic cell death was established in
1995 when Fukunaga-Johnson et al and Kane et al found that the anti-apoptotic protein,
Bcl-2 (mechanism of Bcl-2 action described fully in 3.1.5), could inhibit necrosis in
erythroleukemia cells and in neurons. It was later shown that Bcl-2 hyperexpression on
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the mitochondrial membrane impeded the mitochondrial permeability transition and
blocked the release of various proteases released during a necrotic response (Susin et al.,
1996). These findings suggest that cellular susceptibility to necrosis in these cells may
alter following increases in p53 related proteins such as Bax. In addition, various
inhibitors of protein synthesis (which is normally associated with apoptosis) have been
shown to be very effective at inhibiting necrosis. This has been shown in both hepatic
lesions in rat and in both immature and mature neurons deprived of retrograde support
(Torvik & Heding, 1967; Catsicas & Clarke, 1990; Popp et al., 1978).
Intermediate phenotypes possessing both necrotic and apoptotic features have been
identified in some systems which also suggests the morphological definitions of the two
processes may not be so clear cut. Clarke et al have described 3 types of cell death that
occur in neuronal development (Clarke, 1998). The first of these was termed necrosis,
another type was termed autophagic cell death which contained large abundant autophagic
vacuoles and some membrane blebbing. The third type was named nonlysosomal
disintegration and possessed dilation of organelles and a cytoplasmic type of death more
characteristic of classic necrosis. Although only one or two apoptotic features are present,
the variation between these types of morphology at least suggests variations in the
regulatory mechanisms that governs these cells. Sperandio et al have also identified a non-
apoptotic, non-necrotic type of cell death characterised by cytoplasmic vacuolation
(Sperandio et al., 2000). This death was termed 'parapoptosis' as it utilised some
regulatory functions of apoptosis but was functionally and morphologically disimilar.
The implications of a regulative element to necrosis are of particular interest to
neurooncologists because of the large amounts of intratumoural necrosis. Cell death
within glioblastoma cell populations is thought to occur as a result of a combination of a
decrease in metabolites and appropriate GFs, together with a build up of waste products
and changes in pH. These factors form gradients which vary in intensity from the centre of
the ischaemia to the periphery. Regions containing moderate levels of stress may be prime
locations for the appearance of a combination of pro-apoptotic and pro-necrotic cell death
signals. It is possible that factors normally associated with an apoptotic response, such as
p53, may have the ability alter glioma cell susceptibility to both apoptosis and necrosis.
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1.5. The p53 pathway and carcinogenesis
1.5.1. General introduction to cancer and the p53 pathway
When cells acquire mutations that either abolish the function of pro-apoptotic genes (e.g.
P53) or up-regulate anti-apoptotic genes (eg. MDM2), normal cell death responses are not
activated and cells can remain alive under conditions that normal cells would find
impossible. This in turn can lead to tumour formation depending on the series of
mutations that occur in a particular cell type. Theoretically, by identifying specific
abnormalities in cancerous cells, therapeutic strategies can be adjusted accordingly.
Therefore, intact cell death pathways can be targeted depending on the molecular
background of the tumour, rather than using therapies that are unlikely to be effective and
may cause unnecessary damage to normal tissue.
Because P53 has been implicated in the cellular response to stresses such as hypoxia (An
et al., 1998; Carmeliet et al., 1998; Chandel et al., 2000; Graeber et al., 1996), nutrient
depletion (Moley & Mueckler, 2000) and growth factor withdrawal (Asschert et al.,
1998), it may be important for the onset of cell death within glioma cell populations.
However, to assess the likelehood of the P53 gene playing a role in the onset cell death in
glioblastoma it is first important to understand the implications of P53 and P53 related
aberrations in human cancers and also the frequency by which they occur.
1.5.2. Mutations in the P53 gene
The large number of pathways in which p53 is involved constitutes an explanation for the
high frequency of mutations found at the P53 locus in human tumours. Cells harbouring
such mutations are at a selective advantage compared to normal tissue due the impairment
of mechanisms activating both cell cycle arrest and apoptosis. As a result, the commonest
P53 mutations are those that add significant malignant potential to the cell (Sigal and
Rotter, 2000).
When examining human tumours as a whole, all classes of mutation (deletions, insertions,
transitions and transversions) have been found to occur in the P53 gene. Point mutations,
which alter p53 function, cluster in the hydrophobic central region (the DNA binding
domain- Figure 1) of the protein (87% in exons 5-8), where base substitutions alter the
proteins conformation and/or its function. Although more than 250 codons in the P53
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gene are potential mutation sites, 25% of all mutations found in human tumours comprise
only 5 of these codons (175, 245, 248, 249 and 273) (Greenblatt et al., 1994).
Approximately 30% of glioblastomas contain P53 mutations. Primary glioblastomas show
mutations in approximately 11% of tumours, whereas in secondary tumours this figure is
much higher (-67%). Because P53 mutations occur in glial tumours from grades II- IV it
is suggested that the acquisition of P53 mutations is one of the earliest events in tumours
of this type. However, in a study examining the clonal expansion of astrocytic brain
tumours, the original tumour biopsies were found to contain variable percentages of P53
mutant cells compared to wild-type cells (20-75%) (Tada et al., 1996). Therefore, as only
a fraction of cells in the low grade tumours harbour P53 mutations it is unlikely to be 'the'
initiation event. However, it is difficult to differentiate tumour and non-tumour cells in
some low grade tumours. In addition, in patients with germ-line P53 mutations, 73%
acquire astrocytomas, suggesting a P53 mutation could be a primary occurrence in the
malignant progression of some malignancies. The most frequent alterations found in
glioblastomas are GC-AT transversions that occur at CpG sites by deamination of 5'
methylcytosine and are considered spontaneous (reviewed in Fulci, Ishii and Van Meir,
1998). There are no brain tumour specific mutations and the three most commonly
mutated codons in order of frequency are 273, 248 and 175. In other human tumours
codon 248 is most commonly mutated followed by 249 and 175 (Bogler et al., 1995).
Whether these data are of any value is uncertain, as no work has been completed
indicating a defined role for specific mutants in brain tumourgenesis.
Two classes of P53 mutant are generally found: mutations within codons directly involved
in DNA binding (eg 248W and 273H) and mutations within residues important for the
stable folding of the p53 protein (eg 175H). Although these mutations generally result in
abnormal proteins that seriously impair downstream function (eg the activation of P21,
MDM2 and Bax promoters) of the p53 molecule, they can result in p53 proteins with
varying transactivation abilities (Sigal & Rotter, 2000; Saintigny et al., 1999). Many
mutant proteins (such as the full length murine P53 (A to V)) are able to form tetrameric
complexes with wild-type p53 proteins which result in complete cessation of downstream
transciption in a dominant negative manner. However, although the two DNA binding
mutants 273(R toH) and 248(R to W), have completely lost p53 biological activity, they
do retain 98% and 86% wild-type p53 conformation respectively and heterooligomers
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between these mutants and wild-type p53 are often able to bind DNA. Another common
p53 conformational mutant,175(R to H), is not always fully dominant over endogenous
wild-type p53. This was shown by the maintenance of wild-type p53 activity when
colorectal cancer cells were transfected with a vector containing 175H-p53 DNA
(Williams et al., 1994). Some mutants are actually capable of conferring increased
tumourigenic potential to the cell, ie. separate than those simply causing attenuation of
cell death/growth arrest responses. These type of mutants (such as the murine P53 mutant
132F) are referred to as gain of function mutants. This gain of function can be achieved
through a variety of mechanisms including the blocking of differentiation (Shaulsky et al.,
1991), the increasing of metastatic potential (Crook et al., 1992) and the induction of
vascularisation (Kieser et al., 1994).
Because p53 plays a role in cell cycle arrest and in DNA repair, p53 mutant isoforms are
thought to lead to an increase in the mutation frequency of tumour cells. As is mentioned
earlier, wild-type p53 is actively involved in the repair of damaged DNA by inhibiting
homologous recombination via the RAD protein family (Buchhop et al., 1997). Mutant
p53 proteins allow spontaneous recombination events to occur which can lead to the
acquisistion of additional mutations (which may or may not be tumourigenic). Like
transactivation ability, different p53 mutants show varying abilties to stimulate
spontaneous recombination. 175H and 273P show the highest levels of recombination
events, 273H has a moderate effect on recombination and 175G has no effect on
spontaneous recombination (Marmorstein et al., 1998). Theoretically, the effects of
spontaneous recombination are further exacerbated by the inability of mutant protein to
activate p53R2 (a ribonucleoside reductase gene). This would result in a lack of additional
dNTPs required to rectify any mistakes made during recombination or DNA damaging
events (Tanaka et al., 2000).
1.5.3. Mutations in the CDKN2A locus
Mutations found in other p53 related genes in glioblastoma are relatively rare. In a study
looking at the P21 gene in 81 gliomas including 48 GBMs, no mutations were noted after
screening the entire coding region (Jung et al., 1995). In addition, another report found no
alterations in P21 in 10 different cell lines (Zhang et al., 1996). Similarly, no alterations in
the Bax gene have been demonstrated in glioma (Chou et al., 1996).
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One well-described exception to this are mutations in the INK4 locus (CDKN2A locus).
Because the INK4 locus is responsible for encoding pl6 which inhibits cyclin dependent
kinases (CDK4 and CDK6), mutations can lead to dysregulated cell proliferation at the G1
checkpoint due to the hyperphosphorylation of Rb (Hara et al., 1996). INK4 also encodes
the pl4ARF protein which regulates levels of nuclear p53. When high levels of p53 are
required, pl4ARF shifts MDM2 from the nucleus to the nucleolus leading to the
stabilization and accumulation the p53 protein (Pomerantz et al., 1998). If the pl4ARF
protein is not capable of undertaking this function, increasing levels of nuclear MDM2
cause p53 protein levels to drop. This supports the observation that pl4ARF is able to
induce G1 arrest only in the presence of wild-type P53 (Kamijo et al., 1997). Thus
deletion of the CDKN2A/INK4 locus leads to the alteration of both the p53 and pRB-
dependent tumour suppressor pathways (Ivanchuck et al., 2001).
Mutations in the INK4 locus occur second only to P53 mutations in human cancers (Ruas
& Peters, 1998). Point mutations and small deletions (usually found on exon 2) in the
INK4 locus are relatively common in some cancers, and depending on the position of the
mutation, generally result in either conformational changes in the pl6 protein or affect
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pl6s ability to bind CDK4. No nonsense mutations have been found in pl4 mRNA
(Koh et al., 1995; Byeon et al., 1998). However, most mutations in the INK4 locus
eliminate the entire coding region for both pl6 and pl4ARF (reviewed in Ruas & Peters,
1998). Over half of high grade gliomas lack a functional INK4 locus and most of these are
in tumours that do not contain P53 mutations ie. in primary (de novo) cancers (Jen et al.,
1994; Schmidt et al., 1994). Therefore, MDM2 upregulation due to endogenous
overexpression /loss of the INK4 locus in some tumours and the presence of P53
mutations in other tumours without large homozygous deletions in the INK4 locus, results
in p53 pathway disruption in a large percentage of all glioblastomas (Ichimura et al.,
2000; Fulci et al., 2000). This implies that the p53 pathway is absolutely critical in cell
growth and control in glial cell populations.
Although the p53 system may be be compromised in most glioblastomas, other genes
besides pl4ARF/MDM2 are capable of influencing levels of the p53 protein in wild-type
p53 tumours. For example, the proto-oncogene c-abl can prevent p53 export to the
cytoplasm by MDM2 (Shaul, 2000). In addition, the transcription factor E2F-1 possesses
two p53 binding domains and has been shown to be responsible for the accumulation of
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the p53 protein (Nip et al., 2000). The relationship between various pl4ARF mutants and
MDM2 can also vary (see 1.6.4). This means that the P53 gene may yet play an active
role in tumours with a wild-type P53 gene but with P14ARF abberations. In P53 mutant
tumours, p53-independent regulation of p21 has been demonstrated via an E2F-1/Ras
pathway and TNF-a (Gartel et al., 2000). In addition, overexpression of E2F-1 can lead to
p53-independent apoptosis (Shu et al., 2000). Increases in intracellular levels of Bax have
been associated with p53-independent induction of apoptosis in ovarian cancer cell lines
(Strobel et al., 1996). This shows that downstream targets of p53 may still function at
some level without wild-type P53. In addition, some so-called 'p53 mutants' can actually
activate most of their downstream targets, particularly those where the mutation resides
outside the DNA binding domain. The p53 system may therefore function at some level in
both P53 mutant and non-mutant tumours. As a result, the p53 system may also be
functional to some extent within and around areas of cell death in a large percentage of
both primary and secondary glioblastomas. It is possible that tumours harbouring P53
mutations and those with wild-type P53 may activate endogenous cell death via separate
mechanisms.
1.5.4. p53 related protein expression in glioblastoma
The extensive knowledge of the genetic aberrations found in glioblastoma cell populations
suggests that levels of p53 related protein expression (such as Bax, p21 and MDM2) can
be accurately predicted, if, for example, the P53 genotype is known. However, the
complexity of p53 related signalling pathways, the influence of some non-p53 related
genes and the varying half-lives of molecules in abrogated systems means that this is
rarely the case.
Only minute quantities of the p53 protein are found in normal cells, but accumulation of
the p53 protein is a feature of the 20-40% of GBMs containing P53 mutations. This
phenomenon is well described in many different types of cancer. This is because the
MDM2 protein cannot recognise and bind to mutant forms of the p53 protein and thus
fails to label it for degradation by the proteosome (Haupt et al., 1997 ; Anker et al., 1993).
However, the correlation between P53 mutation and positive immunohistochemistry is
incomplete, since P53 gene deletions may not give rise to translatable mRNA and since
wild-type p53 may also accumulate (Weller et al., 1998). Therefore, upregulation of the
p53 protein in brain tumour biopsy material may indicate the presence of P53 mutations
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but 100% accuracy cannot be obtained. Thus far, no correlation has been found between
P53 status and the levels of apoptosis found in glioblastoma tissue (Ellison et al., 1995;
Kalid et al., 1998).
In a study by Krajewski et al, the Bax protein was found to be overexpressed in nearly
100% of the 49 diffuse astrocytoma biopsies examined. In addition, Bax expression
increased with tumour grade. This coincided with a drop in the anti-apoptotic proteins
Bcl-2, Bcl-X and Mcl-2 (Krajewski et al., 1997). This suggests that the Bcl-2 family may
be differentially regulated in association with tumour progression and differentiation.
However, study by Strik et al (1999) examined levels of Bcl-2, Bcl-X, Bax and Mcl-1
proteins from first glioblastoma resections and their recurrences and found that levels of
anti-apoptotic Bcl-2 increase with tumour grade whereas levels of the pro-apoptotic Bax
protein decrease with tumour grade. These contradictory findings therefore suggest that
patterns of Bax expression in glioblastoma still require some elucidation. From a
therapeutic perspective, Bax has been shown to be an important determinant of
chemosensitivity in pediatric glioma cell lines (McPake et al., 1998) and in some
glioblastoma cell lines (Weller et al., 1998). In these sudies, wild-type P53 status was not
found to be associated with chemosensitivity (Weller et al., 1998). This suggests that Bax
may be activated by molecules other than p53 in response to chemotherapeutic agents.
This is supported by the above described findings using the chemotherapeutic drug
Paclitaxel (1.5.3.) (Strobel et al., 1996). No similar correlation has been found between
Bcl-2 family expression and sensitivity to chemoradiotherapy (Strik et al., 1999). Another
study examining Bcl-2 family members found that the heat shock binding protein Bag-1
(see 1.4.5.) was expressed in 15 out of 19 glioblastoma biopsies (Roth et al., 2000). In
vitro work in the same study suggested that interaction of Bag-1 with Bcl-2 may provide a
survival advantage to cancer cells in ischaemic/hypoxic tumour cell populations, such as
those found in glioblastoma.
Like Bax, p21 expression as assessed immunohistochemically does not reflect the
functional status of p53. Khalid et al found that 2 out of 20 p21 positive GBMs whereas
15 out of 26 mutant p53 GBMS were positive for p21 (Khalid et al., 1998). This suggests
that the p21 observed in this study is not regulated by p53. However, in addition to the
cell cycle arrest function, p21 also has an anti-apoptotic effect susceptible to modulate the
p53 apoptotic signal in gliomas. Thus the expression of p21 and absence of p53 could
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confer a selective advantage to healthy tumour cells (Gomez-Manzano et al., 1997; Li et
al., 1998). How p21 is activated under these circumstances however remains unclear.
Whether p21 is activated when cells are subjected to oxidative stress and whether this is
governed by a p53 related mechanism also remains unknown.
MDM2 gene amplification occurs in approximately 10% of GBMs as assessed by southern
blot analysis (Reifenberger et al., 1993). However, MDM2 immunohisto-chemistry has
revealed that more than 50% of primary GBMs contain cells that over express MDM2,
although the fraction of immunoreactive cells varies considerably between cases (Biernat
et al., 1997). Work using cell lines has shown that MDM2 amplification and over
expression occurs only in cells containing wild-type p53 (He et al., 1994). However,
Biernat et al found that although MDM2 over expression was most common in primary
GBMs (>50%), 10% of secondary GBMs (which most often contain p53 mutations) also
showed MDM2 positivity thus suggesting that there may be some overlap between the 2
tumour types. This supports the conclusion by Biemat that the relationship between
MDM2 amplification and overexpression is complex, as tumours may show simultanous
amplification and overexpression, amplification without over expression, or
overexpression without amplification. Therefore, although intrinsic amplification of the
MDM2 gene may be solely responsible for MDM2 overexpression in some tumour cells,
variations in the P53 status and P14ARF status also may play a part, resulting in the varied
expression patterns seen in both primary and secondary GBMs.
Immunodetection of MDM2 protein expression in tumour biopsies and cell lines often
results in the identification of more than one MDM2 isoform. In addition to full length
MDM2 (90kDa in mouse and 97kDa in humans), three lower bands (85kDa, 75kDa,
55kDa) are often observed (Olson et al., 1993; Bartel et al., 2001). These three proteins
are missing the N-terminus region including the p53 binding domain, and are thought to
have arisen due to alternative spicing or leaky scanning ribosomes (Olsen et al., 1993;
Bartel et al., 2001). Two other MDM2 isoforms have been detected by Rallapalli and
colleagues (1999) and were termed MDMX (80kDa) and MDMX-S (27kDa). The former
is thought not be transcriptionally activated by p53 and is thought to have a much weaker
affinity for p53 than full length MDM2. The MDMX-S isoform is thought to be
transcriptionally activated by p53 and is found in low levels in a variety of mouse and
human transformed cell lines.
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Another MDM2 isoform that is often observed in cell lines is a 57-60kDa sized protein
(Olsen et al., 1993; Zauberman et al., 1995; Blaydes et al., 1997). This 60kDa isoform is
able to bind to p53 but is lacking the C-terminus ring-finger domain after residue 361. The
C-terminus ring finger domain contains the cysteine residue that is vital for ubiquitin-
mediated p53 degradation in the cytosol. It is thought therefore that the 60kDa isoform
can bind p53 and prevent p53 transcriptional activity but is unable to mark it for
degradation (Honda et al., 1997). This 60kDa MDM2 isoform is thought to arise via two
different pathways, where both are truncated at the same residue, 361. The first of these is
produced during the apoptotic response by Caspase 3 cleavage of the full length MDM2
97kDa protein (Chen et al., 1997). The Caspase 3 substrate poly(ADP-ribose) polymerase
(PARP) is also cleaved in cells producing this 60kDa MDM2 isoform (Rosen & Casciola-
Rosen, 1997). During the apoptotic response, cleavage of the entire cellular population of
MDM2 occurs, completely inhibiting MDM2-mediated p53 turnover, thus promoting cell
killing by p53 (Pochampally et al., 1998). Because this 60kDa MDM2 isoform is rapidly
degraded in cells undergoing apoptosis, it is thought there is insufficient to prevent p53-
mediated transactivation of pro-apoptotic downstream target molecules (Pochampally et
al., 1998). The second 60kDa isoform is also thought to arise by protease cleavage of full
length MDM2. However, Caspase 3 is not thought to be responsible since caspase 3
substrate PARP is not cleaved (Pochampally et al., 1999). This 60kDa MDM2 isoform is
thought to be produced in non-apoptotic tumour cells and is prevalent in a subset of breast
and lung tumours where it is found in higher levels than the full length MDM2 molecule
(Bueso-Ramos et al., 1996; Gorgoulis et al., 1996). It has been suggested that this 60kDa
isoform may function as dominant negative regulator by competing with full-length
MDM2 for p53 binding (Pochampally et al., 1998).
1.5.5. Novel therapeutic strategies designed to target apoptotic pathways
Because of the wealth of current research in this area it is impossible to mention every
therapy or prospective therapy currently being researched/ developed in this vast field.
Switching on the production of, and/or introducing pro-apoptotic proteins to glioblastoma
cells has shown mixed results. This is mainly because of the difficulties of tumour cell
selectivity and methods of delivery in vivo.
The most obvious choice for a novel therapeutic agent was initially p53 itself, as it
provided a mode of activation of so many pro-cell cycle arrest and apoptotic pathways.
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Many in vitro studies have shown the benefits of using the p53 pathway as a target for
apoptosis inducing therapies. The introduction of wild-type P53 expessing plasmids into
tumour cells can induce over-expression of recombinant wild-type p53 protein and drive
cells into either growth arrest or apoptosis. This has been shown in many cancer types
with widely diverse genetic backgrounds including glioma (Yonish-Rouach et al., 1991;
Mercer et al., 1990; Merzak et al., 1994; Van Meir et al., 1995; Gomez-Manzano et al.,
1996). In addition, further experiments have demonstrated that the transfer of exogenous
P53 alone or in combination with radio or chemotherapy improves the survival of animals
bearing brain tumours (Badie et al., 1995; Kock et al., 1996; Lang et al., 1998). However,
in addition to the difficulties involved in successfully targeting and tranducing in vivo
tumour cells, a combination of other factors suggests that random introduction of P53
gene sequence into patients suffering from GBMs may be problematic. Firstly, as most in
vitro and in vivo experiments have shown, p53 most often activates P21 and cell cycle
arrest in brain tumour cell lines (Van Meir et al., 1995; Gomez-Manzano et al., 1997).
This may actually result in an increase in relative resistance to therapy in some tumours
(Gomez-Manzano et al., 1997; Li et al., 1998). Secondly, some human brain tumours
possess mutant P53 isoforms which possess 'gain-of-function mutations' which would
nullify any exogenous wild-type p53 activity (Trepel et al., 1998; Sigal et al., 2000). And
thirdly, some wild-type P53 cell lines are resistant to the introduction of additional wild-
type p53 and/or other combined therapies (Komata et al., 2000; Badie et al., 1999).
Gene transfer of Bax also induces apoptosis and can enhance the effectiveness of
radiotherapy and some chemotherapeutic drugs in vitro (Craperi et al., 1999; Strobel et al.,
1996; Arafat et al., 2000). Although it has not been tested in glioma, tumours with high
levels of endogenous Bax are generally more responsive to various chemotherapeutic
reagents (McPake et al., 1998). Antisense Bcl-2 therapy has also shown promise in vitro.
It is thought that the Bcl-2/Bax balance can be tipped in favour of Bax (the pro-apoptotic
family member) when the Bcl-2 antisense oligonuceotide G-3139 (Genta
pharmaceuticals) is introduced to tumour cells. The G-3139 oligonucleotide prevents Bcl-
2 mRNA being translated into protein. Clinical trial data using this technique on patients
with malignant melanomas and in non-hodgkins lymphoma (with the chemotherapeutic
agent dacarbazine) has shown some positive results (Nicholson, 2000; Waters et al.,
2000). However, other Bcl-2 family members will be the dominant anti-apoptotic effector
in some types of cancer and only a 14-45% patient impovement (little to total regression)
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has been noted. At this stage, probably the most promising pro-apoptotic therapies involve
the cell death receptor super family. CD95 (Fas) ligand and the TRAIL (Apo2 ligand) can
trigger apoptosis in cells that possess the CD95 receptor and the KILLER/DR5 receptor
respectively (Waring and Miillbacher, 1999; Wu et al., 1997). Some studies have shown
that, like Bax, the role of the TNF super family in p53 mediated apoptosis appears to be
cell type and signal specific (Malkin, 2001; Takimoto & El Deiry, 2000). However, recent
evidence has shown that approximately 80% of human cancer cell lines inluding glioma
cell lines are sensitive to TRAIL, whereas most normal tissue is relatively resistant (Zhang
et al., 1999; Van Valen et al., 2000; Hao et al., 2001). No testing has yet has been done on
humans although experiments using recombinant TRAIL on human xenografts (including
glioma tissue) in SCID mice have shown very promising results (Ashkenazi et al., 1999;
Walczak et al., 1999; Ashkenazi et al., 2000).
1.5.6. Summary of the p53 pathway and glioblastoma
It is therefore clear that knowledge of the molecular aberrations present in tumour cells is
vital when trying to identify genes/proteins that may responsible for areas of cell
death/necrosis in GBM. It is possible that tumours harbouring P53 mutations may activate
cell death pathways different to those activated in wild-type P53 tumours. In contrast, it is
also possible that due to the presence of p53 pathway abnormalities in a large percentage
of GBMs, a universal mechanism may be employed to activate cell death. Knowledge of
the pathways that activate endogenous cell death within these tumours would therefore be
of considerable importance when devising treatment strategies for individual patients with
glioblastoma. Further ellucidation of the role of p53 and p53 related proteins around such
areas, is therefore required. Unfortunately, it is difficult to use human glioblastoma
biopsy material for such studies. Genetic analysis, such as those described above, using
biopsy tissue, can provide some answers as to likely intact pathways in glioblastoma. In
addition, studies examining regions of cell death in biopsy tissue for changes
protein/mRNA expression and cellular morphology may also answer some questions as to
likely candidates for cell death activation. However, tumour biopsy material does not
allow the evolution of such areas to be assessed. This material provides a 'snap-shot' of a
particular cell population at a specific point in time. Glioblastoma cell populations need to
be modelled over time to examine gene and protein expression as areas of cell death
develop.
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1.6. The brain tumour spheroid system
1.6.1. Introduction to in vitro cell culture systems
Since the introduction of cell culture techniques in 1907 using nerve fibre outgrowths, in
vitro experimentation using both primary cultures and cell lines is now common place in
many biological laboratories. Using these techniques, the effects of drugs, growth factors
and hormones can be studied in relation to the physiology, morphology and pathology of
individual cell populations. These experiments can be performed without the confounding
influences of the immune system and the complexity of the in vivo scenario. Two main
types of cell culture exist, primary culture using ex vivo tissue and cell lines.
1.6.2. Primary culture techniques
Cells prepared directly from the tissues of an organism are called primary cultures. In
most cases, cells primary cultures can be removed from the culture dish and used to form
a large number of secondary cultures; they may be repeatedly subcultured in this way for
weeks or even months in some cases. Glioblastoma cultures of this nature have been
thought to be useful as they retain the heterogeneity present in vivo and are useful for
examining growth factors/growth factor receptors, invasion and susceptibility to the
toxicity of prospective anti-cancer agents (Bouterfa et al., 2000; Engebraaten et al., 1993;
Narla et al., 1998). They are also useful for establishing and preserving xenograft tissue
before insertion into immunosuppressed mice (Sasaki et al., 2001).
Although cultures of non-cancerous cells are generally difficult to preserve, as their life
span is often limited to a certain number of generations, highly malignant glioblastoma
cells can survive much longer. However, monolayer cultures derived from brain tumour
biopsies generally lose their heterogeneity/m vivo qualities quickly due to the selective
pressure of the medium. Experiments performed while primary tumour cell populations
are at their most viable may be misleading as the tissues are going through a transition
period involving changes in growth patterns and the death of some tumour cell
populations less suited to the in vitro scenario. The best example of this is the presence of
normal tissue being admixed with the malignant tissue. This can lead to very confusing
results, for example, if the specimens are being used for drug efficacy assays measuring
cell death/ cell cycle control. Normal tissue does not survive as long as cancerous tissue in
vitro thus cell death assays may pick up dying normal cells rather than tumour cells. If
glioma cell populations explanted from patients are left to grow for up to 40-50 passages,
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they can develop (in approximately 10% of cases) into more homogenous cell populations
which are more resilient and thus are often more malignant. These cells are termed glioma
cell lines (Ishii et al., 1999; Matsumura et al., 1994).
Attempts to encourage 3-dimentional growth of primary glioblastoma tissues have had
mixed results. One advantage of explanting solid tumour tissue in fragments is that cell
and tissue components, which run the risk of disappearing in monolayer, have a chance to
survive for prolonged periods in organotypic cultures. Many studies have shown that
capillaries, macrophages and areas of connective tissue can survive throughout a culture
period of up to 70days (Bjerkvig et ah, 1990). Monolayer cultures derived from both
primary cultures and cell lines have a tendency to change their chromosome number and
DNA content over time. In contrast, studies examining 3-dimentional spheroid explants
do not allow for the selection of specific cellular subpopulations and show the same DNA
profiles as obtained from the original biopsy (Shapiro & Shapiro, 1985). This is most
likely due to the retention of original cell-cell contacts present in vivo thus preventing the
cells from exposure to alien environmental situations. Studies by Janka et al also found
that DNA amplifications found in the original glioblastoma tissue by reverse chromosome
imprinting (RCI) retained the same amplification domains using tumour fragment
spheroids (Janka et ah, 1996). All amplifications which were detected in the biopsy
material were lost by passage 5 using monolayer cultures.
Spheroid fragments derived from biopsy material have been useful for various modes of
research. These revolve centrally around assessing cell proliferative, migratory and
invasive capacities of human primary brain tumour spheroids when exposed to various
drug therapies and growth factors. For example, Engebraaten et al found that the addition
of EGF could increase tumour volume and invasive capacity in primary spheroids derived
from 10 out of 13 GBMs examined (Engebraaten et ah, 1993). In addition, Bouterfa et al
found that retinoids could inhibit glioma cell proliferation and migration in primary
spheroid cultures and also that migration was inhibited in the presense of high
concentrations of a drug (Lovastatin) that inhibits beta-hydroxy-beta-methylglutary CoA
reductase (Bouterfa et ah, 2000a; Bouterfa et ah, 2000b). Therefore, although primary
monolayer cultures are useful when testing various substances on cells, using this ex-vivo
material, cell-cell interactions and protein expression (particularly extracellular matrix
proteins) can be examined in a model that more acurately reflects the in vivo situation.
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Disadvantages of using tumour fragment explants revolve mainly around the growth
kinetics of the tumour cell populations within the fragments. Unlike the in vivo scenario
where the tumour cell mass has layers of rapidly dividing cells increasing the size and
volume of the tumour, glioblastoma fragments do not generally increase or decrease in
size under normal culture conditions. Flow cytometric analyses of BrdU labelled cells
revealed that approximately 10% of the cells in spheroids derived from 8 tumour biopsies
were positive (Bjerkvig et al., 1990). This suggests that a significant level of cell loss
accompanies this proliferation. Therefore, although the heterogeniety of these tumours is
somewhat more preserved than in monolayer culture, the lack of expansive growth means
that the onset of necrotic cell death, as seen in vivo cannot be studied in normal culture
conditions ie. without adding various growth factors and artificial growth enhancers.
1.6.3. Glioma cell lines
By far the most popular way of examining the behaviour of tumour cells in vitro is by
using established cell lines. Glioblastoma cell lines have been used by many researchers in
various fields thus providing a useful database on information such as genetic background
and growth kinetics of cell lines. Most of the commonly used cell lines have retained their
genetic stability over many generations, in terms of known oncogenes and antioncogenes.
Unfortunately, established glioma cell lines often lose many of their in vivo
characteristics. For example, a reduction in EGFR expression, which is abnormally
upregulated in de novo tumours (see 1.2.5.), and ATM (ataxia telangiectasia mutated)
expression (see 1.3.4.), which is involved in the cellular response to DNA damage (Bilzer
et al., 1991; Tribius et al., 2001). Dedifferentiation also often occurs, where all of the cells
take on a bipolar fusiform appearance with little or no expression of GFAP (Franks &
Burrow, 1986; Bilzer et al., 1991b). Although many cells do adopt these characteristics in
vivo, thus providing some validity to this technique, highly heterogeneous tumours (such
as GBMs) in vivo also contain tumour cell populations with more differentiated
morphologies and high levels of GFAP expression
1.6.4. Genetics of glial tumour cell lines
Many studies have examined glioblastoma cell lines in order to categorise their genetic
defects to compare with similar abnormalities found in vivo (seel.2.6). In terms of cell
death regulatory mechanisms, the most informative of these was performed by Ishii et al
in 1999 examining the frequent co-alterations of p53, pl6, pl4ARF and PTEN tumour
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suppressor genes in 34 glioblastoma cell lines. Of these 34 four cell lines, over 75% (26)
contained P53 mutations. This figure is much higher than found in vivo where the figure is
around 25% (Ohgaki et al., 1995). What is suprising is that the cell lines examined in this
study were all thought to be derived from de novo tumours where P53 mutations are rare.
However, this can partly be explained by the suggestion that some low grade precursor
lesions may have escaped detection in some secondary tumours. In addition, cells with
mutated P53 have a survival advantage in vitro. Thus if a small number of cells within a
highly heterogeneous cell population contain P53 mutations, these will survive the
lengthy selection process many generations after the initial plating of the biopsy material.
Only about 10% of GBMs will generate permanent cell lines when put in culture in
standard medium (Ishii et al., 1999). Alternatively, P53 mutations could arise in culture,
but this has been shown to be an uncommon event (Anker et al., 1995; Tada et al., 1996).
P14arf function was lost in 21 out of the 34 glioma cell lines examined in the above study
due to homologous deletions in the gene. This loss of pl4ARF expression is expected to
lead to increased cellular MDM2 levels and augmented p53 degradation (see 1.5.3).
Because 26 of the 35 cell lines had P53 mutations and 6 cell lines that had wild-type P53
but had pi4ARF loss, nearly 95% of the cell lines examined had an altered p53 pathway.
However, there are 3 main reasons why mutations in these 2 genes are unlikely to result in
complete cessation of the p53 pathway response in these cell lines. Firstly, as was
mentioned earlier (1.5.2), different P53 mutants result in different proteins with varying
transactivation abilities. Secondly, different pl4ARF mutants vary in their ability to inhibit
intracellular MDM2 levels. For example, changes in exon 2 of the INK4 locus do not
affect the ability of pl4ARF to induce cell cycle arrest (Ruas & Peters., 1998). Thirdly,
recent research examining E2F-1 mediated apoptotic pathways in human lung
carcinogenesis has brought to light evidence suggesting that the model of pl4ARF/p53
interaction is a complex network rather than a simple linear pathway (Nicholson et al.,
2001).
The finding that 15 (44%) of the 34 cell lines with pl4ARF mutations also contained p53
mutations further supports this theory. Although this phenomena has only been observed
in cell lines, if pl4ARF loss occurs first (which is most likely as all the cell lines were
thought to be derived from de novo tumours), the resulting reduction in wild-type p53
levels were unlikely to be sufficient to alleviate selection for a P53 mutation during the
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initial plating phase (Ishii et al., 1999). Therefore, in GBMs and cell lines containing wild-
type P53 but null pl'^RF, wild-type P53 may still play an important role in mediating the
cell death and cell cycle arrest responses in these cells.
Three of the most commonly used cell lines in experimental glioma biology are the cell
lines U87, U373 and A172. These 3 cell lines are all derived from malignant gliomas and
exhibit features similar to glioblastoma when implanted into SCID mice. They possess
different P53 genotypes and have often been used separately or together to investigate the
effects of various anticancer therapies and other stimuli on cell death (Hirose et al., 2001;
Yee et al., 2001; Komata et al., 2000; Badie et al., 1999). U87 and A172 cell lines possess
a wild-type P53 genotype and U373 cell line possesses a mutant P53 genotype (Ishii et
al., 1999). U87 and A172 both possess mutations in the CDKN2A locus resulting in
deletions in both pl6 and pi4^^ genes (Ishii et al., 1999). U373 is wild-type for these
genes according to most studies. Confusingly, identical names of cell lines used in
different laboratories (particularly when using U87 and U373 cell lines) have displayed
different genetic alterations. This means that when using these cell lines, further genetic
characterisation is required. Another less well-known astrocytic tumour cell line is MOG-
G-CCM. MOG-G-CCM is derived from an anaplastic astrocytoma and nothing is
currently known about the status of any apoptosis- or cell cycle-related genes.
1.6.5. Monolayer and suspension culture using cell lines
Monolayer and suspension culture is by far the most popular way of growing and
experimenting with cell lines including those mentioned above. These cultures are of great
value when assessing detailed cell function and to study regulation of apoptosis. An
example of the latter is the use of P53 gene transfer to examine the effect of excess levels
of wild-type p53 protein on the life span of glioma cells possessing different P53
backgrounds (Komata et al., 2000; Kock., 1996). Other researchers have used cell lines
transfected with recombinant adenovirus P53 to assess the effects of combined radiation
therapy and various chemotherapeutic drugs on levels of downstream target proteins such
as Bax and p21 (Badie et al., 1995; Kock et al., 1996; Lang et al., 1998). Artificial
induction of sense and nonsense RNA encoding for many other proteins associated with
apoptosis have also been investigated in this way (Naumann & Weller, 1998; Gomez-
Manzano et al., 1999). Monolayer cultures are suitable for these experiments because of
their homogeneity and ease of use.
45
The main problem when using monolayer systems is that they do not reconstruct the
cellular microenvironments present within a tumour cell mass and there are no simulated
nutrient gradients. In addition, monolayer cultures derived from cell lines represent only
one type of cell in a specific level of differentiation, which is very different than the vivo
situation and most primary cultures. Most importantly for this research, they do not model
necrosis.
1.6.6. Spheroid culture derived from cell lines
By changing the culture conditions, many permanent cell lines can be grown as three-
dimensional spheroid cultures as well as monolayer cultures. The major advantage of
spherical cultures derived from cell lines is their well-defined geometry with a
reproducible concentric arrangement of different cell populations (Sutherland et al. 1981).
This means that multicellular spheroid cultures are characterised by the emergence of
cellular heterogeneity which is an inherent property of most solid tumours. In tumours in
vivo, such heterogeneous cell populations often show a chaotic and unpredictable
distribution pattern, whereas the diverse properties of cells in spheroids are clearly related
to their radial position (Mueller-Klieser, 2000). In addition, unlike spheroids derived from
primary cultures, spheroids derived from cell lines grow larger and from areas of central
cell death that are phenotypically similar to those seen in glioblastoma in vivo (Figure 2).
To investigate the pathogenesis of endogenous cell death in glioma, a model capable of
forming geographically distinct areas of necrosis, similar to those found in vivo was vital.
Necrosis
Figure 2. Diagram of intratumoural necrosis versus intraspheroidal necrosis. A, in vivo
tumour tissue containing necrosis and B, in vitro 3-dimentional spheroid containing
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necrosis. The medium in B acts as the 'blood-supply' where tissue distinct from this
supply necroses at a particular spheroid size. Diagram from Mueller-Klieser, 2000.
Multicellular spheroids derived from cell lines are made by agitating a tumour cell
suspension to prevent the cells adhering to a surface, such as in monolayer culture. This is
usually done using the spinner flask technique although roller bottles and tubes can be
used. Spherical aggregates of tumour cells form spontaneously and reach diameters of
approximately 100-200qm at the end of the first week in normal growth medium
(Mueller-Klieser, 1987; Lund-Johansen et al., 1992). There are variations in spheroid
formation abilities between cell lines. In some cases, such as the U87 glioblastoma cell
line, spheroids form spontaneously in monolayer culture and detach at a certain size
(Deisboeck et al., 2001). Other cell lines, such as the ovarian carcinoma cell line A2780,
will not form spheroid aggregates in either monolayer or using the spinner flask technique
(Rainaldi et al., 1999). When spheroids do form in culture, they can be removed from the
spinner flask environment and examined immunohistchemically (after being fixed and
embedded in paraffin or frozen) or can be placed in another medium for further analysis
e.g. to examine invasive/migratory activity. Collagen matrices are commonly used for the
latter (Tamaki et al., 1997; Bell et al., 1999).
Although there is considerable variation between tumour types, multicellular spheroids
derived from established cell lines exhibit many features similar to tumours in vivo. Five
of the most well described features include spatially distinct areas of differentiation,
proliferation and invasion, the deposition of extracellular matrix molecules and
differences in the patterns of growth factor expression.
In terms of differentiation, tumour specific patterns are often observed within the tumour
cell mass such as neural rosette formation in teratocarcinoma spheroids (derived from the
cell line PA-l/NR) and the generation of myotube-like, multinucleated giant cells in the
central regions of large, non-necrotic spheroids made from human rhabdomyosarcoma
cells (A673 cell line) (Kawata et al., 1991; Karbach et al., 1992). Cells within tumour
spheroids that exhibit increased differentiation are generally found within a quiescent cell
population situated in a concentric arrangement around the spheroid centre (Mueller-
Klieser, 2000). These observations are important as they suggest that spheroids derived
47
from cloned cell populations are capable of re-differentiating into cells more closely
resembling the tumours from which they originated.
Growth factor expression in spheroid cultures can also mimic the in vivo situtation. A
series of experiments performed by Sutherland et al (1988), showed that using a squamous
cell carcinoma cell line A431, highly differentiated cells found in spheroids were
characterised by a three fold increase in the transcription of TGF-a as well as increased
heme-oxygenase expression compared to monolayer cultures (Knuechel et al., 1990;
Laderoute et al., 1992; Murphy et al., 1993). In addition, wild-type EGFR expression was
reduced in these cells in spheroid culture compared to monolayer and addition of EGF
stimulated growth in spheroid cultures but not in monolayer (Mansbridge et al., 1992;
Laderoute et al., 1992b). All of these results are thought to mirror findings within
squamous cell carcinomas in vivo. These findings are likely to be tumour type specific, as
studies by Ness et al (1994), using 5 glioma cell lines (D-37MG, D-54MG, D-263MG,
GaMG and U-251-MG) found increases in EGFR and TGF-a expression by northern blot
analysis in spheroids as compared to monolayer cultures. These again refect the
expression patterns of these growth factors/growth factor receptors in gliomas in vivo. In
addition, other studies using glioma cell lines (rat C6 glioma cells) and a colon carcinoma
cell line (HT29) have shown that angiogenic factors such as VEGF are induced by 3-
dimentional growth (Acker et al., 1990; Schweiki et al., 1995; Waleh et al., 1995). These
are normally exclusively associated with areas of cell death in vivo and are not found in
monolayer cultures under normal culture conditions.
In vivo, it is vital that normal cells form adhesions to the substratum in order to exit from
Go and proliferate (Donaldson et al., 2000; Fuchs et al., 1997). Many cancer cells do not
require such adhesion and grow well attached to plastic or in suspension, which are
artificial states for the growth and proliferation of tumour cells. The development of a 3-
dimensional culture model allows tumour cells to form aggregates and secrete similar
levels of extracellular matrix molecules as those found in vivo. Varying levels of ECM
molecules may alter the tumour cells susceptibility to divide, invade and metastasise. The
deposition of extracellular matrix molecules such as fibronectin, collagens I, II and III
have been observed within spheroids derived from squamous cell carcinoma (Knuechel et
al., 1990). Waleh et al (1994) found that integrin subunits a6, (31 and (34 were
significantly reduced in spheroids derived from the A431 cell line as opposed to
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monolayer cultures. This was proven at both the protein and mRNA level. These results
together with data using glioblastoma cell lines and the colorectal cancer cell lines HRT-
18 and CX-2, found that spheroids mimic the pattern of integrin expression found in vivo
(Paulus et al., 1994; Hauptmann et al., 1995). These findings indicate that cell-cell contact
and microenvironment regulate expression and distribution of a subset of integrin
molecules. This was found not to occur in monolayer culture using the same cell lines.
More recently, the cell adhesion molecules (CAMs) CD44, ICAM-1 and LFA-3 have been
found to be implicated in the very early stages of tumour formation using 6 day old
spheroid cultures derived from a colon cancer cell line (HT29) and a squamous epidermal
cancer cell line (A431) (Rainaldi et al., 1999). In addition, Byers et al (1995) have shown
that intact E-Cahedrin (another cell adhesion molecule) expression and proper linkage of
this molecule to the cytoskeleton is an essential factor for strong cell adhesion in a 3-
dimentional model of breast and colon carcinoma.
1.6.7. Invasion and migration studies using multicellular spheroids
Migratory and invasive characteristics of tumour cells have been examined at length using
the multicellular spheroid model. When spheroids (of any size) are embedded in a
collagen matrix, cells on the spheroid periphery invade the surrounding matrix (Tamaki et
al., 1997). The separation of the invading cells from the tumour cell mass allows them to
be assessed as an independent cell population. These cells can be examined in terms of
their protein expression in order to identify potential targets to inhibit metastatic growth.
For example, EGFR amplification in vivo has been shown to promote glioblastoma cell
infiltration in vitro (Humphrey et al., 1991). Recent evidence has shown that tryphostin
A25 (a specific EGFR-TK inhibitor) can inhibit EGFR activity significantly thus reducing
the invasive capacity of the invading cell population stemming from implanted glioma
spheroids (Penar et al., 1997). A COX-2 inhibitor (NS-398) has also been tested on
glioma spheroid cultures (using U87 and U251 cell lines) and a significant reduction in
tumour cell migration was observed (Joki et al., 2000). Various current therapeutic
strategies have also been tested on the invading cell population using the spheroid system.
The anticancer drug Paclitaxel (Taxol) was recently tested on glioma spheroids (derived
from cell lines GaMG and D-54MG) and showed a dose dependent decrease in the
invasive capacity of the migrating cell population (Terzis et al., 1997). The dose responses
of irradiation, BCNU and dexamethasone have also been tested on invading cell
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populations derived from glioblastoma spheroids (derived from cell lines C6, U251, U373
and A172) with differing outcomes (Bauman et al., 1999).
The use of glioblastoma derived spheroids in collagen matrices has also provided insight
into the importance of extracellular matrix proteins in tumour cell invasion. Using the
human glioblastoma cell lines SNB19, U251, UWR1 and UWR2, the invasive capacity of
the cells was increased by adding laminin, collagens type I and IV, fibronectin and
hylauric acid to the embedding matrices (Chintala et al., 1996). To the contrary, rat C6
astrocytoma invasion was not effected by adding these proteins to the matrix (Tamaki et
al.,1997).
Another method of testing both invasion and extracellular matrix molecules is using the
tumour confrontation model. Confrontation models involve taking two separate types of
tissue and setting them apart in a chamber within a matrix containing a basement
membrane component (collagens, laminins and proteoglycans) and matrix degdrading
enzyme/their inhibitors and growth factors. A tumour cell aggregate is usually placed in
the gel together with a type of tissue attractant that actively encourages tumour cell
migration in that direction. Specific molecules can then be isolated for their pro-/anti-
invasive properties and various inhibitors and agonists can be tested to reduce that
invasion. Neuro-oncological experimentation using this technique started in 1986 when
Bjerkvig et al set a up simple system analysing the mechanism of invasion and subsequent
death of normal brain using normal fetal rat brain aggregates and tumour cells derived
from fetal BD IX rats. More complex experiments have since been set up examining the
properties of anti-invasive drugs. Tonn et al in 1999 found that matrix-metalloproteinase
inhibitors (MMPI) could inhibit tumour cell migration towards Fetal rat brain aggregates.
Fetal rat brain aggregates produce specific growth factors such as EGF that encourage
monodirectional growth. The reduction in invasion can be then be quantitatively assessed
in response to varying MMPI concentrations.
1.6.8. The spheroid model and proliferation
Beyond a certain size (usually between 100-300pm), a viable rim of cells form consisting
of proliferating cells on the spheroid periphery and quiescent, yet intact and viable cells
nearer the centre. The thickness of the proliferative layer can vary between cell lines and
can be measured after labelling with BrDU (encorporated into cells during S-phase) or the
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Ki67 antibody (labels all cycling cells). The concentric arrangement of the proliferating
cell populations within spheroids clearly mimics the initial avascular stages of solid
tumours in vivo and/or intercapillary tumour microregions with high proliferative activity
close to the capillaries. The medium surrounding the spheroid cultures acts as the 'blood
supply' (Mueller-Klieser, 2000). The behaviour/size of the proliferating cell population
can therefore be studied in relation to the genetics of the cell line used (Kunz-Schughart et
al, 1996) or with the addition of various additives to the medium. The latter has been
achieved using commonly used chemotherapeutic drugs such as paclitaxel and novel
therapeutic drugs such a essential fatty acids, folate antagonists and Protein kinase C
inhibitors (Bell et al., 1999; Terzis et al., 1997; Sommers & Alfieri, 1998).
1.6.9. Spheroid culture and cell death
Probably the least studied aspect of tumour spheroid biology are the regions of central cell
death. It has generally been accepted that the central regions of most large tumour
spheroids derived from cell lines consist of necrotic tissue. However, considering that
metabolic gradients form across the spheroid radius, and that apoptosis has been
associated with sub-lethal stress, it is suprising that little has been mentioned of apoptosis
and the pathways that activate apoptosis in these systems. Because of the apparent
similarity of tumour spheroid growth and tumour growth in vivo, the spheroid model
could potentially be very useful in the identification of the control mechanisms that
initiate these cell death events.
The precise cause of the central regions of cell death in spheroids remains undefined.
Several investigators have tried to link development of central cell death and the adjacent
region of cell senesence in the spheroid system to deficiencies in energy-related
metabolites. For some spheroid types such as WiDr human colon adenocarcinoma and
tumourigenic Rat-Tl embryo fibroblasts, a coincidence of emergence of cell death and
hypoxia during growth has been documented with the thickness of the viable rim
reflecting oxygen availability (Kunz-Schughart et al, 1996). Interestingly, in the same
study, 'pseudo-normal' immortalised Rat 1 fibroblasts aggregates in the same study
showed no decrease in pC>2 levels toward the centre of the spheroids at the same size
although areas of cell death were present. This suggests that not only do different cell
types possess different metabolic requirements, but spheroids may become centrally
depleted via different insults. These findings support the theoretical considerations by
Groebe and Mueller-Kleiser (1996) suggesting that a single limiting factor such as oxygen
depletion or lack of growth factors might explain the development of necrosis. The single
limiting factor may be different in spheroids derived from different cell lines in various
types of medium. However, other research in this field has shown that cell death in
multicellular spheroids could be a multifactoral event affected by lack of
oxygen/nutrients/GFs, accumulation of waste products and low pH as discussed by Acker
and colleagues (Acker et al., 1987).
The modality by which the cells die within central regions in tumour spheroids also
remains undefined. Most studies report that inner spheroid regions may adapt their
metabolism to environmental stress thus maintaining intracellular homeostasis until
shortly before the onset of a wave of necrotic cell death. This is reflected in the steady
state levels of glucose, lactate and energy rich phosphates (including ATP) across the
radius of EMT-6 mouse spheroids (Bredel-Geissler et ah, 1992; Teutsch et ah, 1995;
Walenta et ah, 1990). Reduced numbers of mitochondria towards the spheroid centre
support this theory. To the contrary, several reports suggest that in some spheroid types
apoptotic cell death preceeds the onset of necrosis. In V79 (hamster lung) spheroids,
apoptotic cells are dispersed singular events in small spheroids. These accumulate with
increasing frequency in the spheroid centre as spheroid growth progresses and eventually
merge together to form a central area of cell destruction which morphologically resembles
necrosis (Mueller-Kliesser, 1997). In addition, rat rhabdomyosarcoma spheroids also
exhibit an accumuation of apoptosis in the spheroid centre which subsequently changes
into necrotic morphology possessing an element of structural disintegration (Mueller-
Kliesser, 1997). Interestingly, the latter study also demonstrated a suppression of cell
death by spheroid-mediated differentiation. Thus far, no studies have examined the means
by which cells die within central regions of glioblastoma spheroids.
From a mechanistic stand point, very little research has been completed into the specific
death pathways employed by tumour cells subjected to increasing levels of stress around
and within spheroid central regions. This has been mostly due to the assumption that these
cells die by necrosis and thus do not activate regulative pathways. This theory has
previously been applied to glioblastoma tumour cell populations because areas of necrosis
are observed in vivo and in the centre of glioblastoma spheroid cultures at a particular
time point once the threshold for the onset of cell death has passed. However, the above
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research using various cell lines suggests that apoptosis may preceed the onset of necrosis
and thus regulatory pathways may exist. The few studies examining the expression
patterns of cell death/cell cycle arrest related genes in tumour spheroid cultures are
included below.
The p53 dependent-CDK inhibitor p21 has been implicated in the regulation of Gl-phase
arrest in inner-spheroid zones using MR1 (ras/myc transfected rat embryo fibroblasts)and
MLEC10 (immortalised normal mouse liver) cells (LaRue et al., 1998; Lee et al., 1999).
In the latter study using the MLEC10 cell line, the cells grown as spheroids exhibited a
75% decrease in viable cell number without any association between p53 and apoptosis. A
study using V79 immortalised hamster lung cells has shown that there are significant
increases in the potent antioxidant glutathione associated with the accumulation of
centrally located increases in apoptotic index (Romero et al., 1997). Glutathione has
previously been shown to inhibit p53 mediated apoptosis in various human cell lines (Lee
et al., 2001). Although these findings imply that p53 may not be involved in
intraspheroidal cell death in these cell lines, there are considerable variations in the
response of different cell types to different types of cell stress. It is possible that using
glioblastoma cells, which possess very different genotypic alterations compared to the
above mentioned immortalised normal cell lines, p53 or p53 related genes may play a role
in the onset of central cell death in multicellular spheroids.
In summary, glioblastoma biopsy material does not allow the pathogenesis of endogenous
cell death to be studied. Large areas of pseudopallisading cells and ischaemic tissue can
easily be identified but the events leading to their formation cannot be solely explained by
immunohistochemicial and genetic analysis. The glioblastoma spheroid system allows
preliminary and progressive cell death-associated events to be monitored spatio-
temporally, in terms of both morphology and patterns of protein expression. In addition,
unlike primary cultured biopsy tissue, cell lines can be stably transfected to produce




The aims of this project were:
(i) to fully characterise the glioma spheroid system for the four glioma cell lines, U87,
U373, MOG-G-CCM and A172 and to establish that the system adequately reflects many
of the features found within glioblastoma cell populations in vivo.
(ii) to define the exact time point in spheroid growth when central cell death occurs and to
record the different modes of cell death present both qualitatively and quantitatively.
(iii) to establish which p53-related proteins are associated with areas of cell death within
glioma spheroids and to determine whether any correlation exists between this distribution
and the genetic status of the cell lines.
(iv) to determine whether the distribution of p53 related proteins in spheroid culture is
comparible with that seen in vivo
(iv) to ascertain whether modulating levels of endogenous intracellular p53 will have an
effect on the development of cell death and the expression of p53-related proteins within
glioma spheroid cultures.
These findings should hopefully give us greater insight into the modes and mechanisms of
cell death employed within glioblastoma cell populations when they are exposed to





2.1. Preparation of tissue
2.1.1. Cell lines
Four human glioma cell lines derived from anaplastic astrocytoma or GBM were used in
this study. All cell lines were supplied by the European Collection of Cell Cultures,
Centre for Applied Microbiology & Research, Salisbury, Wiltshire, UK. A172 was
derived from a glioblastoma removed from a 53 year old male. This cell line is non-
tumourigenic in anti-thymocyte serum treated NIH Swiss mice. The culture was at
passage 314 on arrival. MOG-G-CCM was established from an anaplastic astrocytoma of
normal adult brain. This culture was at passage number 54 on arrival. U373 cell line was
derived from a malignant glioma by explant technique. This culture was at passage
number 177 on arrival. The U87 cell line was derived from a malignant glioma from a
patient by explant technique also. It is reported to produce a malignant tumour consistant
with glioblastoma in nude mice. The passage number on arrival of U87 cell line was 4.
Cell lines were grown to confluency at passage 1 from purchase and frozen into aliquots
to preserve maximum heterogeneity throughout this series of experiments.
2.1.2. Culture of cell lines
The cell lines were grown in monolayer in Coming 75cm2 culture flasks (Merck) in
Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10%v/v foetal calf
serum (FCS), penicillin (lOOunits/ml), streptomycin (lOOpg/ml) and L-glutamine (2mM).
These were all purchased from from GibcoBRL, Life Technologies, Paisley, Scotland.
The flasks were placed inside a humidified incubator (Heareaus 'function line' incubator,
Heraeus Instruments Ltd, 9 Wates Way, Brentwood, Essex, UK) supplied with an
atmosphere of 95% air and 5% CO2 at 37°C. All tissue culture procedures were carried
out aseptically in a laminar flow cabinet (Microbiological Class II (Envair 2+); Envair
Ltd, York Avenue, Haslingden, Rossendale, UK) using sterile disposable plastic pipettes
and pipette tips. To ensure that a sterile environment was preserved, the laminar flow
cabinet was thoroughly cleaned before, during and after all operations with a solution of
70% ethanol. In addition, all handling of cell lines was performed using disposable latex
gloves.
Continuous cell growth was sustained through regular subculture and examination of the
cultures was performed using a Leica MDIL inverted microscope (Leica Microsystems
(UK) Ltd, Davy Avenue, Knowhill, Milton Keynes, UK). When 100% confluency was
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reached, the cells were harvested through trypsinisation, diluted 1:10 in medium and
delivered into fresh flasks. Excess cells were either thrown away or centrifuged (at
2000rpm in a Hereaus function line centrifuge) and frozen at -70°C in the above medium
containing 1 part dimethyl sulphoxide (DMSO) (Sigma-Aldrich Company Ltd, Fancy
Road, Poole, Dorset, UK) to 15 parts medium for future use. The process of subculture
involved the aspiration of spent medium from the cells, followed by 2 washes with
Dulbecco 'A' phosphate buffered saline (PBS tablets from Oxoid Ltd, Basingstoke,
Hampshire, UK ) and a 5 minute incubation at 37°C in 5mls lxTrypsin-EDTA (0.5ml of
lOxtrypsin (Gibco-BRL) in 4.5ml PBS). The cells were detached through gentle/heavy
agitation and 15mls of the appropriate medium added to the subsequent cell suspension.
1.5ml of this cell suspension was then seeded into each new flask and was supplemented
with 13.5mls of fresh medium. The flasks were then incubated for 2-3 days until the cells
became confluent.
2.1.3. Monolayer culture experiments
In order to perform immunohistochemistry efficiently on monolayer cultured cells, Lab-
Tek chamber slides were used (Nalge Nunc International, 2000 Aurora Road, Naperville,
IL60563, USA). These slides allow the culture of tissue directly onto glass slides which
can be used in standard immunohistochemical procedures. The day preceeding
immunohistochemical labelling, one flask of cells corresponding to each cell line to be
analysed was trypsinised and 3000 cells (counted using a haemocytometer) were plated
into each well (8 wells per slide). The following day, all of the cells used in this study
were 70-100% confluent. To fix the cells, 500pi of 4% buffered paraformaldehyde (Merck
Ltd, Hunter Boulevard, Magna Park, Lutterworth, Leicstershire, UK) was added to each
well for 15 minutes. Following 2 washes in PBS, the plastic cover providing the 'wells'
was removed and the resulting slides with adherant cells were placed in Tris Buffered
Saline (TBS- 6.05g trizma base (Merck), 8.2g NaCl, 1L ddH20, Ph7.6).
2.1.4. Monolayer cultures treated with oxidative and free radical stress
To examine the effects of oxidative and free radical stress on the expression of p53 related
protein expression, the four cell lines were exposed to hypoxia in one experiment and
H2O2 in another. For the H2O2 experiment monolayer layer cultures derived from each of
the four cell lines were grown in 25cm2 flasks (Corning) until 70% confluent. They were
then exposed to a ImM concentration (in the above medium) of H2O2 (30%v/v solution
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from Sigma) for 6 hours. This concentration and time point have been shown to be
optimal when examining p53 reactivity under these circumstances (Kitamure et al., 1999).
which The cells were then trypsinised, pelleted at 2000rpm (as in 2.1.2)and lysed for
western blot analysis (see 2.3). A 25cm2 flask set up with the same number of cells for
each cell line was also set up to act as a OmM H2O2 control for this experiment.
For the hypoxia experiment, the two cell lines U87 and U373 were grown in 25cm2 flasks
(Corning) until 70% confluent. They were then exposed to hypoxia (5% CO2 and 0.5%
oxygen) for 0,1,2,6,12 and 24 hours in a hypoxia chamber (Heto Holten Cell House 170
multigas incubator). The cells were then trypsinised, pelleted at 2000rpm (as in 2.1.2) and
lysed for western blot analysis (see2.3). This procedure was performed by Kevin Corke at
the Academic Unit of Pathology, University of Sheffield Medical School, Beech Hill
Road, Sheffield.
2.1.5. Spheroid formation
Confluent cultures derived from each cell line were trypsinized and seeded into spinner
culture flasks (Pyrex/Shott flasks from Merck) at a density 3xl06 cells/lOOml of medium
(DMEM medium as described in 2.1.2). These were spun at 180 rpm for 5 weeks
(previously described in Bell et al, 1999) on a 4 position magnetic stirrer (Estem
corporation stirrer from Merck) (Figure 3). The medium was replaced when the phenol
red indicator in the medium turned orange. This occurred more frequently as the spheroids
became larger (approximately every 3 days). Around 200 spheroids from each cell line
were harvested from culture at weekly intervals, 25% for paraffin embedding, 25% for
flow cytometric analysis, 25% for EM processing and 25% for western blot analysis.
2.1.6. Biopsy material
Twenty-five archival cases of glioblastoma multiforme were selected at random from the
Neuropathology files of the Western General Hospital. Following a review of all available
haematoxylin and eosin stained sections by a neuropathologist (Dr S. Wharton), a
representative paraffin block (tissue processed in an identical manner as in 2.1.7) which
contained viable tumour, necrosis and regions of tumour/necrosis interface was selected
for each case.
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2.1.7. Tissue processing for paraffin sections
The brain tumour spheroids derived from each cell line and time point were fixed in 10%
paraformaldehyde (Merck)for 15minutes. Following this, approximately 50 spheroids
were placed in each well of a 24 well plate and a 4% hot agarose (Sigma) solution was
added to a depth of 75mm. Once the 24 well plate had been refrigerated for 30minutes, the
plate was removed and the wells emptied of their contents. The contents of each well
consisted of an agarose disk containing approximately 50 spheroids aligned along the base
of the disk. The disks were then deposited into plastic holding cassettes and placed in a
Tissue-Tek 100 Processor (Bayer Pic, Diagnostics Division, Bayer House, Strawberry
Hill, Newbury Berkshire, UK). The tissue processor saturates the tissue with paraffin for
sectioning. The tissue passes through a series of alcohols (2x70% for lhour each, 1x80%
for lhour, 1x90% for one hour and 3x100% for 1 hour each) then a series of xylenes
(4x100% xylene for 1 hour each) and then into paraffin (4 xl00% for 1 hour each). Once
paraffmised, the tissue was embedded in a Tissue-Tek III Embedding System (Bayer) into
metal holders with the spheroids facing on the outward edge of the block.
The blocks containing the brain tumour spheroids and biopsy tissue (which was already
embedded) were then cut into 5jum sections using a Leica G283 microtome and the
sections placed onto Superfrost electrostatically coated slides (Merck). Paraffin sections
of the brain tumour spheroids were used for haematoxylin and eosin (H&E) staining,
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imunohistochemical analysis and TUNEL labelling. Biopsy sections were used for
immunohistochemistry only. To prepare the tissues for staining the slides were placed in
xylene for 5 minutes to remove the paraffin. This was followed by 2 minutes in 100%,
80% and 70% alcohol (Merck) respectively. The sections were then placed in water to
allow full rehydration.
2.2. Staining & Labelling protocols
2.2.1. Haematoxylin and eosin
The spheroid sections were removed from water and stained in a 10% haematoxylin
solution (Merck) for 2 minutes. They were then washed in tap water and placed in
saturated Lithium Carbonate (Merck) in ddFLO (double distilled water) for 10 seconds for
the haematoxylin to oxidise to a blue colour. They were then washed in water and stained
in eosin solution (Merck) for 2 minutes. Following another wash in tap water, the slides
were then placed in a saturated solution of potassium aluminium phosphate for 10
seconds. Finally the sections were washed (in tap water), dehydrated (in 70, 80, 100%
alcohols), cleaned and mounted using DEPEX (Merck) mounted and coverslips (Chance
Propper coverslips from Merck). With this method nuclei appear blue and cytoplasm,
connective tissue, red blood cells and muscle appear pink.
2.2.2. TUNEL labelling
Spheroid sections were dewaxed and rehydrated as in 2.1.7 and incubated with proteinase
K (Roche Diagnostics Ltd, Bell Lane, Lewes, East Sussex, UK) for 20 minutes at a
concentration of 20pg/ml in lOmM/HCl (Sigma), pH7.6 at room temperature. After
washing in PBS, the sections were incubated in TUNEL reaction mixture (TdT-mediated
dUTP-X nick end labeling). This involves the labeling of free 3'-OH termini with
modified nucleotides in an enzymatic reaction. In this kit terminal deoxynucleotidyl
transferase (TdT) catalyzes polymerization of nucleotides to free3'-OH DNA ends in a
template-independent manner to label DNA strand breaks. Fluorescein is conjugated to
these nucleotides which can be detected using either fluorescent microscopy or by using a
secondary detection system. The secondary detection system in this kit contains an anti-
fluorescein antibody to visualise the fluorescent markers for light microscopy (instructions
as described for In Situ Cell detection kit, AP/POD from Roche).
Two different kits were used in this study. One contained a secondary antibody
conjugated to horseradish peroxidase thus requiring a DAB substrate. The other kit
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contained a secondary antibody conjugated with alkaline phosphatase. The substrate in
this case was 5-Bromo-4-Chloro-3-Indolyl Phosphate/Nitro Blue Tetrazolium Tablets
(BCIP/NBT-from Sigma). This meant that positively labelled cells were blue as opposed
to brown as with the peroxidase secondary system. Following the visualization procedure
the sections were washed, dehydrated, counterstained and mounted as above.
2.2.3. Immunohistochemistry
The immunohistochemistry performed in this study was divided into two groups. The
characterisation phase included GFAP, vimentin and Ki67 antibodies. The cell death
phase included antibodies to p53, Bax, p21, MDM2 and pl4ARF. An antibody against HIF-
la was also tested.
GFAP, vimentin and Ki67 immunohistochemistry was performed on wild-type monolayer
cultures and spheroid cultures to fully characterise the cell lines and spheroid model.
These antibodies were not used on biopsy tissue as their expression in glioblastoma is well
documented (Kleihues et al., 2000; Hirato et al., 1994; Bouvier-Labit et al., 1998;
Watanabe K., 1997). P53, Bax, p21, MDM2 and pl4 ARF immunohistochemstry was
performed on monolayer culture, spheroid culture (both wild-type and transfected cell
lines) and on biopsy tissue. HIF-la immunohistochemistry was performed on monolayer
and spheroid cultures.
The monolayer cultures, spheroid cultures and biopsies were treated as in 2.1.6/2.1.7 and
removed from tap water/buffer. The slides that required citrate pretreament were
submersed in citrate buffer (xlO stock buffer- 6g citric acid, 48.24g of sodium citrate
(anhydrous), 2Litres of ddF^O, pH6) and microwaved on full power for 15minutes (see
Table 1 for details of pretreaments, types of animal sera used etc). This was also
performed on the monolayer cultures where virtually no cell loss was observed.The slides
were then placed in a 3%solution of H2O2 for 20minutes to block any endogenous
peroxidase.
After washing in TBS, the sections were placed in a sequenza (Shandon Life Sciences
International, Astmoor, Runcorn, Cheshire, UK) for the application of blocking agents
and antibodies. The sequenza allows rapid application of liquids evenly across the surface
of the slide. After 2 washes in TBS, a 20% solution of animal sera in TBS was added to
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the slides as a blocking agent. Following this, the primary antibodies diluted in 20%
serum were added to the slides at the appropriate concentration for lhour at room
temperature. Following a further 2 washes in TBS, the appropriate biotinylated secondary
antibody was added to the slides for 30minutes at room temperature at a concentration of
1:200 in animal serum. The avidin-biotinylated enzyme complex (ABC kit)used was a
vector elite kit (Vector Laboratories, 3 Accent Park, Bakewell Road, Peterbourgh, UK).
This binds to the biotin that is conjugated to the secondary antibody and provides a target
(horseradish peroxidase) for the subtrate chromagen. The solutions were made up as per
instructions in the kit and added to the slides after a further 2 washes in TBS. The
sections were incubated in the ABC reagent for 30minutes at room temperature.
Following a further two washes in TBS the slides were removed from the sequenza and
incubated in a 3,3'-Diaminobenzidine Tetrahydrochloride (DAB) solution (kit from
Vector Ltd.) for approximately 5minutes. Consequently, positively labelled tissue
appeared brown in colour. All sections were then lightly counterstained with































































































Dako Ltd, Angel Drive, Ely, Cambridgeshire, UK.
2Novocastra, Ballilol Business Park West, Benton Lane, Newcastle-Upon Tyne, UK.
3Santa Cruz, Autogen Bioclear Ltd, Holly Ditch Farm, Mile Elm, Wiltshire, UK.
Vector Laboratories, 3 Accent Park, Bakewell Road, Peterbourgh, UK.
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5Scottish Antibody Production Unit, Law Hospital, Carluke, Lanarkshire, UK.
6Abcam Ltd, 31 Cambridge Science Park, Milton Road, Cambridge, UK.
Table 1. Antibodies used for immunohistochemistry and western blotting experiments
2.2.4. Flow cytometry (FACS analysis)
Wild-type brain tumour spheroids were disaggregated following centrifugation (2000rpm
for 5 minutes) in universal tubes using trypsin (0.5g trypsin and 0.2g EDTA in 250ml
PBS) in a water bath at 37°C for 5 minutes. To avoid membrane damage, cycles of
resuspension were used to break down spheroids from weeks 3-5. Disaggregated cells
were removed after each cycle and added to lOmls of DMEM (containing 10% FCS, as
above) to inhibit the action of the trypsin. The cells were then centrifuged again , the
supernatent removed and the cells suspended in 100pi of Annexin V/propidium iodide
solution (Roche Diagnostics Ltd) for 15minutes at room temperature. 400pl of PBS was
then added and the resulting cell suspensions were analysed using a Coulter EPICS XL
flow cytometer with EPICS XL-MCL System II software. This identified apoptotic and
necrotic cells on the basis of side scatter and fluorescence associated with Fluorescein
labelled Annexin V and propidium iodide (Creutz, 1992). In the early stages of apoptosis,
phosphatidyl serine residues flip to the external side of the cell membrane. These can be
labeled with the Annexin V probe. The cell membranes of necrotic cells become
permeabilized early on, allowing the entry of both the Annexin V probe and Propidium
Iodide. Therefore, the combination of high Annexin V labeling with low propidium iodide
labeling indicates an apoptotic cell whilst high labeling for both Annexin and Propidium
iodide indicates a necrotic cell.
2.3. Western blotting protocol
2.3.1. Isolation of protein from cultured cells
Cells were grown in monolayer culture to 80-100% confluency in 75cm2 culture flasks.
The cells were washed twice in lOmls of PBS, drained completely and trypsinised using
the above described technique (2.1.2). The cells were then centrifuged at 2000rpm in PBS
in universal tubes (Sterilin tubes from Merck) and the supernatent removed. For the
spheroid cultures, approximately 50 spheroids were removed from culture and washed in
lOmls of PBS (x2). Centrifugation was not required as the spheroids could easily be
separated from the medium by leaving them to settle at the bottom of the universal tubes,
lml of RIPA buffer was then added to the monolayer pellet/spheroids (RIPA buffer-
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lxPBS, 1% Igepal CA-630 (Sigma), 0.5% sodium deoxycholate, 0.1% SDS) and the
samples vortexed for 20seconds. The samples were then incubated on ice for 30minutes
(lhour for spheroid cultures) and then sonicated for one 5second pulse using a Sanyo
Soniprep 150 sonicator. The samples when then centrifuged in a microcentrifuge for
15minutes at 4°C and the supernatant removed. ImM of PMSF (phenyl-methyl-sulphonyl
fluoride) was then added to each sample (as a proteinase inhibitor) and the samples were
stored at -70°C.
2.3.2. Quantification of total protein concentration
In order to standardise the quantity of protein in each well for each sample the Coomassie
Plus-200 Protein Assay Reagent (Pierce, 3747 N. Meridian Road, P.O. Box 117,
Rockford, IL61105, USA.) was used.
A fresh set of protein standards were first set up. This involved diluting a 2.0mg/ml BSA
(bovine serum albumin) stock sample into standards of 25ug/ml, 125pg/ml, 250pg/ml,
500pg/ml, 750pg/ml, lOOOpg/ml, 1500pg/ml in ddH20. lOpl of each sample (plus a
Opg/ml control) was pipetted into 8wells (x2 for an average reading)of a 96 well plate.
300pl of the Coomassie Plus reagent was added to each of the 8standard wells and placed
on a bench top shaker for 30seconds. For each unknown sample, 10ul of sample was
added to 300pl of Coomassie Plus reagent and added to other wells on the standard plate.
The plate was read on a Bio-Rad540 plate reader at a 580nm absorbance reading. A
standard curve was then prepared by plotting the average blank corrected 580nm reading
for each BSA standard versus its concentration in ug/ml. Using the standard curve, the
protein concentration for each unknown sample could be determined.
2.3.3. SDS-Polyacrylamide Gel electrophoresis of proteins (PAGE)
This procedure is based on the discontinuous buffer system described by Laemmli (1970).
Electrophoresis was performed using the Mini-Protean II vertical electrophoresis system
(Biorad laboratories Ltd).
The electrophoresis glass plates were washed in a weak detergent solution, rinsed
thoroughly and the side to be in contact with gel washed in 100% ethanol. The plates were
then assembled according to Bio-rad instructions. The resolving gel was prepared
(protocol in Table 2) and then poured (~4mls) into the gap between the plates up to about
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3cm from the top of the plates. This was over laid with 0.5ml ddtkO to flatten the surface
of the gel. This was removed using blotting paper once the gel had set. Once the resolving
gel had set (after ~15minutes), the stacking gel was prepared (Table 2) and poured into the
remaining space at the top of gel. A ten-well Teflon comb (6mmxl0mm for each well)
was then inserted, ensuring no airbubbles were trapped. The gel set up was then left to
polymerise for 30 minutes at room temperature.
After completion of polymerisation the comb was removed and the wells washed with de-
ionised water to remove unpolymerised acrylamide. The gel could then be mounted into
the gel mounting apparatus and reservoir buffer (Table 2) placed in the top and bottom
reservoirs. 50pg protein samples (volume determined by the Coomassie Blue Assay)were
then set up containing a 1 in 4 dilution of 4x PAGE loading buffer (Table 2). The samples
were then boiled in a water bath for lOminutes and incubated on ice prior to loading into
the bottom of the wells using Prot/Elec tips (Bio-Rad Laboratories Ltd). The samples were
loaded alongside 10p,l of prestained SDS-Page standards (Low range- 24,000-
102,000Daltons). The gel was run at 200mVolts (60Amps) until the bromophenol blue
was seen to run off the bottom of the gel (approximately 45minutes). The Ampage at this
point drops to approximately 20mA. Bromophenol blue run alongside 15kDa proteins.
2.3.4. Transfer of Proteins from SDS-Polyacrylamide Gels to Nitrocellulose.
The gel was removed from the glass plates and the stacking gel part of the gel removed
using a gel cutting device. The remaining resolving gel was then measured and the
dimensions taken used to cut 2 pieces of blotting paper (Whatmann 3Mmpaper) and a
piece of nitrocellulose the same size. The blotting paper and nitocellulose were then
immersed in transfer buffer (Table 2) for a few seconds. Blotting paper, nitrocellose, gel,
and blotting paper were then positioned on top of a transfer cassette in that order. The
cassette was then placed inside the transfer apparatus (TE 22 Mighty Small Transfer Tank,
from Amersham Pharmacia Biotech) with the nitrocellulose on the side of the anode. This
means the current passes from the cathode to the anode displacing the proteins from the
gel onto the nitrocellulose. The remaining transfer buffer was then poured intothe transfer
apparatus and the voltage set at 220Volts (400mA). The transfer took place in
approximately 30minutes after which the nitrocellulose was removed from the cassette
and emmersed in TBS (Table 2).
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2.3.5. Immuno-detection of p53 related proteins immobilised on nitrocellulose
Protein detection was carried out using the luminol western detection system (Santa cruz).
The nitrocellulose membrane was removed from the TBS and incubated in blocking
serum (5%milk solution in TBST) for 1 hour at room temperature in a shallow container
on an orbital shaker. This solution was then removed and the primary antibody solution
(antibodies all diluted in blocking solution at varying dilutions-see Table 1) added for
lhour. The actual total volume added depended on the size of container. The membrane
was subsequently drained and washed for 5minutes (x3) in TBST. Once the wash buffer
had been removed, the secondary antibody was then added to the membrane (mouse IgG
horseradish peroxidase-linked whole antibody) diluted 1:1000 in TBST for 45minutes.
The membrane was then drained completely and washed 3 times in TBST for 5 minutes
and once in TBS for 5 minutes to irradicate the high levels of detergent. The nitrocellulose
was then incubated for lminute with the two luminol detection detection reagents
(0.125mls per cm2) previously mixed in equal quantities. HyperfilmTM-ECL was exposed
to the membrane for 30seconds, 1 minute, 2minutes and 4 minutes to ensure optimum
exposure. The film was then passed through a photographic hyperprocessor to develop the
film.













lOOpl APS (Ammonium persulphate)
lOpl TEMED
Stacking gel
1.25ml 4x stacking gel
3.0ml ddH20
0.67ml 30% acrylamide







0.1% SDS in final lx buffer (5mis 10%
PAGE-loading buffer 1x41





SDS in 500mls) 0.200ml 0.1% bromophenol blue
0.225ml ddHaO
Transfer buffer Blot washing buffer (TBST1
4.5g Tris base 5ml 1M Tris
21.6g Glycine 15mls 5M NaCl
15ml 10%SDS 500ml ddH20
1200ml ddH20 0.250ml Tween-20
300ml methanol
Table 2. List of reagents used in western blotting experiments
2.4. Electron microscopy
Tissue processing for electron microscopy was performed by Mr Frank Donnelly,
Department of Neuropathology, Western General Hospital, Edinburgh.
Wild-type brain tumour spheroids derived from the cell lines U87, U373, MOG-G-CCM
and A172 were fixed for 2 hours at 4°C in 3% gluteraldehyde in 0.1M Sodium
Cacodylate/HCl buffer pH 7.2-7.4. They were then washed 3 times in double distilled
water for 20 minutes and fixed for 45minutes in 1% osmium tetroxide. Following
dehydration to 100% ethanol, the spheroids were submerged in propylene oxide for 30
minutes then left overnight in Emix resin (Taab Laboratories, Aldermaston, Berks, UK) at
room temperature. Once the spheroids had polymerised (20 hours at 70°C), 90nm sections
were cut with a glass knife on a Reichert OMU2 microtome and mounted on 300 mesh
copper grids. The sections were then stained by the Uranyl Acetate/Lead Citrate method
and examined using a Jeol 100CXII transmission electron microscope with an operating
voltage of 60KV. Photographs were taken using Kodak 4489 film and developed using
Ilford P&Q Universal developer on Ilford Multigrade glossy photographic paper.
The spheroids were examined to identify any ultrastructural differences between the
modes of central cell death employed by the different cell lines. This was done over the 5




2.5.1. Isolation of genomic DNA from cultured cells
The four wild-type cell lines U87, U373, A172 and MOG-G-CCM were washed and
pelleted using a Haereaus function line centrifuge at 2000rpm. The cells were then
transferred to a 1.5ml eppendorf tube and 500pl of lysis buffer (0.32M sucrose, lOmM
tris-HCl, pH7.5, 5mM MgCl2, 1% Triton X-100). These were inverted 5-6 times and
centrifuged at 10,000rpm for 5 minutes. Following this, 500pl of phenol and 250pl
chloroform: isoamyl alcohol were added to the samples. These were mixed then
centrifuged for 3minutes at 10,000rpm. The supernatent was then transferred to a fresh
tube and 250pi of phenol and 500pi chloroformrisoamyl alcohol were added. These were
again centrifuged at 10,000 rpm and the supematent removed. This last step was repeated
until the supernatent became clear. Subsequently, 50pl NaOac (Sodium Acetate) and 1ml
EtOH were added to the supernatent and the mix lightly tilted until a precipitation was
seen. The sample was then spun at 10,000 rpm and the supernatant discarded. The pellet
was resuspended in 50-100pl ddH20 and stored at 4°C for 24hours to allow the DNA to
dissolve.
2.5.2. Amplification of genomic P53 sequences
The entire coding region of the P53 gene (exons 2-11) was polymerase chain reaction
amplified (PCR). A series of primers were used that spanned across all llexons (Figure
4). The coding sequences were divided into 3 segments of 500-1000 base pair fragments.
The primer sequences were all situated on exons and were between 15 and 25 base pairs
longs (Table 3).
Genomic DNA isolated from the cell lines was diluted to approximately lOOng/pl. All
PCR reactions were carried out in 500pl microtest tubes on a Hybaid Omni-Gene PCR
machine. Because multiple samples were to be analysed, bulk solutions containing Taq
polymerase, reaction buffer, dNTPs, primers and water were prepared. The total volume
of solutions was 300pl and was made up of 193pl ddH20, 30pi reaction buffer(xlO), 48pl
dNTPs (1.25mM of each dNTP), 15pi of sense primer (50pg/ml), 15 pi of antisense
primer (50pg/ml) and lpl Taq DNA polymerase (5units/pl). The reaction buffer, dNTPs
and Taq polymerase were purchased from Life Technologies Ltd, 3 Fountain Drive,
Inchinnan Business Park, Paisley, UK. The primer combinations were made by Genosys
(a Sigma subsidiary). This 300pl stock mix was divided into 50pl aliqouts and lpl of
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DNA (100ng/|u.l) of DNA to be tested from each cell line was added to each tube. The
contents of the tubes were thoroughly mixed and 50pl of mineral oil (Sigma) added to
prevent evaporation. In all PCRs 30 amplification cycles were employed. Each cycle
consisted of lminute at 95°C for the denaturation phase, 30seconds at 58°C for the
annealing phase and 1 minute at 72°C for the extention time.
Region 1 (Product size 694bp)
P53ex.2.1 5 G GAG CGT GCT TTC CAC GA3'(143-204)
P53ex.6.1 5 CAG TAG GTT TAT GAG GTG TGC G3' (837-815)
Region 2 (Product size 814bp)
P53ex4.1 5 TCC CAA GCA ATG GAT GAT TTG3 (322-342)
P53ex8/9.2 5 C ACG AGC GAA TCA CGA GGG A3' (1136-1117)
Region 3 (Product size 675bp)
P53ex5.1 5 AC CAT GAG CGC TGC TCA GAT A3' (745-767)
P53exl 1.1 5"CAC CCC TTG TTC TTC ACC3' (1420-1402)
Table 3. Primer sequences for regional amplification of the P53 gene
2.5.3. Gel electrophoresis of PCR products
The PCR products (see Figure 4 for regions) were analysed by electrophoresis in 2%
agarose gels. lOOmls of 2% gel was prepared using lxTAE buffer (made from a 50x stock
of 242g Tris base, 57.lg glacial acetic acid, 100ml 0.5M EDTA pH 8.0. made up to 1L)
and 2g of PCR grade agarose (Sigma), lpl of lOmg/ml ethidium bromide was added prior
to pouring the agarose into a sealed, level mini-gel tray carrying a 12 well comb. The gel
was run in a mini-gel apparatus (Bio-Rad) containing enough buffer to cover the gel. 8pi
of each PCR reaction together with 2pl of DNA loading buffer (0.25% Bromophenol blue,
0.25%xylene cyanol FF, 15% Ficoll Type 4000, 120mM EDTA) was added to each well
alongside lOpl of lOObp ladder. Electrophoresis was performed for 30-45 miuntes at
lOOmV, after which the gel was examined and photographed under UV transillumination.
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Figure 4. Map of the P53 gene with region locations
2.5.4. Preparation of samples for chain termination sequencing
The 3 regions of DNA for each sample were directly sequenced using Thermosequenase
radio-labelled terminator cycle sequence kits (Amersham-USB Life Sciences, 26111
Miles Road, Cleveland, Ohio 44128, USA). All of the following reagents, excluding the
TO
termination [a- PJddNTPs, were used from this kit.
Following identification of the correct sized bands (Region 1, 694bp; Region 2, 814bp;
Region 3, 675bp) for each region to be sequenced, 5pl of each PGR product was mixed
with lpl of Exonuclease 1 (10units/pl) and lpl of Shrimp alkaline phosphatase
(2.0units/pl) and incubated at 37°C for 15minutes. The samples were then incubated at
80°C for 15minutes to denature the enzymes. Exonuclease I removes residual single
stranded primers and any extraneous single stranded DNA produced by the PCR. The
shrimp alkaline phosphatase (SAP) removes the remaining dNTPs from the PCR mixture
which would interfere with the labelling procedure in the sequencing process.
To set up the sequencing reaction, the termination mixes were prepared using 2pl of
dNTPs and 0.5pl of each[a-33P]ddNTP (G, A, T, or C-one of each per sequence) to
produce a termination mix for each ddNTP. Therefore 4 tubes were set up for each sample
to be sequenced.
To set up the reaction mixture, a stock solution of ddH20, reaction buffer, primer,
polymerase and sample DNA was made up to be divided between the four above tubes.
The quantities used in the reaction mixture were: 2pl reaction buffer (xlO), 7pl
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DNA(from the exonuclease/SAP stage), lpl Primer (only 1(0,1 of one primer is required as
the mix only contains DNA ending or beginning with this oligonucleotide sequence), 8pi
ddlbO, 2pl Thermo Sequenase Polymerase- added last (4U/pl). 4.5pi of the reaction
mixture was then added to each of the four permination tubes ie. 4.5pl to the 'G' tube , 4.5
pi to the 'A' tube etc. Each termination mix was then mixed and overlaid with 25pi
mineral oil (Sigma). The cycling programme was then started, again using a Hybaid
Omni-Gene PCR machine, using the same programme as described above (at 94°30",
58°30", 72°1'). Once the programme had finished, 4pl of stop solution was added to each
of the termination mixes and the samples were briefly mixed and centrifuged to separate
the oil from the aqueous phase. The samples were then stored at 4°C overnight before
loading the sequencing gel the following day.
2.5.5. Separation of termination sequences using 6% polyacrylamide gels
Before pouring the sequencing the gel, the plates were thoroughly washed and the sides
facing the gel were wiped down with 100%ethanol to remove any excess water. Spacers
were then placed between the two plates with the shorter plate on top. Crocodile clips
were used to hold the plates together in position. The gel mixture was then prepared (see
Table 4 below). A 50ml syringe without needle was used to fill the gap between the plates
with the gel solution. This was done with relative haste to prevent polymerisation of gel
before the gel was fully poured. The gel was tilted to encourage the flow of the solution
and to prevent air bubble formation. Once the plates were full, two sequencing combs
were inverted and the flat side pushed into the top end of the gel by around 2cm. This
provides a flat surface for the samples when the combs are orientated to provide wells.
The gel was then left to polymerise for 30minutes. The total size of the gel was
30x40x0.4cm.
Once polymerisation had occurred the gel was moved into an upright position and
clamped into the gel running apparatus (Life Technologies Sequencer II). lxTBE was
then poured into the top and bottom chambers of the apparatus. The combs were removed
from the inverted position and were placed with the serrated edge down into the well, with
the teeth slightly penetrating the gel. The gel was then set up for a pre-run to warm up the
plates for 30minutes at 100W.
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TBE fxlOl buffer ClLl 6% stock sequencing sol. 6% sequencing eel
108 g Tris base 190ml ddH20 65ml 6% stock sequencing
55 g boric acid 50ml TBE(xlO) solution
40ml 0.5M EDTA 75ml 30% Acrylamide 400pl APS




Table 4. List of reagents for sequencing gel
The termination reactions were then removed from the fridge and heated to 90°C on a hot
plate for 3 minutes. The wells in the gel were then washed using lxTBE with a fine gauge
needle. 4pl of each termination mix (which were kept on ice) was then loaded into each
well in the order of G, A, T and C for each set of samples. These were left to run for 2
hours at 80W. A second batch of the same samples were then introduced to the spare
wells on the gel to provide a short run and a long run thus allowing more of the gel to be
read when sequencing was complete. After another 2 hours the buffers were drained from
the gel running apparatus and the gel separated from two plates using a sequencing gel
separator. The whole gel was then spread onto Whatmann T4 blotting paper, covered in
clingfilm and dried using a large Bio-Rad 650 gel dryer for a further 2 hours.
Subsequently, the clingfilm was removed and the blotting paper was exposed to
autoradiographic film over night. The film was then developed in a photographic
hyperprocessor. The films were then screened p53 mutations by comparison with the wild
type sequence using the website; www.perso.curie.fr/ p53/Thierry.Soussi/ index).
2.6. Production of mutant and wild-type P53 transfectants
2.6.1. Construction of P53WTEGFP vector
The wild-type p53 vector (Figure 5) was purchased from Clontech Laboratories Inc, 1020
East Meadow Circle, Palo Alto, California, USA. This plasmid encodes a p53-EGFP
signalling probe, which is a fusion of enhanced greeen fluorescent protein (EGFP) and
p53. The expression of the p53-EGFP is driven by the human CMV immediate-early
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promoter. The SV40-poly A sequence directs proper processing of the 3' end of the fusion
construct. The vector backbone also contains an SV40 origin for replication in
mammalian cells expressing the SV40 T- antigen. A pUC origin of replication for
propagation in E. Coli is also included. A neomycin resistance cassette (neor) allows
kanamycin resistance in E.Coli and geneticin (G418) resistance in eukaryotic cells. The
p53-EGFP signalling probe can be used to monitor the presence of transfected p53 in
target cells by observing changes in EGFP flourescence. The EGFP signalling probe was
used in all the of the expression vectors in this study as a means of standardizing protein
expression and detection.
After the transformation and cloning procedures were performed using two selected
colonies (2.7.1), a PCR for a section of the P53 gene was set up to confirm the cloning
procedure had amplified the P53 wild-type vector correctly. The reactions were set up as
in 2.5.2 using the primers ex2.1 and ex6.1 (Table 3).
A/of I
Figure 5. The pp53-EGFPvector construct
2.6.2. Construction of the Plasmid Only vector
In order to perform a controlled experiment for the presence of the P53 vector in
transfected cell lines, a plasmid-only control vector was created. This was done by
digesting the above plasmid to remove the 1.2kilobase P53 encoding region and re-
ligating the free ends. This was done between the CMV promoter sequence and the P53
sequence and also between the P53 sequence and EGFP sequence. The resulting vector is
shown in Figure 6 (also without pCMV promoter region at the start of the p53 sequence).
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The digestion to remove the P53 insert was performed using the restriction enzymes
Hindlll (restriction site-A/AGCTT) and Bglll (restriction site-A/GATCT). This resulted
in free complementary base pairs (GATC/CTAG) that could be ligated together to create a
circular vector for cloning and transfection procedures. The digestion mix (Table 5) was
incubated at 37°C in either a water bath or the Hybaid Omni-Gene PCR machine.
Figure 6. The plasmid-only vector construct
Digestion of dd53-EGFP Ligation of free ends of emntv vector
83/rl ddH20 7.5/xl cut vector
10/zl buffer (xlO) -React 2 (Life Tech) 0.5/xl ligase
I III Hind III/ Bgl II (Life Tech) 2/zl buffer (x5)
5/rl pp53-EGFP vector (Clontech)
Table 5. List of reagents for the creation of PO-EGFP
The digestion products (all 100/xl of the digestion mix) were then run on a 0.7% agarose
gel (2.5.3) for 45 minutes. This allowed the two vector fragments (1.2Kb and 4.7kb) to be
fully separated. Using a UV light box, the 4.7kB fragment (the empty EGFP vector) was
cut from the gel with a scalpel. To purify the 4.7kB fragment from the 0.7% agarose gel,
0.5 mis of paper water (ddH20 containing shredded Whatmann paper) was added to a
1.0ml eppendorf tube with a small hole in the bottom. This was then placed inside a 2.0ml
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eppendorf tube and briefly centrifuged on a desk top centrifuge for 10 seconds. This
created a small paper filter in the base of the smaller tube. The larger tube was then
emptied and the 4.7kB agarose fragment was inserted into the tube containing the filter
and spun at 10,000rpm for 15 minutes. The liquid collected at the bottom of the larger
tube contained the purified plasmid. 8pl of this product was then run a 1% agarose gel to
confirm that the purification procedure was successful. 7.5pl of the plasmid was then used
for the ligation reaction (Table 5), which was performed overnight at 16°C. The plasmid
was then removed from the waterbath and stored at -20°C.
Aval Ncol
With P53 insert Without P53 insert With P53 insert Without P53 insert
1938bp 2290bp 1904bp 1904bp
1844bp 1938bp 1809bp 1809bp
1676bp 445bp 770bp 703bp
448bp 717bp 257bp
70 bp
Table 6. Restriction fragment sizes with the presence or absence of the P53 insert
Once the vector copy number was increased using the transformation and cloning
procedures (2.7), various checks were performed on the plasmid in order to confirm the
absence of the P53 insert. This was done using a variety of restriction enzymes followed
by sequencing. The restriction enzymes used were Avail (restriction site - G/GWCC) and
Ncol (restriction site - C/CATGG). These were set up in 20pi reactions (lpl vector, lpl
enzyme, 2pi buffer (xlO) and 16pl water) and run on 1% agarose gels (2.5.3). Table 6
shows the fragment sizes that reflected the presence or absence of the P53 insert. To
confirm absolutely the absence of the P53 insert, the vectors were then sequenced back
from exon 6 (using primer 6.1 - Table 3) over the ligation point. This technique followed
the same protocol as in 2.5.4/2.5.5, excluding the shrimp alkaline phophatase/exonuclease
I stage (there were no free ddNTPs in the vector solution). In addition, because the
plasmid DNA from each vector was extremely concentrated, only 0.5pi of dissolved
vector was required for the sequencing procedure (as opposed to 5pi of genomic DNA
from the cell lines). The sequencing protocol was otherwise unchanged.
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2.6.3. Construction of P53Mtl35EGFP vector
The p53Mtl35EGFP (5.9kbp) vector was constructed by removing the p53mtl35
sequence from a pCMV vector (also by Clontech) called pCMV-p53mtl35 (4.7kbp) and
ligating it into an empty EGFP vector. The P53 mutant contains a Gf]A mutation at codon
135 (TGCnTAC: Cysf]Val), resulting in a protein that can interact with wild-type P53
and inhibit DNA binding. Two enzymes were used for this assay, Hindlll (restriction site-
A/AGCTT) and BamHI (restriction site-G/GATCC). These were used to cut both pCMV-
p53mtl35 and pp53-EGFP. Both these vectors contained a Hindlll and a BamHI site at
either end of the P53 insert. Thus this restriction digest provided the corresponding
ligation points necessary for joining the p53mtl35 sequence to the empty EGFP vector.
5ql of each vector was used in the two restriction digests (Table 7). 0.7% agarose gels
were then run of the cut sequences to separate the inserts from the vectors (2.5.3). The
pp53-EGFP vector resulted in a 4.7Kb EGFP -containing fragment (similar to that in 2.6.2
with a different tail end sequence) and a 1.2 Kb fragment containing the wild-type P53
insert. The pCMVp53mtl35 vector resulted in a 3.5kBp fragment and a 1.2kb fragment
containing the mutant p53 insert. The EGFP 4.7kb fragment was then cut from the gel,
together with the 1.2kb mutantl35 p53fragment. These were then purified from the 0.7%
agarose as in 2.6.2 and ligated at 16°C overnight (Table 7). A greater amount of the 1.2kb
insert was introduced to the mixture to ensure no ligation of mis-matching base pairs at
the free ends of the 4.7kb EGFP vector. This would theoretically result in empty 4.7kb
EGFP vectors that would multiply during the cloning procedure. Following the ligation
procedure the samples were stored at -20°C.
After the transformation procedure (2.7.1), PCR reactions were set up using 10 random
colony lysates (a cocktail stick was inserted into the middle of each colony, mixed into
10ql of ddHaO and heated to 90°C) to amplify and detect the p53mtl35insert within the
EGFPvector. This was done using 2 primers, one of which recognised a sense sequence on
the CMV promotor region (CMVI) and antisense primer ex4.3 (on exon 4) which was
postioned well into the p53gene (630bp). The PCR reaction was set up as in 2.5.2. Once
the samples had been run on a 1% agarose gel (2.5.3), 2 positive colonies were chosen at
random, cloned, purified then sequenced from the anisense primer 6.1 (on exon 6) over
nucleotide 1017 to confirm the presence of the point mutation. Because the purified vector
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was sequenced directly, the protocol was followed exactly as that in 2.5.4./2.5.5.
excluding the shrimp alkaline phosphatase/exonuclease I stage.
Digestion of Digestion of pp53-EGFP Ligation of mtl35 insert
pCMVp53mtl35
81 pi ddH20






10pi buffer (xlO) -React 1
3pi Hind III
lpl BamHI




lpl 4.7kb empty EGFP
vector
0.5 pi T4 ligase
4pl buffer (x5)
Table 7. List of reagents for the creation of p53mtl35EGFP. All reagents are from Life
technologies unless otherwise stated.
2.6.4. Construction of P53Mtl44EGFP vector
The p53mutantl44 insert (mutation at codon 144: CAGnTAG) encodes a mutant p53
protein that is incapable of activating the down stream effector molecules of p53. It does
not have a dominant negative effect similar to the mtl35 protein. The mutantl44 sequence
was PCR amplified from the pC53-SCX3 vector, originally designed by Vogelstein et al
in 1990, and ligated into an empty EGFP vector. The pC53-SCX3 vector does not have
compatible Hindlll/BamHI restriction sites either end of the P53 insert that correspond
with sites on the empty EGFP vector. As a result, of the two primers used to amplify the
mutant 144 P53 insert, one contained a 'free' HINDIII site attached to the sense primer
sequence on exon 2 (2.1HIND)and the other contained a BamHI site attached to the
antisense primer sequence on exon 11(11.1BAM). The primer sequences are shown in
Table 8. An ACGT sequence was added to the restriction sites on each primer to aid
restriction enzyme recognition. A large volume PCR reaction was set up (100pi) in order
to amplify enough mtl44 insert for the ligation phase (Table 9). The PCR reaction was set
up for 30 cycles at 94°C for 30 seconds, 58°C for 30 seconds and 72°C for 1 minute for
each cycle. Once the PCR reaction was complete, 8pi of the product was run on a 1%
agarose gel (2.5.3) to confirm the size of the insert was correct (1.2Kb). The remaining
PCR product was digested using Hindll and BamHI restriction enzymes (Table 9) at 37°C
for 1 hour to clear the ligation ends of ddNTPs. Following this, a ligation reaction was
77
performed using the digested 1.2Kb fragment and the empty 4.7Kb EGFP vector from
2.6.3 that contained the appropriate compatible ligation points (Table 9). This reaction
was performed at 16°C overnight and then stored at -20°C preceeding the transformation
of chemically competent cells.
Ex2.1BAM 5' ACGTGAGATCCGTGGGGAACAAGAAGTGG
Exl 1.1 HIND 5' ACGTAAAGCTTCAGCCAGACTGCCTTCCG
Table 8. Primer sequences for the amplification of the mutant 144 vector. Restriction sites
are marked in Abold.
PCR of mutant 144 insert Digestion of mutant 144 Ligation of mtl44 insert
95pl ddH20 insert with EGFP vector
15pi reaction buffer 84pl mtl44insert PCR 14.5pi 1.2kb mtl44insert
24pi ddNTPs product 1 pi 4.7kb empty EGFP
7.5pi Ex2.1 HIND primer lOpl buffer (lOx, react 1) vector
7.5pl Exl 1.1BAM primer 1 pi BamHI 0.5pl T4 ligase
1 pi Taq polymerase 3pi Hindlll 4pl T4 buffer (x5)
1 pi pC53-SCX3 vector
Table 9. Reagent list for the development of p53mtl44EGFP. All reagents are from Life
technologies unless otherwise stated
To confirm the presence of the mtl44 form of P53, PGR reactions were set up, using 3
colony lysates (only 3 colonies grew on the plate), to amplify the fragment between sense
primer ex4.1 and antisense primer ex6.1 (Table 3). After the gel was run the samples
which contained a band at 518bp were digested with the enzyme Hhal. Hhal recognises
and cuts DNA at G/CGC. Because a vector containing the mutant 144 insert contains one
more GCGC site than the WT insert, this restriction digest could distinguish between the
two inserts should the WT insert have remained attached to the EGFP vector. The
mtl44PCR product cuts into a 320bp fragment plus 4smaller fragments, whereas the WT
fragments cuts into a 370bp fragment plus 3 smaller fragments. Once a sample was found
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to contain the 320bp fragment, ie. a mtl44 vector identified, the PCR product was
sequenced as in 2.5.
2.7. Cloning procedure
2.7.1. Transformation of chemically competent E.Coli
Invitrogen One Shot TOPIO chemically competent cells (Invitrogen BV, PO Box 2312,
9704 CG Groningen, The Netherlands) were transformed with the above plasmids (pp53-
EGFP, PO-EGFP, pp53mtl35-EGFP and pp53mtl44-EGFP). The ligation reactions were
thawed, centrifuged and placed on ice. For each transformation, one 50pl vial of One Shot
cells was also thawed on ice. 1 to 5pi of each ligation reaction was pipetted directly onto
the competant cells and mixed by gentle tapping. The remaining ligation mixture was
stored at -20°C. The vials were then incubated on ice for 30 minutes. Following this, the
vials were incubated for exactly 30seconds at 42°C in a waterbath then promptly removed
and placed on ice. 250pl of pre-warmed SOC medium was then added to each vial under
sterile conditions. The vials were then placed in a microcentrifuge rack on it side and
shaken at 37°C for lhour at 225rpm in a shaking incubator. Approximately 100pi of each
transformation mixture was then spread onto LB agar plates (12g bactoagarose in 1L
ddH20, autoclaved and poured into petri dishes)containing a 200pM concentration of
kanamycin. The plates were then inverted and incubated overnight at 37°C.
The following day colonies were picked and in some cases tested for the possession of the
appropriate insert (for the mutant vectors, see 2.6.3 and 2.6.4) using boiled cell lysates.
Single colonies derived from bacteria containing each of the 4 vectors were then picked
using cocktail sticks and placed in 500ml of nutrient broth (5g yeast extract, lOg
bactoagarose, lOg NaCl, 1L ddH20) containing 300pl (50mg/ml) kanamycin in 1.5L
conical flasks. These were then grown at 37°C for 12-16hours with vigorous shaking
(~300rpm) until a cell density was reached of approximately 2-4xl09 cells per ml.
2.7.2. Plasmid purification protocol
Plasmid purification was performed using a Qiagen Plasmid Maxi-prep kit (Qiagen,
Boundary Court, Gatwick Road, Crawley, West Sussex, UK). Each 500ml bacterial
suspension was divided between two 250ml sorvall containers and centrifuged at 6000g
for 15 minutes at 4°C using a Sorvall SS15 rotor. 5mls of resuspension buffer was then
added to each container and mixed to resuspend the pellet. The resulting lOmls of
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resuspended bacteria was then transferred to a 30ml centrifuge tube and lOmls of lysis
buffer added. The lysate was then mixed gently by inverting 4-6 times and incubated at
room temperature for 5 minutes. 4mls of precipitation buffer was then added and the
mixture was inverted 4-6 times and incubated on ice for 20minutes. A white fluffy
material then formed and the lysates became less viscous. This precipitated material
contained genomic DNA, proteins, cell debris and SDS. The mixture was then centrifuged
at 20,000g for 30minutes using a sorvall SS-34 rotor. While the lysate was being
centrifuged, lOmls of equilibrium solution was added to equilibrate the Qiagen-tip before
adding the dissolved plasmid DNA. The Qiagen-tip column contains a filter which traps
plasmid DNA. It flows automatically by a reduction in surface tension due the presence of
detergent in the equilibium buffer.
Immediately after the centrifugation process was finished, the supernatent (which should
be clear) was removed from the tube and pipetted into an equilibriated Qiagen-tip column.
Often a second centrifugation step was required to maximise transfer of plasmid DNA and
to remove as much protein as possible. Once the supernatent had passed completely
through the column, 20ml of wash buffer was added to remove any contaminants from the
plasmid DNA and to ensure all of the DNA had passed into the filter. The DNA was then
eluted by adding 15mls of elution solution to the column and collecting the eluate in
another 30ml tube. The DNA was then precipitated by adding 0.7 volumes (10.5mls) of
room-temperature isopropanol. The resultant solution was then mixed and centrifuged at
15000g for lhour at 4°C. A small white pellet should be apparent at the base of the tube.
The supernatant was then removed and 1ml of 70% ethanol was added in order to wash
the pellet. The pellet was then dislodged from the 30ml tube and transfered it to a 1.5ml
eppendorf tube. The tube was then centrifuged at 15000g for lOminutes using a benchtop
centrifuge. Once the supernatent was removed the pellet was airdried for 5-10 minutes and
0.5ml of ddHaO added. The plasmid could then be stored at 4°C until required.
2.8. Linearisation of EGFP vectors
2.8.1. ApaLI restriction digest
To increase the likelyhood of stable transfectants forming during the transfection
procedure (2.9.1 and 2.9.2), the plasmid only/ P53 signalling vectors were linearised. This
was done using a restriction digest using the restriction enzyme ApaLI (Table 10). One
suitable restriction site existed on all 4 vectors created. This site was situated on the pUC
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origin of replication for the propagation of E. Coli. This region was no longer required as
the cloning procedure had been completed. Once the restriction digest was complete (after
lhr at 37°C), a lpl sample was run on a 0.7% gel (for lhour). This was run to check that
the product was the correct size, 4.7kb in the case of the plasmid only vector and 5.9kb in
the case of the vectors containing the various P53 sequences. Non-linearised vectors are
usually supercoiled and do not run on agarose gels at the correct size.
Linearisation restriction digest
300pl plasmid
150pl buffer (xlO) (NEB)
15 pi BSA (xlOO) (NEB)
5 pi ApaLI (NEB)
1030pl H20
Table 10. ApaLI restriction digest
2.8.2. Precipitation of linearized vectors
The DNA was then precipitated and reconstituted to reduce the volume of the linearised
vector back to the original 300pl. This technique also removed any residual protein
present from the cloning procedure and also the restriction enzyme from the linearisation
digest. The 1500pl samples were split into 1.5 eppendorf tubes in 300pl aliquots and
300pl of Phenol and 300pl chloroform added to each. They were then spun at 10,000rpm
for 2 minutes and the top layer of transparent liquid transferred into separate tubes. Care
was taken not to disturb the intermediate layer containing any impurities such as protein.
60pl of Sodium Acetate (NaOAc) was then added to each sample together with 500pl of
100% ethanol. The samples were then mixed and spun at lOOOOrpm for lOminutes to
precipitate and pellet the plasmid. The supematent was then poured off and 70% ethanol
added to wash the sample. The plasmid samples were then spun again for lOminutes and
the supernatent removed. Following airdrying for 5 minutes, 60pi of ddH20 was added to
each of 5 tubes containing the same plasmid. These were then mixed together to produce
300pl of linearised plasmid. To determine the concentration of each of the four plasmids a
spectrophotometer was used.
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2.9. Liposomal Transfection of U87 and U373 cell lines
2.9.1. 24-Well Optimization Protocol using Lipofectin™ reagent
In order to optimise the quantity Liposome and plasmid DNA for maximum transfection
efficiency, a 24-Well Optimization Protocol was used. For each cell line to be tested a 24
well tissue culture plate was seeded with 2000 cells per well (DMEM with 10%FCS) and
incubated overnight at 37°C. The following day the cells were approximately 80%
confluent at the time of transfection.
To a 96 well plate, 20pl of serum free Opti-MEM medium was then added in a 6x4 format
to 24 wells (similar to that of a 24well plate). For each of the two 24 well plates 60pl of
Lipofectin™ reagent (LifeTechnologies Ltd) was diluted 1:5 with Opt-MEM medium
(LifeTechnologies Ltd) to a final volume of 350pl. From this solution, 5, 7.5, 10, 12, 5,
15, 17.5pi were then added to the appropriate wells of the 96well plate: one lipid volume
per column (Figure 7). The lipofectin mixes were then left to incubate for 30minutes at
room temperature. These dilutions give a final range of 1 to 3.5pl of stock lipid.
The DNA solutions were then prepared. The plasmid only vector was used to optimize
DNA concentration. For each 24 well plate to be tested, 1.4,2.8, 5.6, 8.4pg plasmid DNA
(calculated from a 1.22mg/ml plasmid-only stock solution) was pipetted into 140ul
volumes of Opti-MEM (giving a range of 0.2-1.2pg per 20pl well) (Figure 7). 20pl of
DNA solution was then added to the appropriate wells in the 96-well plate (one DNA
concentration per row) and incubated at room temperature for 45 minutes to allow DNA-
lipid complexes to form..
The cells in the 24well plates were then washed in PBS and incubated at 37°C in 5%C02
for 30minutes in Opti-MEM to remove traces of serum. 160pi of Opti-MEM was then
added to each lipid/DNA solution. The medium was then removed from the cells and the
lipid-DNA complexes added. The cells were then incubated for 4 hours in an a 37°C
incubator with 5%C02. Following this, the DNA/lipid solutions were removed from the
wells and replaced by normal growth medium containing serum and antibiotics. The cells
were examined after 24 and 48hours using fluorescent microsopy to assess transfection




0.2pg 0.4pg 0.8pg 1.2pg
Figure 7. Liposome/DNA concentrations in 24well optimization protocol
2.9.2. Transfecting cell lines using 8cm petri dishes
Once the optimum transfection concentrations of lipid and DNA were established, the
• 2
U87 and U373 cell lines were grown to 60% confluency in 8cm petri dishes in order that
a large number of cells could be transfected for experimental procedures. 3mls of opti-
MEM serum free medium was added to the cells 30minutes preceeding exposure to the
DNA/liposome complexes.
To set up the DNA/lipid complexes, 160pl of Opti-MEM was first added to small
universal containers for each dish to be transfected. The liposomal mix was then made
using Lipofectin™ reagent diluted 1:5 with Opt-MEM medium. 120pl of this was then
added to each universal container and incubated for 30minutes at room temperature. This
quantity corresponds with the 3 pi dilution as optimized from above (in bold). The stock
DNA solutions were then made up using the 4 linearized vectors at 9.6pg/160pl
(corresponds to the highest DNA dose from the optimization study). The plasmid stock
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solutions, as read on the spectrophotometer, were: plasmid-onlyEGFP, 1.22mg/ml;
p53WTEGFP, 1.28mg/ml; P53mtl35EGFP, 0.98mg/ml; p53mtl42EGFP, 1.15mg/ml.
Each 160pil dilution was then added to the universals and incubated for 45minutes at room
temperature. 1280pl of opti-MEM was then added to the DNA/lipid complexes. The
medium was then removed from the cells and the total volume of each universal added to
the cells for 4hours in a 37°C/C02 incubator. Following this, normal growth medium
medium was added to the cultures for 2 days.
2.9.3. Geneticin (G418) selective antibiotic response curve
Because spheroid cultures are grown for 6 weeks, it was important that stable transfectants
were developed. Transient transfections can lose their EGFP signalling probes thus
reverting them back to their WT genotype.
The neomycin resistance cassette (neor) within the EGFP signalling probe allows
geneticin (G418) resistance in eukaryotic cells. To establish the optimal concentration of
G418 required to maintain and select cells containing the neor cassette, a G418 selective
antibiotic response curve was created using the Wild-Type cell lines.
G418 antibiotic (Sigma) was diluted to a concentration of 50mg/ml in tissue culture grade
ddH20. A 24 well plate was then set up containing 200 cells per well in normal growth
medium and left to grow overnight in a 31°d5% C02 incubator. The following day the
medium was removed and 1ml of medium containing G418 was added to the wells. A
range from 100-1200pg/ml in 100pg increments was used. 2 wells were used for each
concentration. The medium was changed every 3 days and the appropriate dilution of
antibiotic added. After lOdays the medium was removed and the cells were washed in
PBS and stained with 0.5%methylene blue and 50% methanol for 20minutes. The plates
were then scored by calculating the percentage of survival by the number of individual
colonies for percent confluence. A dose response curve was then generated by plotting the
percentage of survival on the Y axis versus the concentration of G418 selective antibiotic
in pg/ml on the X axis. The minimum concentration at which 100% of wild-type cells
were non-viable was the concentration used to select for resistant neor containing cells.
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2.9.4. Selection procedure for transfected cells containing the neor cassette
48hours after the transfection procedure the G418 antibiotic was added to the 8cm culture
dishes. A concentration of 400pg/ml (6OO11M) G418 was chosen from the antibiotic
selection curve for both U87 and U373 cell lines. Following 4 days at this concentration
the cells in the petri dishes were washed with PBS and examined under the fluoresencent
microscope. As a result of the selection process, most of the cells that remained fluoresced
green. A cell scraper was used to disadhere each viable green colony from the bottom of
the dish and the cells were washed into separate petridishes. These were grown for 1
month in selective medium to ensure stable transfectant had been selected. Fortunately,
due to the high cell turnover, large numbers of stably transfected cells (derived from each
of the 4 vectors) were produced and could be used for experiments 1.5 months after the
initial transfection procedure.
The U87 and U373 transfected cell lines were grown as both monolayer and spheroid
cultures (2.1.2, 2.1.3 & 2.1.5). Spheroid cultures were grown for 3 weeks where they
reached a pre-necrotic state. They were then assessed immunhistochemically and by
immunoblot analysis for p53, Bax, p21, MDM2 and pl4 expression using the methods
described (2.2 & 2.3).
2.10. MTT assay
The proliferative rates of cultured cell lines (including transfected cell lines) were
determined using the MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) assay.
Cells were grown in 96well plates and supplemented with lOOpl of growth medium per
well. 50pl of MTT solution at a concentation of 1.5mg/ml of culture medium was
aliquoted into each test well using a multi-channel pipette (Titertek plus; ICN
biochemicals Ltd.) and the cells incubated at 37°C for 2 hours. Subsequently, 130pl of the
assay mixture was carefully aspirated from each well. The formazan crystals, produced as
a result of the activity of intracellular dehydrogenases, were solubilised by suspension in
150[il of dimethylsulphoxide contaiing 0.5%v/v FCS. The plates were then shaken at
room temperature on an orbital shaker for 15minutes to ensure complete dissolution of
the crystals and the absorbance of the resulting solution measured at 540nm on a
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microplate reader (model 450; Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire,
UK).
5 plates corresponding to days 0-4 were used for both the MTT assay and cell counts, with
8 wells employed for each sample cell line. Each well was plated at a density of 500
hundred cells per well. Every 48 hours the medium was removed and replaced by lOOpl
of fresh medium. At every 24hour interval 1 plate was removed from the incubator and
the cell number assessed using the MTT assay (4 wells) or by counting using a
haemocytometer (4 wells).
Cells to be counted were washed twice with PBS and incubated with 20pl of lxtrypsin -
EDTA for 2 minutes at 37°C. 80pi of growth medium was then added and the lOOpl of
mix was pipetted into the growth chamber of the haemocytometer. The cell counts were
used to validate the findings of the MTT assay for the assessment of cell proliferation and
were not used for every MTT assay performed in this study.
2.11. Light microscopy
2.11.1. Phenotypic characterisation of wild-type monolayer and spheroid cultures
All light microscopy and photomicroscopy was done using an Olympus BX40 microscope
with camera attachment.
Monolayer and spheroid wild-type cultures were initially examined and photographed for
GFAP, vimentin and Ki67 labelling in terms of the number of positive cells and intensity
of staining. The spheroid sections were also examined to establish the regional staining
patterns of TUNEL, Ki67, GFAP and vimentin staining. These were all recorded
photographically. This allowed comparisons to be made in terms of the qualitative
distribution of these markers between monolayer and spheroid cultures. Phenotypic
differences between the cell lines were also recorded.
Ki67 and apoptotic indices were quantitatively analysed for the monolayer cell lines. For
consistency with spheroid cultures, H&E morphological counts were used to assess
apoptotic index. A basic 'square grid' optical graticule was used to count ten 100pm




Figure 8. Diagram of the spherical graticule used for spheroid counts
H&E stained preparations were used for measurement of the radius of the spheroids for
each cell line at each given time point (over the 5 week period) using a graticule. The 10
largest spheroids were measured on each slide and the average taken. These sections were
also used to establish the time point for each cell line when a central area of cell death first
appears. The number of cells per spheroid were also counted to determine spheroid
packing density. This was done using a specially designed graticule (Graticules Division
Pyser-SGl Ltd, Edenbridge, UK), to count individual segments of each spheroid examined
(Figure 8). A segment representing 10% of the area of each spheroid was counted and the
10 largest spheroids (as above) from each slide were chosen. Morphological apoptotic
counts were also recorded using H&E stained sections using the above technique. An
apoptotic index was determined for each cell line as a percentage of total cell counts per
spheroid (AI).
2.11.2. Assessment of HIF-la expression in monolayer and spheroid cultures
A qualitative assessment of HIF-la distribution was recorded for the monolayer cultures
and wild-type spheroid cultures. Examination was particularly focused on spheroid central
regions and areas of necrosis in vivo. Wild-type monolayer cells were assessed to establish
basal levels of HIF-la expression.
2.11.3. Qualitative assessment of p53 and p53 related antigens in monolayer cultures,
spheroid cultures and human glioblastoma biopsies
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The immunohistochemical staining of biopsy sections, monolayer culture sections and
spheroid culture sections were assessed semi-quantatively according to staining intensity
(0 absent, 1 weak, 2 moderate, 3 strong) and by an estimate of the proportion of cells
staining (+ <25%, ++ 25-50%, +++ 50-75%, ++++ 75-100%). The presence of only
isolated positive cells was considered negative.
The expression of Bax, p21, MDM2 and pl4ARF was compared to the p53 status of the cell
lines used in the spheroid experiments and the extent of p53 protein expression in the
biopsy cases. Over expression of the p53 protein in morphologically healthy tumours cells
suggests the presence of P53 mutations (both the antibodies used in this study labelled
both mutant and wild-type p53 protein). For the purposes of statistical analysis the biopsy
cases were divided into two groups for each antibody, those with no, or focal expression
and those with higher expression. In the case of p53, where staining ranged from none to
very strong and diffuse, the low expression group was defined as those with scores of 0,
1+ or 2+ and the high expressor group as >2+. For p21, Bax and MDM2, expression was
generally weaker and more focal.
In addition to recording the staining intensity and number of stained cells, the distribution
of staining within the study material was also examined. Any enhancement of protein
expression was recorded within central regions of pre-necrotic spheroids and around the
perinecrotic zone in larger spheroid cultures (weeks 3-5) and biopsy material.
Enhancement of staining around the periphery of the spheroid cultures and any variation
in the cellular localization of the proteins was also recorded (eg.a nuclear to cytoplasmic
shift).
2.11.4. Analysis of cell death in spheroids transfected with wild-type and mutant P53
vectors
The U87 and U373 cell lines transfected with wild-type P53 vectors and mutant P53
vectors were labelled with H&E as in 2.2.1 and the size and apoptotic index recorded as in
2.11.1. The different clones could then be compared in terms of overall growth patterns
and type and extent of central cell death.
2.11.5. Analysis of p53 and p53 related antigens within transfected week 3 spheroids
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Week 3 spheroids derived from the U87 and U373 transfected cells lines were labelled
with p53 and p53 related antibodies. These could be compared in terms of level, intensity
and distribution using the same criteria as in 2.11.2. Particular care was taken to observe
any changes in protein distribution around central areas of necrosis.
2.12. Statistics
A split plot analysis of variance (SPANOVA) was used to assess the MTT data for the
four cell lines examined (MOG-G-CCM, U87, U373 and A172). The null hypothesis was
set up where 'total cell number remains the same between monolayer cell lines over the 5
day period'. After finding that Mauchly's test of sphericity was significant (establishes
that the values are spread within a normal curve), the F-ratio was obtained using the new
degrees of freedom calculated using the Huynh-Fel Epsilon value.
A split plot analysis of variance (SPANOVA) was used to assess the in situ cell counts,
apoptotic index results and growth data over the 5 week period of spheroid growth. To
analyse the in situ cell counts, the null hypothesis was set up where 'the total number of
cells per spheroid remains the same between cell lines and transfected cell lines over
time'. After finding that Mauchly's test of sphericity was significant (establishes that the
values are spread within a normal curve), the F-ratio was obtained using the new degrees
of freedom calculated using the Huynh-Fel Epsilon value. To analyse the distribution of
apoptotic index over time, the null hypothesis was set up where 'The apoptotic index of
each spheroid remains the same between cell lines over time'. After finding that
Mauchly's test of sphericity was significant, again the F-ratio was obtained using the new
degrees of freedom calculated using the Huynh-Fel Epsilon value. To analyse spheroid
size between cell lines over time, the null hypothesis was set up where 'The radius of each
spheroid remains the same between cell lines over time'. Again, after finding that
Mauchly's test of sphericity was significant, again the F-ratio was obtained using the new
degrees of freedom calculated using the Huynh-Fel Epsilon value.
A split plot analysis of variance was also used to assess the in situ cell counts, apoptotic
index results and growth data over the 5 week period of growth for U373 and U87
spheroids transfected with P53 wild-type and mutant vectors. The null hypotheses were
set up where 'The number of cells within spheroids derived from U87 cells transfected
with P53 wild-type and mutant vectors spheroids remain the same over time' and 'the
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number of cells within spheroids derived from U373 cells transfected with P53 wild-type
and mutant vectors remain the same over time'. Also the null hypotheses were set up
where 'The radius of spheroids derived from U87 cells transfected with P53 wild-type and
mutant vectors spheroid remain the same over time' and 'The radius of spheroids derived
from U373 cells transfected with P53 wild-type and mutant vectors spheroid remain the
same over time'. In addition, the null hypotheses were set up where 'The apoptotic index
of spheroids derived from U87 cells transfected with P53 wild-type and mutant vectors
spheroid remain the same over time' and 'The apoptotic index of spheroids derived from
U373 cells transfected with P53 wild-type and mutant vectors spheroid remain the same
over time'. After testing these hypotheses using the SPANOVA test, Mauchly's test of
sphericity was applied. After being found to be significant, the F-ratio was obtained using
the new degrees of freedom calculated using the Huynh-Fel Epsilon value.
To analyse the ultrastructural data (the electron microscopy), a Chi2 analysis was
completed to determine whether the observed apoptotic and necrotic indices where
significantly different between cell lines at week 3.
For the biopsy cases, distributions of high and low expression for different p53 related
antibodies (Bax, p21, MDM2) were compared with extent of p53 expression using the
Chi-squared test with continuity correction for small numbers. Multiple pairwise
comparisons were made and the Bonferroni correction procedure was used. Five
comparisons were made with each antibody, so that a threshold for significance of P =
0.01 was used.
All statistical analyses were performed with help from Dr Mark Walker at the Department







Most studies utilising the glioma spheroid system have focused on invasion and the
importance of certain extracellular matrix molecules (Bell et al., 1999; Terzis et ah, 1997;
Paulus et ah, 1994; Tamaki et ah, 1997). This is not surprising, due to the highly invasive
nature of the diffuse astrocytoma group of tumours. However, no studies, as yet, have
purely concentrated on the regulation of central cell death within glioma spheroids.
Studies using spheroids derived from other tumour types have previously examined
metabolite levels within populations of cycling, non-cycling and dying cell populations
(Durand et ah, 1998; Walenta et ah, 2000; Mueller-Kleiser et ah, 1986). These studies
have come to very interesting conclusions about the way in which tumour cell populations
respond to stress. A summary of these findings published in 2000, suggests that different
cell types possess different cell death responses to metabolic stress (Mueller-Klieser,
2000). For example, V79 hamster lung cancer spheroids form areas of central apoptosis
preceding changes which morphologically resemble necrosis. In contrast, other spheroid
types such as EMT6 sarcoma spheroids, exhibit massive necrosis as the preliminary cell
death event. The variation in the cell death responses of these two cell types suggests that
the pathways involved in activating cell death in these systems are different. To
investigate the development and control of cell death in glioblastoma spheroids it is
therefore vital to elucidate the primary cell death events. Because spheroid studies
examining endogenous patterns of glioma cell growth and death are rather limited, it was
first important to fully characterize the glioma spheroid system using a variety of cell
lines.
In the first part of this study, glioma spheroids derived from the cell lines U87, U373,
MOG-G-CCM and A172 were assessed over a 5 week growth period. The aims of these
experiments were (i) to determine the phenotypic similarity of glioma spheroids to
glioblastoma tissue in vivo (ii) to identify overall growth patterns and specific zones of
proliferation, differentiation and death (iii) to define the time course of the onset of central
cell death (iv) to establish the initial and subsequent modes of cell death employed by
cells in the centre of the glioma spheroids (v) to determine whether proteins that are
normally upregulated in response to metabolic stress in glioblastoma are associated with
these areas of cell death.
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3.2. Results
3.2.1. Phenotypic characterisation of monolayer and spheroid cultures
In monolayer culture, the 4 cell lines U87, U373, MOG-G-CCM and A172 exhibited a
mainly epithelial-like morphology. U373 and A172 cultures rarely contained cells
dissimilar to this, although a few cells exhibiting fibroblast-type (spindle shaped with
process formation) morphologies were seen. U87 cell line formed 3-dimensional
aggregates in monolayer culture, which would often dissociate from the culture flask
(Figure 9A). In between this 3-dimentional network, a fine mesh of fibroblast-like cells
grew across areas of the flask not inhabited by the epithelial-like cultures (Figure 9A).
MOG-G-CCM cells were the most phenotypically diverse in culture (Figure 9C), with
approximately 30% of cells exhibiting a fibroblast-like morphology and others with large
cell bodies, centrally located nuclei and up to 5-10 processes, imparting a morphology
similar to that of neurons.
Examination of spheroids derived from the 4 cell lines revealed that U87, MOG-G-CCM
and A172 shared almost identical phenotypic traits (Figure 10). Two days after seeding
the cells formed aggregates in culture, which after 7 days formed uniform spheres of a
similar size. These spheres continued to grow over the 5 week period in the same uniform
shape. In contrast, U373 formed spheroids after 7 days that were often irregularly shaped.
Examination under the inverted microscope revealed that this was due to small spheroids
(from days 1-3) sticking together to form irregularly shaped aggregates (Figure 14C). As
the U373 spheroids grew over the 5 week period, the shape of the aggregates did not
appear to become more complex. Therefore the initial 2-3 days of U373 culture seemed to
be the single time point when the small spheroids fused together. Because the U373
spheroids continued to grow in consistent shapes from this time point onwards,
measurements could be taken in cross-section at the narrowest point from the spheroid
periphery to the spheroid centre in an identical manner to the more spherical U87, MOG-
G-CCM and A172 spheroids.
In cross section, large spheroids (weeks 3-5) derived from all 4 cell lines appeared to
consist of 3 concentric zones. At the periphery, small, rounded cells were present. Inside
this layer of cells, a tightly packed layer of concentrically orientated, bipolar cells were
present, circling the spheroid centre (Figure 10C). These two zones were collectively
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Figure 9. Photomicrograph of U87 (A), U373 (B), MOG-G-CCM (C), A172 (D) monolayer cultures
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Figure 10. GFAP labelling in spheroid cultures. A, week 1 U87 spheroids showing random GFAP
labelling across the radius B, central labelling pattern observed at week 2 in U87 spheroids. C&D,
concentric arrangement of GFAP labelling around the spheroid centre from weeks 3-5 in U87 spheroids.
E&F, U373 spheroid exhibiting uniform GFAP labeling pattern at weeks 1 and 4 respectively. All
bars= 100pm.
termed the 'viable rim'. In the spheroid centre, areas of necrosis formed containing
numerous pyknotic and karyorrhactic cells (Figure 10D).
Ultrastructural examination of individual spheroids derived from the 4 cell lines revealed
that the cells formed intermediate junctions and became closely packed together as the
spheroids became larger (Figure 15A). This was particularly apparent within the viable
rim at weeks 3-4. The cells around the periphery of the spheroid became polarised with
the nucleus basally located towards the spheroid centre (Figure 15B). The cells situated
within the region of differentiation (GFAP positive cells) formed a concentric
arrangement around the spheroid centre (data not shown).
3.2.2. GFAP and Vimentin labelling
Expression of glial fibrillary acidic protein (GFAP) in the 4 cell lines, MOG-G-CCM,
U87, U373 and A172 confirmed their glial status in monolayer culture (Figure 9).
Staining was strongest in U373 and MOG-G-CCM (Figures 9B and C) cell line followed
by U87 cell line and A172 cell line (Figures 9A and D). A172 possessed isolated, strongly
labelled GFAP positive cells. Strong GFAP labelling was seen within the centre of the 3-
dimentional aggregates in U87 monolayer culture. In addition, flat, fibroblast-like cells
were observed in U87 and MOG-G-CCM cells and these labelled very strongly with the
GFAP antibody (Figure 9A). Approximately 60-90% of cells were weakly/strongly GFAP
positive in the four cell lines examined.
In spheroid cultures the distribution of GFAP labelling varied over the 5 week period. In
spheroids derived from the cell lines U87, MOG-G-CCM and A172, GFAP positive cells
were diffusely scattered across the radius of the spheroid at week l(Figure 10A). As the
spheroids became larger at week 2, GFAP labelling was observed in the centre of the
spheroids (Figure 10B). By week 4 GFAP positive cells were found in a ring around the
centre of the spheroid (Figure 10C and D), with loss of staining in the spheroid centre and
no labelling of the outer proliferating cells. In U373 cell line, strong GFAP labelling was
distributed across the entire spheroid mass from weeks 1 to 5 (Figure 10E and F). The
antibody against human vimentin demonstrated a similar pattern to GFAP although the
staining was fainter (data not shown).
96
3.2.3. Monolayer and spheroid growth kinetics
To assess cell proliferation in monolayer culture, accurate comparisons could not be made
between different cell lines using the MTT assay alone. This is because the activity of
intracellular dehydrogenases in different cell lines may vary. However, initial experiments
using cell counts in parallel with the MTT assay showed that in the case of the four cell
lines used in this study, the MTT assay was an accurate way of measuring the viable cell
population over a 5 day period (Figure 11A). The A172 cell line was found to have a
significantly faster growth rate than the other cell lines studied (p<0.01). This was
followed by U87 and U373 cell lines which had very similar growth rates. MOG-G-CCM
cell line possessed the slowest growth rate compared to the other 3 cell lines (p<0.01)
(Figure 11B).
The 4 cell lines showed similar shaped growth curves when grown as spheroids (Figure
12A). At the end of the first week the spheroids were approximately 100pm in diameter.
This increased over 4 weeks until the spheroids reached an average diameter of
approximately 1.2mm. There was a significant difference in the radius measurements
taken between A172 and MOG-G-CCM cell lines over time (p<0.01). A172 spheroids
grew to nearly 1.4mm in diameter compared to approximately 1mm by week 5 in the
MOG-G-CCM cell lines. There was no significant difference between U87 and U373 and
any of the other cell lines. Between weeks 1-3 the cell counts remained low (below or
around 2000 cells/spheroid). This was followed by a large increase in cell number from
weeks 3-4 (Figure 12B). By week 5 the cell numbers had plateaued out at approximately
10,000 cells per spheroid. The differences in cell number over time were statistically
significant over time between cell lines. A172 spheroids contained the largest number of
cells over the 5 week period compared to the other 3 cell lines (p<0.001) with a maximum
cell number of 14,000 cells at week 5. There was no significant difference in cell number
between U87, MOG-G-CCM and U373 cell lines. The low number of cells present
between weeks 1 and 3 was reflected in the packing density (number of cells per mm2),
which dropped considerably over this time frame (Figure 12C).
3.2.4. Ki67 labelling in monolayer and spheroid culture
Ki67 labelling was observed in the four cell lines as a granular nuclear stain (Figure 13).
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Figure 11. Graph showing the growth of U87, U373, MOG-G-CCM and A172 cells when grown in
monolayer culture. A, number of cells per well (n=10) over 5 days. B, optical density MTS reading
(n=10) over 5 days. Error bars illustrate the standard deviation from the mean.
Figure 12. Graphs showing the growth characteristics of U373, U87, MOG-G-CCM and A172 cell lines
when grown as spheroids. A, length of spheroid radius over time for each cell line. B, number of cells
per spheroid for each cell line over time. C, packing density for each spheroid derived from each cell
line over time (number of cells per mm2). D, extent of necrosis in each cell line over time, ie. the
percentage of the radius consisting of necrotic cells. E, graph showing the percentage of spheroids
(derived from all four cell lines) containing areas of necrosis over weeks 1-5. F, apoptotic index (AI) for
each spheroid derived from each cell line over time. N=10 for each point on the above graphs. Standard










U373 and A172 all had Ki67 labelling indices of around 65-70%, whereas MOG-G-CCM
cell line had a Ki67 labelling index of approximately 30%.
In spheroids derived from the above cell lines, the Ki67 antibody labelled cells randomly
across the radius of the spheroids with a similar distribution to GFAP but with a nuclear
pattern of staining at week 1 (Figures 14A and C). However, by week 2 Ki67 was
confined to the perimeter of the spheroids and no positive cells were observed in the
centre (Figures 14B and D). This proliferative rim was approximately 100pm in diameter
and was consistent in all of the cells lines examined. Because of the irregular shape of
U373 spheroids, the Ki67 peripheral labelling was often not as evenly distributed as with
the other cell lines (Figures 14C and D).
3.2.5. Qualitative analysis of cell death in monolayer and spheroid cultures
In monolayer culture, random apoptotic cells were observed in each of the cell lines at
80% confluence. These were identified by the appearance of pyknotic nuclei, nuclear
fragmentation and/or membrane blebbing (Figures 16A and B).
In spheroid culture, central cell death developed over week 3 in all four cell lines
examined although the spheroids varied in size at this time point (approx.600pm-800pm).
The extent of necrosis varied considerably between lines (Fig 12D). At week 3 nearly all
the spheroids derived from each cell line contained areas of necrosis (Figure 12E). Thus
necrosis could be accurately predicted at a certain time point and size for each cell line.
By week 5 the areas of necrosis were very large in 3 of the 4 cell lines, U87, MOG-G-
CCM and U373 (Figure 12D). Although unlike U87 and U373 spheroids, some cellular
regrowth appeared in MOG-G-CCM line over week 4. The remaining cells became
closely packed together around the periphery thus no significant changes were observed in
overall packing density (Figure 12C). A172 exhibited a different pattern of necrosis where
the percentage of the radius that was necrotic over weeks 3-4 did not increase above 10%
(Figure 12D).
Using week 3 spheroids it was possible to identify three morphological types of cell death
using electron microscopy. The first type was characteristic by large swollen cells,
dilation of organelles and break up of the cell membrane, features typical of necrosis
(Figure 15C). The second type was characteristic of apoptosis: electron dense cells
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Figure 13. Ki67 labelling in monolayer culture. A, U87 cell line (65% labelling index). B, U373 cell line
(70% labelling index). C, MOG-G-CCM cell line (30% labelling index). D, A172 cell line (70%
labelling index). All bars=l OOgm.
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Figure 14. Ki67 labelling in spheroid cultures. A, week 1 U87 spheroids exhibing a random distribution
of Ki67 positive cells. B, peripheral localization of Ki67 positive U87 cells (week 3). C, an irregularly
shaped week 1 U373 spheroid exhibiting a random distribution of Ki67 labelling. D, peripheral
localization of Ki67 positive U373 cells (week 3). All bars= 100pm.
Figure 15. Electron micrographs showing A, an intermediate junction formed between adjacent cells in
A172 cell line (x 51000). B, a MOG-G-CCM cell showing evidence of nuclear polarization and
autophagic activity (x 16000). C, an A172 necrotic cell (x 16000). D, a U373 apoptotic cell (x 16000).
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Figure 16. Photomicrographs of A, an H&E stained apoptotic cell in monolayer culture (U87)
(Bar=20pm). B, an H&E stained apoptotic cell in monolayer culture (U373) (Bar=20pm). C, a TUNEL
labelled U87 (week 3) spheroid (Bar= 100pm). Arrow points to a TUNEL negative apoptotic cell.
(resulting from cell shrinkage), condensation of chromatin, nuclear fragmentation and a
convoluted cell membrane (Figure 15D). A distinct pattern of cell death emerged where
the central area of cell death was necrotic and apoptotic cells were seen scattered in the
surrounding viable rim. This pattern was present in all of the cell lines examined.
A third type of cell death observed was termed vacuolar cell death. Here, the cells
contained huge vacuoles, which often appeared to arise from the dilation and fusion of
organelles. The cytoplasm was very electron dense and the cell membrane appeared to be
intact, although in some instances a slight blebbing effect was observed (Figure 15E).
In addition, an autophagic morphology was identified in some cells (Figure 15F). This
phenotype was present in all of the cell lines to some extent, but was particularly prevalent
in MOG-G-CCM cell line. It was not clear whether these cells were involved in a cell
injury/death response. These cells contained lysosomal vacuoles, often containing myelin
whorls or fragments of organelles. In addition, these cells were often slightly more
electron dense then normal cells although it was unclear whether this was due to cell
shrinkage. In the MOG-G-CCM cell line, some cells in the proliferative zone exhibited
this phenotype.
TUNEL labelling was present in the centre of week 3 to week 5 spheroids in all of the cell
lines (Figure 16C). These were cells which had ultrastructurally been shown to have a
necrotic pattern of cell death. Scattered cells within the viable rim and zone of
differentiation were also observed, although there was a sharp decline in TUNEL labelling
from the centre of the spheroid to the periphery. Close examination using high power light
microscopy revealed that many apoptotic cells around the spheroid centre were not
TUNEL positive. For this reason, the TUNEL results were not quantitatively assessed.
3.2.6. Quantitative assessment of cell death in monolayer and spheroid cultures
The mean apoptotic indices of the four cell lines differed in monolayer culture. U373 cell
line and MOG-G-CCM cell lines had the highest apoptotic indices at 1.0% and 0.9%
respectively. U87 and A172 cell lines had lower apoptotic indices at 0.5% and 0.2%
respectively (Table 11). Approximately 1000 cells were counted for each cell line.
106
In the spheroid cultures, morphological counts of apoptotic cells using H&E stained
sections showed that at weeks 1-2 the apoptotic index was between 0.04% and 0.05% for
all of the cell lines studied (Table 11). This increased by week 3 once the central core of
cells had begun to necrose. By week 5, the apoptotic index had increased, ranging from
0.61% in A172 cell line to 2.75% in U87 cell line (Figure 12F and Table 11). Statistical
analysis revealed that at week 5, U87 had a significantly higher apoptotic index over time
than the other 3 cell lines (p<0.001). A172 had a significantly lower apoptotic index than
U373 and U87 cell lines (p<0.001).
Cell line Monolayer Week 1 Spheroid Week 5 Spheroid
U87 0.50±0.16% 0.04±0.02% 2.75±0.23%
U373 1.00±0.21% 0.05±0.02% 1.60±0.19%
MOG-G-CCM 0.90±0.18% 0.04±0.02% 0.84±0.11%
A172 0.20±0.13% 0.04±0.02% 0.61±0.08%
Table 11. Table showing the apoptotic indices (using morphological counts) of
monolayer, week 1 spheroids and week 5 spheroids in the cell lines U87, U373, MOG-G-
CCM and A172 (±SEM).
For spheroid cultures at week 3, the numbers of cells demonstrating each type of cell
death/injury on ultrastructural examination were recorded for each cell line (Table 12).
This was done using the above described criteria (i.e., apoptosis, necrosis, autophagic and
lysosomal cell death). The distribution of apoptotic versus necrotic cells was compared
across the cell lines at week 3 and the results statistically analysed. Relative levels of
apoptosis and necrosis were found to differ between cell lines (p<0.001). The largest
contribution to this variation was accounted for by A172 which demonstrated the largest
number of necrotic cells. The remaining cell lines still showed a significant variation in
the proportions of apoptosis vs. necrosis (p<0.05), accounted for by higher levels of
apoptotic cells in U87. Therefore the apoptotic indices graphed at week 3 in Figure 12F
are lower than those in Table 12. Due to better resolution, larger numbers of apoptotic
cells were identified using EM than found with the apoptotic counts using the H&E
stained cells. Overall, the electron microscopy results compared favourably with levels of
cell death found using light microscopical techniques. The latter was found to be the best
way of assessing apoptosis and necrosis, because large numbers of spheroids could be
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examined. The distribution of autophagic and vacuolar phenotypes were not analysed
statistically, but the vacuolar morphology was observed most frequently in U87, and
autophagic cells were observed most frequently in MOG-G-CCM cell line.
Cell line Apoptosis Necrosis Autophagic Vacuolar
U87 52 35 5 18
U373 37 46 2 4
MOG-G-CCM 11 21 21 8
A172 6 67 2 0
Table 12. Levels of apoptotic, necrotic, autophagic and vacuolar cell death phenotypes
observed per spheroid using electron microscopy.
To further quantify apoptosis and necrosis in glioma spheroids, Annexin V flow
cytometry was employed. Although this method confirmed that the proportions of non¬
viable cells present in spheroids increased over time, it did not distinguish between
apoptosis and necrosis in a substantial proportion of the cells analysed (Figure 17). All
cells derived from spheroid cultures were either labelled with both Annexin V and
propidium iodide or neither (the healthy cell population). It is possible that the
trypsinisation process required for disaggregation was too aggressive causing
permeablization of the cell membranes of non-necrotic cells allowing the entry of
propidium iodide. Monolayer experiments using the same techniques showed valid
apoptotic cell populations, suggesting that the high trypsin concentrations required for
spheroid disaggregation may be the reason for the lack of detection of an apoptotic cell
population in these experiments. Morphologically, viable and nonviable cells in spheroid
cell populations were distinguished by their laser scatter characteristics. Using the U87
cell line as an example, two distinct populations with different forward and side scatter
were observed in disaggregated spheroid cell populations (Figure 17B1 and 5). The
Annexin V labelling in the total cell populations are shown in Fig 17B2&6 and was
1.68%+/- 0.53% at 2 weeks in U87 spheroids and 7.68%+/-4.16% at four weeks of culture
of the same U87 spheroid preparation. This therefore shows a decrease in cell viability in
U87 spheroid cultures over 2 weeks of approximately 6%. During spheroid culture, U373
and MOG-G-CCM had similar decreases in viability (5-6%) and A172 spheroids had an
overall decrease in viability of 3.5%+/-!.2%. The use of flow cytometry in this study
108
B
Figure 17. A, Annexin V/propidium iodide labelled U87 cells (Bar=20pm). B, flow cytometric analysis
of the U87 cell line grown as spheroids at week 2 (1-4) and week 4 (5-8). 1 & 5 are the flow laser
scatter characteristics where SS= side scatter and FS= forward scatter. 2 & 6 show the Annexin V
labeling index of the whole cell population in each group where v= viable cells and nv=non-viable cells.
3 & 7 show Annexin V labelling in the viable cell population (population n from scatter plot A). 4 & 8
show the number of cells Annexin V positive in the non-viable cell population (population nv from
scatter plot 5).
allowed the proportion of dead cell cells to be identified. However, the type of cell death
occurring was not distinguishable.
3.2.7. HIF-a expression in monolayer cultures, hypoxic monolayer cultures and spheroids
Very little endogenous HIF-la expression was present in untreated U373 and U87
monolayer cultures. Darker labelling was however visible within the 3-dimensional
aggregates present in U87 monolayer cultures (Figure 18C).
HIF-la expression was upregulated in response to hypoxia in monolayer U87 and U373
cell cultures (Figures 18A and B). Western blotting experiments showed that HIF-la was
present after one hour exposure to 0.5% oxygen and this increased over a 24hour period.
HIF-la was therefore upregulated irrespective of the p53 status of the cell lines.
HIF-la expression was upregulated in the centre of spheroids derived from the two cell
lines U87 and U373 (Figures 18D and E). Similar experiments were not performed on
MOG-G-CCM and A172 cell lines. Positive nuclei were identified in a small number of
cells in the centre of the spheroids at week 3. Where necrotic cell loss had occurred, a few
positive cells were scattered amongst the perinecrotic tissue. Levels of HIF-la expression
increased over time as the spheroids became larger. By week 5, when the necrotic central
regions of spheroid derived from the cell lines were very large, HIF-la expression was
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Figure 18. HIF-la expression in U87 and U373 cell lines. A, western blots shows an upregulation in
HIF-la (120kDa) expression in U87 (A) and U373 (B) cell lines in response to hypoxia (1-5=0, 1, 2, 6,
24hrs exposure to 0.5% O2). C, HIF-la immunopositivity in the centre of U87 monolayer aggregates. D
and E, week 3 U87 and U373 spheroids with central HIF-1 a labelling. F, week 5 U87 spheroid showing
HIF-1 a positive cells adjacent to the proliferative rim (N=necrosis). All bars= 100pm.
33. Discussion
3.3.1. Summary of results
The phenotypic organisation of growing glioma spheroid cultures have been established in
this section. The morphology of glioma spheroid cultures was shown to compare
favourably with the organisation of glioblastoma tissue in vivo, from the initial avascular
growth stage of maligancies to the arrangement of heterogeneous cell populations as
determined by the distance from the vasculature These heterogeneous cell populations
were observed as regions of peripheral proliferation, GFAP positive non-cycling cells and
a central core of cell death. Central cell death occurred at the same time point (week 3) in
all four cell lines examined and was initially observed as necrotic foci which became
enlarged as the spheroids increased in size. Subsequent increases in apoptotic index were
observed around this area of necrosis. HIF-la, which is expressed in response to
hypoxia/hypoglycaemia in many cell types (Moley and Mueckler, 2000; An et al., 1998),
was present in central regions from week 3 onwards.
3.3.2. Morphology and differentiation of glioma spheroid cultures
As multicellular tumour spheroids grow larger in culture, they become spherical creating a
diffusion-limited tissue model where spatially distinct regions proliferation,
differentiation, non-cycling cells and dying cells can be monitored in a concentric pattern
outwards from the spheroid centre. It is thought that these three dimensional aggregates
retain characteristics similar to in vivo tumour cell populations which co-exist at varying
distances from the vasculature. The brain tumour spheroids grown in this study showed
similar characteristics. Monolayer cultures derived from the four cell lines U87, U373,
MOG-G-CCM and A172, exhibited markedly different cellular morphologies. However,
as multicellular spheroids, all exhibited similar phenotypes, both at early and late stages of
development. Therefore, spheroids derived from different cell lines, like individual
tumours with different genetic backgrounds, formed tumour cell populations with a
phenotypically similar end point. In addition, the concentric arrangement of
heterogeneous cell populations within each spheroid could be compared with similar areas
of heterogeneity in vivo. Other morphological observations such as the presence of
intermediate junctions within the central spheroid regions confirmed this system as a good
phenotypic representation of glioblastoma.
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GFAP expression was observed in three of the cell lines (U87, MOG-G-CCM and A172)
in an intermediate zone between the spheroid centre and periphery. In these cultures, the
outer proliferative zone did not express GFAP. This is consistent with reports that GFAP
is rarely expressed in cycling cells in human glioma in vivo (Schiffer et al., 1986;
Kleihues et al., 2000). The cell line U373 did not exhibit this pattern of GFAP labelling.
GFAP positive cells were observed throughout the spheroid mass irrespective of their
position. It is unclear why this is the case. Because U373 spheroids are irregularly shaped
compared to spheroids derived from the other lines, the distinct concentric arrangement is
not as pronounced. Therefore, it is possible that the distribution of metabolites within the
spheroid mass may not occur as a uniform decrease from the spheroid periphery to the
centre. However, other evidence such as the distribution of the proliferating cell
population and position of regions of cell death suggests this is unlikely. In addition, U373
cell line exhibited the greatest number of GFAP positive cells in monolayer culture
(>80%), and a Ki67 labelling index of approximately 60%. This suggests that some U373
cells are cycling and expressing GFAP simultaneously.
3.3.3. Growth characteristics of glioma spheroid cultures
Past research has shown that if spheroids are cultured from genetically stable cell lines at
low passage numbers, spheroid growth kinetics and histological structure are relatively
reproducible. This means that volume growth kinetics, viable rim thickness and
onset/diameters of necrosis averaged over a certain number of spheroids are relatively
invariant between different sets of experiments (Mueller-Klieser, 2000). However, in
some cases a considerable amount of inherent variance, is present between individual
spheroids within the same culture, particularly in terms of spheroid size (Acker et al.,
1984). In terms of growth measurements in this study, these findings were not relevant as
the 10 largest spheroids from each weekly sample were used for further analysis.
Variation between cell lines and different cell types is to be expected.
All four cell lines showed identical patterns of proliferation. Ki67 positivity was restricted
to an outer zone of 100pm in width, thus implying that the cell lines required similar
metabolic requirements in which to stimulate proliferation around the nutrient rich
periphery of the spheroids. Within the proliferative zone, virtually all cells were Ki67
positive. Because the diameter of the proliferative zone was limited to 100pm, the ratio of
the proliferative zone to total volume decreased as the volume of the spheroid increased.
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The consequent decline in growth fraction would itself therefore contribute to the slowing
of overall growth at high volumes in spheroids, as in solid tumours. The diameter of the
proliferative zone itself may well be a reflection and measure of the ability of tumour cells
to proliferate under conditions of variable metabolite accessibility. Thus together with the
cell death response, ability to proliferate under less than optimal conditions may be
another way by which the tumour cells response to stress determines the growth
characteristics of the tumour. These findings are consistent with the proliferative
characteristics of cell lines derived from other glioma cell lines (Tamaki et al., 1997). All
the cells situated inside the proliferative zone were essentially quiescent.
Although complex growth dynamics were not analysed using this system, there were
some basic differences between the cell lines in terms of overall growth. A172 cell lines
showed significantly increased growth rates compared to the other lines in monolayer
culture and similar findings were observed in spheroid culture. Although the thickness of
the proliferative band remained consistent in all four cell lines, the A172 cell line grew
larger as spheroids than the other three cell lines (up to a diameter of nearly 1.4mm
compared to an average of 1mm for the other lines). This was not due to any increases in
cell size as the cell packing density remained consistent between the four cell lines. Cell
number was consistently higher in A172 spheroids from weeks 4-5 of spheroid culture. It
was thought that less overall cell loss occurred within spheroids derived from A172 cells.
3.3.4. Phenotypic onset of central cell death
The predictable onset of cell death in this model has allowed for the examination of the
earliest structural changes present in the central regions of brain tumour spheroids as they
become larger. Ultrastructural examination of the spheroids at 3 weeks, when onset of
necrosis occurred in all four cell lines, revealed the presence of both apoptotic and
necrotic cells in a particular pattern. In all four cell lines cell death in the centre of the
spheroids was necrotic in type (Figure 19). Apoptotic cells surrounded this area and
decreased in number towards the spheroid periphery. The cells within the central area of
cell death were labeled with the TUNEL reaction, despite the fact that death in this area
was proven ultrastructurally to be necrotic. The TUNEL method has previously been
shown to lack specificity, in that it may label necrotic as well as apoptotic cells (Grasl-
Kraupp et al., 1995; Gold et al., 1994). In our system too, TUNEL lacked the ability to
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discriminate between different cell death patterns. It may also label very actively
transcribing nuclei (Kockx and Knaapen, 2000).
Figure 19. Distribution of necrosis (N), apoptosis (red spheres), region of differentiation
(D) and region ofproliferation (P) through a quarter cross-section of a glioma spheroid
It was hypothesised that the area of central cell death might arise by apoptosis rather than
necrosis. Sublethal injury may induce apoptosis in a variety of settings including hypoxic
states in vivo (Ruan et al., 1999; Banasiaka et ah, 2000) and in cell lines grown in
monolayer culture (Lennon et ah, 1991). In the case of the spheroid model, an increase in
cell stress associated with increasing diameter might initially be expected to produce a
sublethal insult. Certainly, in some spheroid systems the onset of an apoptotic response
preceeding a necrotic response, appears to occur. For example, in rhabomyosarcoma
spheroids the occurance of central apoptosis preceeds the onset of central necrosis
(Mueller-Klieser et al, 1997). V79 hamster lung spheroids also show pre-necrotic,
centrally located increases in TUNEL positive cells (Mueller-Klieser et al, 1997).
However, in the glioma spheroid cultures in this study, the central area of cell death
appeared necrotic at the earliest time point, although a few admixed cells with apoptotic
morphology were seen. This was apparent in all four lines examined. There is emerging
evidence that apoptosis and necrosis are not entirely distinct processes, but may coexist,
with the energy status of the cell determining whether apoptosis or necrosis occurs (Leist
et al., 1997; Nicotera et al., 1997). Thus, an initially apoptotic process might become
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necrotic. Such a pattern has been documented in human and experimental myocardial
infarction (Veinot et al., 1997; Olivetti et al., 1996; Akiyama et al., 1997). A very early
apoptotic phase preceeding necrosis cannot be entirely excluded in this glioma spheroid
model, but certainly completion of cell death for most of the central cells is necrotic in
type, indicating that central energy depletion rapidly becomes too severe to allow an
apoptotic mode of death. EMT6 spheroids show a similar cell death phenotype to glioma
spheroids, where sudden onset of necrosis occurs without any pre-apoptotic phase. EMT6
spheroids exhibit a rapid reduction in ATP levels immediately before the onset of
necrosis. The morphological similarities between the two systems again suggests a sudden
decrease in energy levels leading to a primary centrally located necrotic response in
glioma spheroids.
Although variations existed between cell lines, nearly all the apoptotic cells observed
within the spheroids were surrounding the central area of necrosis. This could be a result
of sublethal injury to these cells as the radius of the spheroid became larger. However, this
seemed unlikely as apoptosis was not stimulated to any great extent when the central
regions of pre-necrotic spheroids were subjected to a similar stress. It is likely that
necrotic tissue in the centre of the spheroids may have stimulated an apoptotic response in
surrounding cells, suggesting the presence of a relationship between the two processes.
Products of phospholipase degradation of membranes and reactive oxygen intermediates
released during necrosis are possible candidate pro-apoptotic agents (Leaver et al., 1998).
This is supported by the increase in the number of apoptotic figures observed elsewhere
within the spheroid cell mass from weeks 3-5, after areas of necrosis have formed.
Whereas the apoptotic index was nearly zero from weeks 1-2, the index rose rapidly
following the onset of necrosis.
Although necrosis was the predominant form of centrally located cell death in spheroids
derived from all 4 lines, ultrastructural examination revealed two other cell injury
morphologies. In one process, termed vacuolar cell death, contained huge vacuoles, which
often appeared to arise from the dilation and fusion of organelles. The cytoplasm was very
electron dense and the cell membrane appeared to be intact, although in some instances a
slight blebbing effect was observed. Some of the features appeared intermediate between
classical apoptotic and necrotic morphologies and it was thus difficult to classify this form
of cell death. Vacuolar cell death patterns were mostly associated with the U87 cell line
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and were observed mainly in the centre of the spheroid admixed with necrotic cells.
Examples of non-apoptotic/necrotic cell death featuring cytoplasmic vacuolation have
been observed in other biological systems and pathologies, such as neural development
and degeneration (Clarke,1998), in vivo rat hepatocarcinoma when exposed to SBA
(sodium 5,6-benzylidene-L-ascorbate) (Asano et al., 1999) and in neurons in patients with
ALS (amyotrophic lateral schlerosis) (Mourelatos et al., 1996). It is interesting that the
latter two circumstances involve the abnormal production of free radicals (ascorbate
radicals and H2O2 in hepatocarcinoma experiments and hydroxyl radicals in the ALS
patients). Perhaps, like the onset of apoptotic cell death as described above, the close
association of perinecrotic cells to the toxic waste products of the necrotic tissue resulted
in this phenotype in spheroid cultures. A vacuolar morphology is also associated with a
type of cell death termed 'parapoptosis' (Sperandio et al., 2000). Again, this phenotype
was identified in neurons during development and in some cases of neurodegeneration.
'Parapoptosis' is associated with a caspase-9 activity which is Apaf-1 independent
(Sperandio et al., 2000; Wyllie and Golstein, 2001). It is possible therefore, that the
vacuolar phenotype observed in spheroid cultures may have arisen via a cell death
programme distinct from those normally associated with apoptosis or necrosis.
Another phenotype that was particularly prevalent in the MOG-G-CCM cell line was
characterised by the presence of abundant myelin-like membrane whorls within the
cytoplasm. It was unclear whether this autophagic pattern was an injury response which
would eventually lead to the death of the cells concerned, as many of the cells around the
periphery of the spheroids derived from MOG-G-CCM cell line also express this
autophagic pattern as well as cells towards the centre. Similar autophagic patterns of cell
injury have been observed in developing neurons (Clarke, 1998).
The significance of the varying morphological patterns which we have observed in the
spheroid model suggests that there may be other mechanisms and/or intermediate
phenotypes involved in cell death in glioma besides those of necrosis and apoptosis.
3.3.5. Quantitative analysis of cell death
Even though the four cell lines used in this study were derived from different tumours,
onset of central cell death occurred over week 3 in all 4 lines. Around 60% (38% in A172
cell line to 80% in U87 cell line) of spheroids derived from the 4 cell lines possessed
117
some element of cell loss from central regions. The remaining 40% of spheroids contained
central regions phenotypically consistent with dead or dying cells. An element of
variability within spheroid cultures derived from each cell line is to be expected as the
spheroid diameters vary by a coefficient of approximately 8% at this time point, despite
being selected for their size.
Although central cell death appeared in all of the cell lines at week 3, the spheroids
exhibited marginal differences in size. A172 cell line for example, had a diameter of
nearly 800pm whereas MOG-G-CCM cell line had a diameter nearer 600pm. These
measurements are crucial as the spheroid radius is the limiting factor for the passage of
metabolites from the spheroid periphery to the centre. These results are at the upper end of
the scale compared to spheroids derived from other tumour types. Spheroids derived from
WiDr human colon carcinoma cells and EMT6 mammalian sarcoma spheroids begin to
necrose at diameters of 400-500pm (Mueller-Klieser, 2000). MR1 oncogene-transformed
rat embryonic fibroblast spheroids are a similar size to glioma spheroids at onset of
necrosis at around 700-800pm (Mueller-Klieser, 2000). As the glioma spheroids increased
in size, the extent of central necrosis varied between cell lines over time. In A172 cell
line, the central necrotic area remained small over time (<10%) but in the other cell lines
this area increased to over 60% by week 5. This is surprising as in other spheroid systems
including U87, U373 and MOG-G-CCM spheroids the area of necrosis increases in size at
almost exactly the same rate as the whole spheroid (Mueller-Klieser, 2000). As a
consequence, the thickness of the viable rim remains constant at various spheroid sizes.
Centrally located cells in the A172 spheroid therefore appeared to be more resistant to
death than the other 3 glioma cell lines.
Apoptotic index over time was measured using 3 techniques, morphological counts using
H&E stained sections, TUNEL labeling and Annexin V flow cytometry. Using H&E
staining stained sections, significant differences in apoptotic index between cell lines were
observed. Between weeks land 2 the apoptotic index in all of the cell lines was nearly
zero but by week 3, U87 spheroids had significantly more apoptotic figures than the other
three cell lines. U373 and MOG-G-CCM cell lines had intermediate levels of apoptosis.
A172 had the least number of apoptotic figures over time and this was confirmed by the
ultrastructural data at week 3. Annexin V flow cytometery reflected these results in terms
of cell viability i.e. U87, MOG-G-CCM and U373 lines had significantly larger non-
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viable cell populations over time compared to the A172 cell line. However, it could not
distinguish accurately between apoptotic and necrotic cell populations due to membrane
damage during trypsin disaggregation. As TUNEL was not accurate in labelling all of the
observed apoptotic figures present and often labelled necrotic cells as well as apoptotic
cells, H&E stained sections of paraffin embedded spheroids proved to be the best method
of quantifying apoptosis in glioma spheroids.
Overall, A172 showed decreased susceptibility to cell death compared to the cell lines
U373, MOG-G-CCM and U87, and this was reflected in terms of apoptotic index and the
extent of necrosis. This reinforced the earlier evidence suggesting that necrosis may play a
role in the stimulation of apoptosis in this model. It certainly implies that inducible
apoptosis in the glioma spheroid system does not occur independently of necrosis.
3.3.6. Spheroid metabolism and HIF-la distribution within glioma spheroids
It is not surprising that for many years the development of central necrosis was attributed
to an insufficient oxygen supply. Recent evidence has shown that this may not necessarily
be the case. Most spheroids that are commonly used in such studies have not shown a
particularly hostile intra-spheroidal environment that would induce either cell-cycle arrest
in the areas within the proliferative rim, or central cell death. It has been demonstrated in
many spheroid types, that cells inside the proliferative zone adapt their metabolism to
specific environmental conditions in a 3-dimensional arrangement by reducing their
metabolic turnover rates (Mueller-Klieser, 1997). Other factors, such as cell-cell and cell-
matrix interactions, availability of growth factors, expression and accessibility of growth
factor receptors and adhesion molecules may be involved in emergence of cell cycle arrest
in these spheroids thus preparing them for an environment that would otherwise be highly
toxic if they were rapidly proliferating (Mueller Klieser, 1997). Because the metabolic
requirements of such cells are so low, these cells become resistant to both various
intratumoural stresses but also to various therapeutic drugs (Acker et al., 1984). Onset of
necrosis is likely to be the result of a variety of factors leading to a sudden drop in ATP
content as mentioned previously. This variety of factors are likely to include a sudden
reduction in oxygen and glucose content plus an increase in highly toxic acidic waste
products (Mueller Klieser, 2000). A variety of studies have shown that glucose, oxygen
and ATP content can remain at normal levels up until just before a necrotic response
occurs (Mueller Klieser, 2000; Durand et al., 1998; Walenta et al., 2000). This supports
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the earlier findings in this study, where increases in apoptotic index are not observed until
a core of central necrosis appears. Then, toxic waste products and subsequent acidosis and
free radical production from the necrotic core may be to blame.
The only way of absolutely determining the metabolite and waste product distribution is
to measure intraspheroidal O2, glucose and lactate levels. However, because HIF-la
(hypoxia inducible factor 1 alpha) expression is seen to increase in response to glucose
deprivation and hypoxia (<0.05%pC>2) in glioma cells in vivo and in vitro (An et al., 1998;
Zagzag et al., 2000; Zundel et al., 2000; Moley and Mueckler, 2000), in this study it was
used as a marker of the distribution of metabolic stress within the spheroid mass. HIF-la
expression was initially observed in spheroid central regions at week 3 in the cell lines
(U87 and U373) examined. Labelling was rather faint and only a small number of cells
were labelled. This distribution suggested that hypoxia and/or hypoglycaemia occurred
just before and during the onset of central necrosis. Subsequent high levels of HIF-la
expression within perinecrotic tissue suggested that central spheroid regions were
continually being exposed to high levels of metabolic stress. The western blotting
experiments examining HIF-la expression using monolayer cultures in response to
hypoxia over time showed that HIF-la could be upregulated in less than 2 hours post-
hypoxia, and this expression increased over the 24 hour exposure period. Therefore, it was
unlikely that other regions of spheroid were severely hypoxic before week 3. These
findings using HIF-la therefore supported the morphological assessment of cell death in
the glioma spheroid cultures, which suggested that the distribution of metabolites
remained relatively high until a crucial central event occurred centrally at a specific
spheroid size.
It is important to mention that three of the four cell lines, U87, U373 and A172 cell lines
have previously been shown to possess mutations/polymorphisms in the PTEN gene (Ishii
et al., 1999). The PTEN tumour suppressor gene has been shown to negatively regulate
HIF-la expression by downregulating Akt and PI(3)K kinases (Zundel et al., 2000).
Therefore mutations in the gene may result in abnormal expression in these kinases and/or
HIF-la. However, monolayer studies examining HIF-la expression in the two glioma cell
lines studied showed no abnormal expression of the protein.
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3.3.7. Characterisation summary
Although using cell lines it is impossible to completely replicate the highly heterogeneous
in vivo scenario, the spheroid system provides a good reproduction of regions of
differentiation, cell death and proliferation present in vivo. Necrosis appeared to be the
preliminary central cell death event, most probably due to a combination of oxygen
depletion, hypoglaecemia and waste product build up. Corresponding increases in HIF-la
expression were observed around this time period. Apoptosis and variety of other
intermediate morphologies were observed interspersed with the necrotic cells, and
surrounding the necrotic cells, following the initial onset of necrosis. Overall onset of
central cell death was predictable within all four cell lines examined which was vital for
further experiments measuring onset and extent of death in response to genetic
manipulation. The extent of central cell death and apoptotic index varied between cell
lines with A172 showing the least necrosis and apoptosis and U87 showing the greatest.
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CHAPTER 4




Knowledge of the strategies that tumour cells employ when faced with hypoxia, nutrient
withdrawal and waste product build-up may be of relevance when targeting specific cell
death pathways therapeutically. Preliminary research completed using this spheroid system
showed that the primary central cell death event was consistent with necrosis. This initially
implied that regulatory pathways present around such areas of cell death may be limited.
However, evidence demonstrating the presence of regulatory molecules in pre or peri
necrotic cells (Bootman et al., 2001; Wharton et al., 2000; Fukunaga-Johnson et al, 1995;
Kane et al, 1995) together with the observed increase in perinecrotic apoptotic indices,
suggests that a variety of regulatory pathways may operate in relation to cell death in the
spheroids. In addition, the diversity of cell death morphologies observed both within
individual spheroids and between cell lines suggests that the distribution of cell death
associated proteins may vary across the radius of spheroids as well as between cell lines
harbouring a variety of genetic aberrations. The concentric arrangement of cell morphologies
within glioma spheroid cultures means that apoptosis and necrosis can be individually
assessed in terms of protein content.
The p53 protein is central to the cell death response in many tissue types. Although most
glioblastomas harbour genetic alterations in the p53 system (Rasheed et al., 1999), implying
defective operation, a role for p53 and associated proteins in regulating aspects of cell death
seems likely. Previous studies have shown the presence of poly (ADP-ribosyl)ation (Wharton
et al., 2000), Fas/Fas ligand (Tachibana et al., 1996; Tohma et al., 1998) and HIF-la (Zagzag
et al., 2000) around areas of necrosis in GBM. Poly ADP-ribose polymerase activity (PARP),
Fas and HIF-la have all been associated with a p53-mediated apoptotic response either
upstream (HIF-la) (An et al., 1998), down stream (Fas) (Fulda et al., 1998; Sheard et al.,
2001) or both (PARP) (Simbulan-Rosenthal et al., 1999). However, it is not known whether
p53 itself is directly involved. Upregulation of wild-type p53 and other directly associated
target molecules within perinecrotic tissue may suggest a role for the p53 system in
endogenous cell death in glioblastoma. It was therefore hypothesised that p53 and p53 related
proteins may play a role in the pathogenesis and regulation of cell death in glioblastoma In
addition, it was hypothesised that the distribution of p53 related proteins may vary according
to the p53 status of the tumour cell populations examined. In this part of the study, the aims
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were (i) to compare the P53 genetic status of the cell lines with basal levels of p53, Bax, p21
and MDM2 protein expression in the cell lines U87, U373, MOG-G-CCM and A172, (ii) to
establish whether p53, Bax, p21 and MDM2 proteins are upregulated in response to oxidative
and free radical stress in the four cell lines, (iii) to determine whether there is an increase in
these proteins within and around areas of central cell death in spheroid cultures and in biopsy
tissue and (iv) to compare P53 status and levels of protein expression with the levels of cell




Of the four cell lines sequenced, the two cell lines U373 and MOG-G-CCM contained P53
mutations (Figure 20). U373 had a mutation at codon 273 (CGT-»CAT). This mutation leads
to an Arginine being replaced by a Histidine at codon 273 on exon 5. The mutation in the
MOG cell line results in an Alanine being replaced by a Valine at codon 159(GCC->GTC).
Cell lines U87 and A172 had no mutations between exons 2 and 11 of the P53 gene.
4.2.2. p53, p21, Bax, MDM2 and pl4ARF expression in monolayer and spheroid cultures
The p53 antibodies used in this study were; p53 (Bp53-12) and p53 (Pabl801). Bp53-12
labels the p53 molecule between residues 32-79. Pabl801 antibody labels the carboxyl
terminal of the p53 molecule. In monolayer, spheroid cultures and biopsy specimens the two
p53 antibodies generally showed similar patterns of nuclear expression, although Bp53-12
showed slightly stronger staining compared to Pabl801 (Figure 21A-D, Table 13). In
addition, Pabl801 often labelled the cytoplasm of positive cells as well as the nucleus. In
monolayer, strong staining was present in 70-80% of cells in the mutant U373 cell line
(3++++). Moderately strong p53 labelling was observed in MOG-G-CCM cell lines in
approximately 60% of cells (3+++). U87 and A172 cell lines showed considerably weaker
p53 labelling which was in approximately 40-50% of cells (2++). This labelling pattern was
confirmed by western blotting (Figures 21E and F). U373 cell line had the strongest band at
53kDa and U87 and A172 the weakest. Like the immunohistochemistry, p53Bp53-12
antibody showed stronger bands than the Pabl801 antibody.
Nearly 100% of cells were strongly p53 positive (3++++) within spheroids derived from the
U373 cell line at week 1 (Figure 22, Table 13). Slightly weaker labelling was seen in MOG-
G-CCM cell lines at this time point. Weaker labelling was seen in U87 and A172 cell lines at
week 1 in approximately 30-50% of cells. There was no perinecrotic enhancement of p53
labelling as the spheroids became larger in any of the cell lines. In U373 cell line there was
an actual decrease in p53 labelling in cells directly adjacent to the central core of necrosis
(Figure 22F). By weeks 4 and 5, p53 labelling was only found around the spheroid periphery




Figure 20. P53 mutation analysis. A, shows the mutation at codon 273 (CGT—»CAT) in U373 cell line.
B, shows the wild-type sequence of the same region. C, mutation at codon 159 (GCC—»GTC) in the
MOG-G-CCM cell line. D, shows the wild-type sequence of the same region. The red arrow points to
the mutation sites. G=guanine, A=adenosine, T=thymidine, C=cytosine.
Figure 21. P53 (Bp53-12) immunohistochemistry in U87 (A), U373 (B), MOG-G-CCM (C) and A172
(D) cell lines in monolayer culture. Note the significantly darker and more prolific labelling in U373 (B)
and MOG-G-CCM (C) cell lines (all bars=100/xm). E&F show p53 western blots using whole cell
lysates from the four cell lines. Antibody P53(Pabl801)=E. Antibody P53 (Bp53-12)=F.
A B C
Figure 22. P53 labelling in spheroid cultures. A, week 2 U87 spheroid showing moderate strength
diffuse p53 labelling. B, week 3 U87 spheroid showing peripheral localization of p53. C, weak
peripheral p53 labelling in a U87 week5 spheroid. D, strong diffuse p53 labelling in a week2 U373
spheroid. E, week 3 U373 spheroid showing strong p53 labelling across the spheroid radius. F, p53
negative cell adjacent to the necrotic centre at week4 (see arrow). All bars=l 00/xm.
Cell line
Weeks
Monolayer 1 2 3 4 5
U87 2++ 2+++ 3++ 2+-H- 2++ 3++
P53 U373 3+++ 3++++
Bp53-12 MOG 3+++ 3++++ 3+++ 3++++ 3+++ 3+++
A172 2++ 2++ 3++ 3+ 2++ 3+
U87 2++ 3++ 3+ 2+ 2+ 2+
P53 U373 3+++ 3+++ 3+++ 3++++ 3++-H- 3++++
Pabl801 MOG 3++ 3+++ 3+++ 3+++ 3++ 3++
A172 2++ 2+ 2++ 2+ 2+ 2+
U87 3+ 2+ 0 2+ 2+ 3+
P21
U373 1+ 0 0 0 0 0
MOG 1+ 1 + 0 0 0 0
A172 2++ 2+ 2+ 0 1+ 2+
U87 2++++ 1+ 2++++ 1+ 1+ 2++
U373 1++++ 1++ 1++
Bax
Ji 1 1 r J) 1 1 1 1
MOG 1 I l l l £ i 1 1 1 Z 1 II 1 Z 1 1 1 1 ^ t I- 1
A172 1++++ 2++Z 1 1 1 1 Z 1 1 1 1 J 1 II
U87 3 I M l 2+++ 3+++ 2+ 3+ 3+++
MDM2 U373 3-H-++ 3+++ 2+ 3++ 3+++ 3++
(SMP-14) MOG 3 I I I I 2+-H- 2++ 3+ 3+ 3+++
A172 3+++ 2++ 2++ 3++J-M 1 Z 1 1 1 1
U87 2++ 1++ 1++ 1++ 1+ 1+
MDM2 U373 2++ 1++ 1+ 1+ 1+ 1+
(C-18) MOG 2++ 1++ 1+ 1++ 1+ 1+
A172 2++ 1++ 1++ 1+ 1+ 1 +
U87 0 0 0 0 0 0
PI4arF U373 0 0 0 0 0 0
MOG 2+++ 1+ 0 0 0 0
A172 0 0 0 0 0 0
Table 13. Semi-quantitative assessment of the staining intensity (0 absent, 1 weak, 2 moderate, 3 strong)
and proportion of cells staining (+ <25%, ++ 25-50%, +++ 50-75%, ++++ 75-100%) for p53 (BP53-12
and Pabl801), Bax, p21, MDM2 (SMP-14 and C-18) and pl4ARF in monolayer cultures and brain
tumour spheroids derived from U87, U373, A172 and MOG-G-CCM cell lines.
Weak to moderate cytoplasmic Bax expression was noted in monolayer cultures in 80-90%
of cells from each cell line (1++++ to 2++++) (Figures 23A-D, Table 13). U87 cells
exhibited the strongest Bax labelling followed by U373, MOG and A172 cell lines although
there was little difference between them. These differences were not apparent on the
photomicrographs as U87 cells were smaller and more rounded. The Bax labelling therefore
tended to be more condensed into the smaller cell volume. The Bax western blots using the
wild-type cell lysates confirmed that Bax expression was slightly higher in monolayer U87
cells compared to the other cell lines (Figure 23E).
A similar percentage of cells were Bax positive in small spheroids as were found in
monolayer culture (Figures 24A and D, Table 13). There was a very slight perinecrotic
enhancement in U87 cell line at week 3 (Figure 24B). However this disappeared by week 4
(Figure 24C). The outermost layer of cells at week 4 in U87, MOG-G-CCM and A172 cell
lines showed very high levels of Bax expression (Figure 24C). At this time point few Bax
positive cells were observed in central regions of the spheroid mass in these three lines. U373
cell line showed consistently high levels of Bax across the spheroid radius and this did not
change over the 5 week period (Figures 24D-F). There appeared to be no relationship in the
quantity or distribution of Bax labelling between p53 mutant and non-mutant cell lines.
In monolayer, A172 exhibited moderate intensity nuclear p21 labelling in approximately 30-
40% of cells (Figure 25D, Table 13). U87 cell line possessed stronger intensity labelling in
approximately 20-30% of cells (Figure 25A). Labelling was particularly strong around the
periphery of the 3-dimensional aggregates present in this cell line. Uniform nuclear labelling
was present in the U87 cell line whereas A172 cell line exhibited a more granular, nuclear
labelling pattern. In MOG-G-CCM cell line, a very small percentage of cells exhibited weak
nuclear labelling pattern (<2%) (Figure 25C). In U373 cell line, a fine, granular staining
pattern was observed in approximately 5% of cells, similar to that found in A172 cell line
(Figure 25B). The western blotting experiments confirmed these findings where U87 and
A172 cell lines had stronger bands at 21kDa than MOG-G-CCM and U373. No band was
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Figure 23. Bax immunohistochemistry in U87 (A), U373 (B), MOG-G-CCM (C) and A172 (D) cell
lines in monolayer culture (all bars=100/rm). E, shows the western blot analysis using Bax antibody on
the four whole cell lysates. Note that U87 cell line has a slightly darker band than the other 3 lines.
A B
Figure 24. Bax immunohistochemistry in spheroid cultures. A, week 1 U87 spheroid. B, central region
of a week 3 U87 spheroid showing a slight increase in perinecrotic expression of Bax. C, week 4 U87
spheroid showing peripheral Bax labelling. D, strong Bax labelling in a week 1 U373 spheroid. E and F,
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Figure 25. p21 immunohistochemistry in U87 (A), U373 (B), MOG-G-CCM (C) and A172 (D) cell lines
in monolayer culture (all bars=100/xm). E, shows the western blot analysis using p21 antibody on the
four whole cell lysates. Note that U87 and A172 cell lines exhibit considerably darker p21 labelling than
the two p53 mutant lines, U373 and MOG-G-CCM.
In spheroid cultures, no visible p21 labelling was observed in U373 cell line at any stage of
spheroid development (Figure 26C and D, Table 13). MOG-G-CCM exhibited weak focal
labelling in around 1-2% cells at week 1 and this disappeared from week 2 onwards. In U87
and A172 cell lines, moderate focal labelling (2+) was present in approximately 5% of cells
from weeks 1-5 (Figure 26A and B, Table 13). p21 labelling was most apparent around the
spheroid periphery in these lines over weeks 3-5 (Figure 26B). No perinecrotic enhancement
was observed in any of the cell lines.
Two MDM2 antibodies were used in this study; MDM2 (SMP-14) and MDM2 (C-18). SMP-
14 binds to an epitope corresponding to amino acids 154-167 of the human MDM2 molecule.
C-18 labels the carboxy terminal of the human MDM2 molecule. High levels of MDM2
expression were recorded in all four cell lines in monolayer culture, using the monoclonal
antibody SMP-14 (Figure 27, Table 13). U87, U373 and MOG-G-CCM cell lines showed
strongly labelled cytoplasm and/or nucleus in nearly 100% of cells (Figure 27A-C). A172
cell line exhibited strong labelling in approximately 60% of cells (Figure 27D). Western
blotting confirmed these findings in terms of strength of labelling. However, the most
prominent bands on the gel were at 60kDa. Fainter bands were observed at 94kDa (Figure
27E).
In spheroid cultures, SMP-14 levels remained high in all four cell lines at weeks 1 and 2, in
terms of both staining intensity and number (Figures 28D and G, Table 13). This labelling
was both in the cytoplasm and in the nuclei of all cell lines examined at this time point. By
week 3, MDM2 (SMP-14) labelling had become localized towards the centre of the spheroids
preceding the onset of central cell death in U373 and MOG-G-CCM cell lines (Figures 28A,
B and E). Again, equal amounts of labelling were present in both the nuclei and in the
cytoplasm. Staining around the spheroid periphery became weak and almost disappeared in
these lines by week 4 (Figure 28C). The cells directly adjacent to the region of central
necrosis were MDM2 (SMP-14) negative in U373 cell line (Figure 28F). In A172 and U87
cell lines, perinecrotic MDM2 (SMP-14) was present in slightly larger amounts than
elsewhere within the tumour cell mass (Figures 28H and I). The perinecrotic labelling and
absence of MDM2 (SMP-14) in surrounding tissue was not as marked in U87 and A172 cell
lines as in the MOG and U373 cell lines. Like the p53 mutant lines, perinecrotic MDM2
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Figure 26. P21 immunohistochemistry in spheroid culture. A, week 1 U87 spheroid showing positive
p21 labelling in approximately 5% of cells. B, week 3 U87 spheroid showing peripheral p21 labelling. C
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Figure 27. MDM2 (SMP-14) immunohistochemistry in U87 (A), U373 (B), MOG-G-CCM (C) and
A172 (D) cell lines in monolayer culture (all bars=100/im). E, western blot showing the MDM2 (smp-
14) antibody binding mainly to a 60kDa product as well as to the full-length 94kDa form in monolayer
whole cell lysates from the 4 cell lines.
 
labelling was both nuclear and cytoplasmic in all spheroid regions examined. Therefore the
two mutant P53 cell lines (U373 and MOG-G-CCM) exhibited greater amounts of
perinecrotic MDM2 (SMP-14) labelling than the wild-type cell lines (U87 and A172).
The antibody that recognises the carboxyl-terminal of MDM2, C-18, labelled monolayer
cultures only weakly and in isolated cells. Western blots of these monolayer cultures revealed
that the C-18 antibody labelled only the 94kDa MDM2 protein (Figure 29). No obvious band
was seen at 60kDa for this antibody in contrast to the SMP-14 antibody. It was therefore
clear that the 60kDa MDM2 isoform (recognised by the SMP-14 antibody) was lacking a
carboxyl-terminal domain (as recognised by the C-18 antibody). In spheroid cultures, the
distribution of C-18 expression was markedly different from the SMP-14 antibody (Figure
30). No peri-necrotic labelling was observed with this antibody. Morphologically healthy
cells situated across the spheroid radius were labelled weakly positive for C-18 in U373,
MOG-G-CCM and U87 spheroid cultures. Labelling was predominantly cytoplasmic in
spheroids derived from all four cell lines.
In monolayer culture pl4ARF expression was highest in MOG-G-CCM cell line (Figure 31).
Labelling in this cell line consisted of small dark disks situated within the nucleus (Figure
31A). This occurred in approximately 90% of cells. U373 contained a few isolated cells with
this pattern of labelling (2-3%) and A172 and U87 cell lines contained no visible P14ARF
labelling. Western blotting confirmed these findings (Figure 3IB).
In spheroid culture pl4ARF labelling was found only in MOG-G-CCM cell line. Random
positively labelled cells were distributed across the spheroid radius. pl4ARF labelling was not
present in spheroids derived from U87, U373 and A172 cell lines. Some weak peripheral
labelling was observed in MOG-G-CCM spheroids from weeks 1-5.
4.2.3. p53, p21, Bax and MDM2 expression in biopsy tissue
As in the spheroid study, both p53 antibodies, Pabl801 and BP53-12, yielded similar results
when applied to the biopsy material, apart from the presence of some focal cytoplasmic
staining of tumour cells with Pabl801 in most cases (Table 14). Some expression of p53 was
detected in 80% (20) of the cases. 52% (13) of cases were classed as being high expressors
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Figure 28. MDM2 (SMP-14) immunohistochemistry in spheroid cultures. A, a pre-necrotic MOG-G-
CCM spheroid exhibiting central MDM2 localisation . B, a post-necrotic MOG-G-CCM spheroid
showing peri-necrotic MDM2 labelling. C, a large week 4 MOG-G-CCM spheroid exhibiting strong
peri-necrotic MDM2 labelling. D, week 1 U373 spheroids exhibiting nuclear MDM2 labelling. E,
centrally located MDM2 positive cells in a week 3 U373 spheroid. F, peri-necrotic MDM2 labelling in
week4 U373 spheroid. Note the absence of MDM2 labelling in cells directly adjacent to the necrotic
centre. G, nuclear and cytplasmic MDM2 labelling in a weekl U87 spheroid. H, slight increase in
central MDM2 labelling in a week 3 pre-necrotic U87 spheroid. I, week5 U87 spheroid exhibiting lack
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Figure 29. MDM2 (C-18) western blots using cell lysates from the 4 cell lines U87, U373, MOG-G-
CCM and A172. Note the absence of a clear band at 60kDa.
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Figure 30. Comparisons between MDM2 (SMP-14) and MDM2 (C-18) immunohistochemistry in
spheroid cultures. MOG-G-CCM week 3 spheroid labelled with MDM2 (SMP-14) in A and MDM2 (C-
18) in B. U373 week 3 spheroid labelled with MDM2 (SMP-14) in C and MDM2 (C-18) in D. U87
week 3 spheroid labelled with MDM2 (SMP-14) in E and MDM2 (C-18) in F. Note the absence of
perinecrotic MDM2 using the C-18 antibody in any of the cell lines. All bars=100/xm.
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U87 U373 MOG A172
Figure 31. Pl^4ARF labelling in MOG-G-CCM monolayer culture (A) (bar=20/mi). Western blot using
P14arf antibody on whole cell lysates of the four monolayer cell lines U87, U373, MOG-G-CCM and
A172 (B).
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Figure 32. Comparisons between MDM2 (SMP-14) and MDM2 (C-18) immunohistochemistry in
glioblastoma biopsy material. Note the peri-necrotic labelling using the MDM2 (SMP-14) antibody in
figures A and C and the lack of peri-necrotic labelling using the MDM2 (C-18) antibody. N=necrosis,











1 3++ 3++ 2+ 1++ 3+ 1+
2 3+ 3+ 0 0 0 0
3 2+ 2+ 0 0 0 0
4 2+ 2+ 0 1+ 2+ 1+
5 0 2+ 0 1+ 2+++ 1+
6 0 1+ 0 3++++ 0 1+
7 1+ 1+ 0 1++ 0 0
8 0 2+ 0 3++ 1+ 0
9 3+++ 3+++ 0 0 1+ 0
10 0 0 0 1 + 0 0
11 3+++ 3+++ 0 2+++ 1+ 1+
12 0 2++ 2+J 1 1 II J 1 1 1 1 £ 1 1 I
13 3+++ 3++ 0 1++ 0 1+
14 3+++ 3+++ 3+ 2+ 1+ 0
15 1 + 2++ 0 1+++ 0 ND
16 3++ 3+++ 0 1+ 1+ ND
17 2+ 3++ 2+ 1+++ 0 ND
18 1 + 1+ 0 0 2+ ND
19 1 + 1+ 0 2+++ 1+ 0
20 0 1+ 0 1++ 1+ 0
21 2+ 2+ 0 1++ 0 0
22 2+ 2++ 0 1+ 1+ 1+
23 3+ 2+ 0 3+++ 2+ ND
24 1+ 1 + 0 3+-H- 0 1+
25 3++ 3++ 0 2+ 0 0
Table 14. Semi-quantitative assessment of the staining intensity (0 absent, 1 weak, 2 moderate, 3 strong)
and proportion of cells staining (+ <25%, ++ 25-50%, +++ 50-75%, ++++ 75-100%) for p53 (BP53-12
and Pabl801), Bax, p21 and MDM2 (SMP-14 and C-18) in 25 brain tumour biopsies. ND=not done.
(>2+ with either of the two antibodies). Nuclear expression of p21 was observed in 12% (3)
of cases (Table 14). Expression of MDM2 (SMP-14) was detected in 80% (20) of cases with
24% of cases showing greater than focal weak expression (>1+) (Table 14). SMP-14
expression in tumour cells was mainly nuclear, although some cytoplasmic staining was also
observed. MDM2 (C-18) showed considerably less overall staining than MDM2 (SMP-14).
C-18 labelling was observed in around 50% of cases with no cases showing more than weak
cytoplasmic expression (<1++) (Table 14). Antibodies to Bax demonstrated granular
cytoplasmic expression in 84% of cases with 64% (16) being high expressors (Table 14). In a
few cases, staining was both strong and diffuse. No association was demonstrated between
p53 over expression and MDM2 (SMP-14 and C-18), Bax and p21.
All of the proteins examined showed some expression on perinecrotic tumour cells, but for
p53, p21 and Bax this was similar to the expression on surrounding viable tumour. In the
case of MDM2 (SMP-14) however, an upregulation of expression was noted in 80% of cases,
which in some cases was striking (Figures 32A and C). In contrast to the predominantly
cytoplasmic staining of intervening viable tumour, peri-necrotic staining was both
cytoplasmic and nuclear. The MDM2 (C-18) antibody, which labels the central acidic
domain of the MDM2 molecule, exhibited markedly decreased MDM2 labelling compared to
MDM2 (Smp-14). No perinecrotic labelling was observed (Figures 32B and D). Only cells
within morphologically healthy tumour cell populations labelled positively for this antibody.
All MDM2 (C-18) labelling was cytoplasmic. There was no correlation between the presence
of perinecrotic MDM2 (SMP-14 or C-18) expression and p53 expression in the tissue
samples (Table 14).
4.2.4. p53, p21, Bax and MDM2 expression in monolayer cultures and spheroids exposed to
oxidative stress
Western blotting using the p53 antibodies Pabl801 and Bp53-12 revealed that levels of p53
were upregulated in U87 and A172 cell lines after exposure to ImM H202 for 6 hours (Figure
33). Visible bands were almost non-existent in the untreated groups of cells. Levels of p53
expression were unchanged in the U373 and MOG cell lines when the cells were exposed to
H202. p21, Bax and MDM2 levels were unchanged in all four cell lines in response to H202.
The western blot for MDM2 failed to pick up 90kDa MDM2 in any of the samples tested.
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This is probably due to the lack of sensitivity of the assay. Although levels of apoptosis were
not assessed, the wild-type monolayer cultures (U87 and A172) could be seen to be
considerably less viable subsequent to H2O2 treatment than the p53 mutant cultures. All
incubation medium was spun down to capture all non-adherant cells following treatment (see
Figure 33 for all blots).
Levels of p53 expression increased in U87 cell line when exposed to 0.5% oxygen for
varying lengths of time (Figure 34). An upregulation of p53 was noted after 2 hours exposure
and became more pronounced after 6, 12 and 24 hours. No change in p53 expression was
seen in the U373 cell line in response to hypoxia (Figure 34). Levels of p21 increased in the
U87 cell lines in a similar pattern to p53 in response to hypoxia. No such changes were seen
in p21 expression in U373 cell line. There appeared to be a slight increase in 90kDa MDM2
in the U87 cell line in response to hypoxia. No similar increase was seen in the U373 cell
line. No changes were observed in the expression of Bax in either cell line in response to































Figure 33. P53 related protein levels in U87, U373, MOG-G-CCM and A172 cell lines in response to
H202. Blots show that U87 and A172 cell lines show upregulation of the p53 after exposure to H202.
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Figure 34. P53 related protein levels in U87 and U373 in response to prolonged exposure to hypoxia
(0.5% O2). l=non-hypoxic control, 2=lhr, 3=2hrs, 4=6hrs, 5=24hrs. p21, p53 and 94kDa MDM2 show
an increase in expression in U87 cell line in response to hypoxia.
4.3. Discussion
4.3.1. Summary of results
Levels of apoptosis and necrosis were not found to differ between p53 mutant lines (U373
and MOG-G-CCM) and p53 wild-type lines (U87 and A172). p53, p21 and 90kDa MDM2
were found to be reactive in the p53 wild-type line U87 in response to hypoxia exposure.
Similar findings were observed following exposure to H202 in both U87 and A172 cell lines.
However, there was a decrease in p53 and p21 expression, and no change in 90kDa MDM2
expression, within central regions of pre and post necrotic glioma spheroids derived from
these p53 wild-type lines. No upregulation of p53/p21/90kDaMDM2 was identified in the
p53 mutant lines U373 and MOG-G-CCM either in response to hypoxia/H202 or within
perinecrotic tissue. High levels of endogenous Bax remained consistent both in monolayer
culture and all stages of spheroid growth in all 4 of the cell lines examined. Of the
experiments performed in this study, 60kDa MDM2 was the only protein to be localised
within perinecrotic tissue in vitro and in vivo. This expression was found in both p53 wild-
type and mutant lines. This 60kDa MDM2 isoform was thought to be lacking a C-terminal
domain.
4.3.2. P53 mutation analysis
Of the four cell lines examined, previous research has shown that U87 and U373 were P53
wild-type and mutant respectively thus allowing the hypothesis to be addressed (Ishii et al.,
1999). In order to confirm these findings and to determine the status of the two other glioma
cell lines used in this study, A172 and MOG-G-CCM, the P53 gene was sequenced in all
four cell lines from exons 2-11. U373 possessed a previously identified mutation at codon
273 (CGT-»CAT, Arg->His), a mutation 'hotspot' on the P53 gene*. Approximately 15% of
P53 mutant glioblastomas have mutations at codon 273. This results in the removal of critical
residues normally in contact with DNA, causing loss of sequence specific DNA binding
(Sigal et al., 2000). However, this mutation retains 98% folding of the wild-type p53
configuration and many experiments have demonstrated the ability of this mutant to bind to
and transactivate a p53 responsive reporter (Park et al., 1994; Gollahon et al., 1996; Hachiya
et al., 1994). In addition, protection from apoptosis in cells possessing this mutation has
been shown to be low when exposed to cisplatin (Sigal et al., 2000). However, marked
148
decreases in the production of various downstream targets (such p21 and MDM2) have also
been reported in various cell lines exhibiting p53His273 mutations suggesting that p53
binding ability may differ between target genes and cell lines (Saintigny et al., 1999). This is
further supported by studies examining the dominant/negative characteristics of various P53
mutants (Kawamura et al., 1996). When a human squamous cell carcinoma cell line
exhibiting wild-type P53 was transfected with a vector containing a P53His273 sequence,
the resulting protein failed to enhance cell growth (Kawamura et al., 1996). In contrast,
normal breast epithelial cells when transfected with a similar vector resulted in an increase in
lifespan in all derived clones with one clone actually becoming immortalized (due to
subsequent alterations) after a period of growth arrest (Gollahon et al., 1996).
MOG-G-CCM cell line has not previously been sequenced for P53. A P53 mutation was
found at codon 159 (GCC-»GTC, Ala->Val). Few recorded cases have been found in the
literature of this particular mutant and none have been found in astrocytic tumours (van
Meyel et al., 1994; Giglia et al., 1998). The DNA binding region of the p53 protein is
between residues 102 and 292 thus the P53159Val mutation is situated within this section
(Prives et al., 1999). However, like the P53His273 mutant, the P53Vall59 mutant is
unlikely to result in a protein with a significant configurational change due to the similarity
of the replacement amino acid to the original (both have non-polar side chains). Experiments
analysing the transcriptional activity of the mutant protein using the yeast functional assay
found that 98% of yeast colonies turned red as a result of successful activation of a wild-type
P53 promoter sequence (de Cremoux et al., 1999). This means that the P53159Val mutants
may retain significant wild-type p53 transactivational ability. The functional status of
P53159Val mutants have not been functionally assessed in normal or transformed human
cells. Analysis of activation of artificial promoter sequences sometimes do not reflect the
actual transcription of target mRNA in cell cultures (Tada et al., 1996)
A172 has previously been described as having a mutation at codon 242 (CGT-»TTC,
Cys^Phe) (Kataoka et al., 2000), but this was not identified in the cells used in this study. In




therefore, U87 and A172 cell lines were wild-type for the P53 gene and U373 and MOG-G-
CCM were P53 mutant.
4.3.3. p53 related expression in monolayer cultures and biopsies
In order to fully assess P53 related protein distribution in spheroid cultures and biopsy tissue,
it was first important to review the endogenous expression of these proteins in monolayer
culture and on biopsy sections. It is important that expression of these proteins is compared
with known genetic aberrations in the cell lines, particularly P53 status and other known
common alterations, such as MDM2 over expression. The biopsy tissue was assessed in
terms of general levels of expression, as a mode of comparison with the in vitro experiments.
The inability of MDM2 to bind to and inactivate the mutant p53 protein means that many
P53 mutations can be identified immunohistochemically due to an increase in the half life of
the mutant p53 protein (Haupt et al., 1997 ; Anker et al., 1993). Using monolayer cultures,
this was confirmed in both U373 and MOG-G-CCM cell lines. This suggests that the full
length MDM2 protein, which is present in small amounts in these cells, does not recognise
the two mutant p53 proteins p53His273 and p53Vall59. Although the biopsy material was
not sequenced for P53 status, of the 25 GBM biopsy cases examined, 52% labelled strongly
for p53, suggesting the presence of P53 mutations. This latter result should be taken with
caution due to recent studies using 316 breast cancer biopsies which showed that
immunohistochemical determination of P53 mutations can pick up a considerable number of
false negatives due to large scale deletions and transversions. These can result in severely
truncated forms of the p53 protein which cannot be recognised by commonly used p53
antibodies such as BP53-12 and Pabl801 (Sjogren et al., 1996). In addition, some tumours
and tumour cell lines show upregulation of the wild-type p53 protein in the absence of P53
mutations. This has been observed in smaller studies in glioma where more low and high
grade tumours exhibited strong p53 labelling then those possessing detectable P53 mutations
(Marchenko and Moll, 1997; Pykett et al., 1998). All the samples with P53 mutations in the
latter study did have p53 protein upregulation.
To determine whether p53 is likely to be upregulated in relation to necrosis, the expression of
several proteins known to be activated by p53, and which may play a role in the pathogenesis
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and regulation of cell death were studied. These were p21, Bax, MDM2 and pl4ARF. In
monolayer culture, reductions in p21 labelling were observed in the p53 mutant cell lines
U373 and MOG-G-CCM, compared to the other cell lines. No p21 labelling was observed
immunohistochemically in either of the p53 mutant cell lines and only a very faint band was
observed using western blotting. Mutations at codon 273(CGT ->CAT) have previously been
shown to reduce transactivation of the WAF1 promotor (Saintigny et al., 1999). Therefore,
findings in this study show that the P53159Val mutant may also have a reduced WAF1
transactivation ability. In contrast, levels of p21 expression showed no correlation with
increased p53 protein expression in the biopsy cases. Only 3 cases were strongly p21 positive
and all exhibited high levels of the p53 protein (suggesting the presence of a p53 mutation).
These findings are consistent with larger scale studies where no inverse correlation was
found between p21 expression and p53 overexpression (Khalid et al., 1998). In addition,
other experiments have shown that P53 genetic status is unrelated to p21 expression (Weller
et al., 1998). This may be due to the presence of different P53 mutations in these tumours,
resulting in proteins with varying DNA binding abilities. In addition, recent evidence has
suggested a mechanism for p53 independent regulation of p21 via a E2F1/Ras pathway and
TNF-a (Kobayashi et al., 2000; Gartel et al., 2000). Other studies have shown that
expression of p21 and absence of p53 could confer a selective advantage to healthy tumour
cells (Gomez-Mazano et al., 1997).
Constitutive expression of Bax was very high in the four cell lines examined regardless of
P53 status. In the biopsy cases Bax expression was observed in 90% of cases. These findings
support the findings of Krajewski et al, where both gliomas and glioma cell lines where
shown to exhibit consistently higher levels of constitutive Bax than normal astrocytes,
regardless of P53 status (Krajewski et al., 1997). In addition, phyllodes tumours of the breast
harbouring specifically P53His273 mutations have been shown to accumulate large
quantities of Bax protein (Kuenen-Boumeester et al., 1999). It was not clear in these
experiments whether such increases in expression are a result of the mutant p53 protein
having some residual transactivation activity or whether Bax is upregulated via a p53
independent pathway. It is clear however that this high endogenous expression of Bax is
unlikely to be in the activation of apoptotic pathways in these monolayer cultures and in the
biopsy material. In monolayer culture for example, nearly 100% of the cells were Bax
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positive in the 4 cell lines examined and basal levels of apoptosis ranged from 0.2% in A172
cell line to 1% in U373 cell line. These data are supported by experiments showing that
retroviral transfer of Bax into many glioma cell lines fails to have an effect on cell death
indices when grown under normal conditions and when exposed to various chemotherapeutic
reagents (Naumann et al., 1998).
Like Bax, endogenous MDM2 expression was extremely high in both the P53 wild-type and
mutant cell lines and in monolayer cultures, contrary to evidence suggesting U87, U373 and
A172 all exhibit low levels of endogenous protein (He et al., 1994). Using two different
MDM2 antibodies (Smp-14 and C-18) which label different parts of the MDM2 molecule, it
was clear that the largest proportion of MDM2 in each of the four glioma cell lines was a
60kDa MDM2 protein lacking in a carboxyl terminus. It is thought that this truncated form of
MDM2 may provide a new entry point for cellular signals to regulate p53 turnover, both in
living and dying cells (Pochempally et al., 1998). The implications, structure and regulation
of this truncated 60kDa MDM2 isoform are discussed in 4.3.6-4.3.7.
When the glioblastoma biopsy tissue was examined for both MDM2 isoforms, like the cell
lines, a far greater level of the 60kDa MDM2 isoform was found. When examining tissue for
the presence of full length MDM2 overexpression, which is common in primary
glioblastoma, it is clear that an antibody or a combination of antibodies, that recognise full
length MDM2, should be used. There was no correlation between p53 expression and MDM2
(either 90kDa or 60kDa isoform) expression in the biopsy tissue. This was similar to the cell
lines where the two mutant lines showed similar levels of 60kDa MDM2 to the P53 wild-
type lines. Initially, it was thought that only cell lines possessing wild-type P53 contained
high levels of various truncated MDM2 isoforms (Landers et al., 1997; Pochempally et al.,
1998). However, shortened MDM2 splice variants found in a study by Matsumoto et al
together with the data in this study suggests that various MDM2 isoforms exist in tumour cell
populations with both P53 mutant and wild-type backgrounds (Matsumoto et al., 1998).
It is unlikely that the 60kDa MDM2 molecule would be affected by the CDKN2A genetic
status of the cell lines because the N-terminus of the wild-type pl4ARF protein interacts with
the C-terminus of the MDM2 molecule. Therefore, if the C-terminus of the MDM2 molecule
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is absent, no such interaction can take place. This association would normally lead to
repression of the MDM2-dependent suppression of p53 (Pomerantz et al., 1998; Zhang et al.,
1998).
Lower levels of the full length 90kDa protein were found in each of the cell lines compared
to the 60kDa isoform. Experiments using the MDM2 (C-18) antibody showed that similar
levels of 90kDa expression were found in all four lines, thus the expression of both isoforms
appeared to be independent of the P53 status. There appeared to be no relationship between
the expression of full length 90kDa MDM2 and pl4ARF status/expression. Low levels of
pl4ARF in three of the lines U87, U373 and A172 were observed. Homozygous deletions have
been shown to exist in the CDKN2A locus in both U87 and A172 cell lines whereas U373
was wild-type for this locus (Ishii et al., 1999). High levels of pl4ARF protein were observed
in MOG-G-CCM. MOG-G-CCM was the only cell line not previously characterised for
CDKN2A mutation status thus it was not known whether the immunoreactive product found
in this study was viable. Different proliferative signals, such as c-myc (Zindy et al., 1998),
E1A (de Stanchina et al., 1998) and E2F (Bates et al., 1998) lead to P14ARF activation and
p53-dependent apoptosis in normal cells. Differences in proliferative signals between lines,
in combination with CDKN2A alterations in the U87 and A172 cell lines, are likely to result
in the observed variations in pl4ARF protein accumulation.
4.3.4. p53 related expression in response to oxidative and free radical stress
In order to test the hypothesis that the accumulation of p53 and its downstream target
proteins are associated with areas of endogenous cell death in glioblastoma cell populations,
it was first important to establish that at least one cell line was capable of mediating a p53
response to stress. If levels of p53 were not raised in response to different types of oxidative
stress in these experiments then it is unlikely they would be raised within glioma spheroid
cultures. In addition, any observed upregulation of p53-regulated proteins such as Bax, may
be due to a p53 independent mechanism in the absence of a concurrent increase in p53
expression. Many studies have shown that the p53 protein is stabilized after exposure to an
oxidative insult (Graeber et al., 1996; An et al., 1998). Tumour cells that develop P53
mutations demonstrate a diminished apoptotic potential in response to oxidative stress
(Graeber et al., 1996). Of 7,202 transcripts known to be induced by p53 before the onset of
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apoptosis only 14 have been found to be markedly increased in p53-expressing cells
compared to control cells. Nearly all of these encode proteins that could generate reactive
oxygen intermediates or respond to oxidative stress (Polyak et al., 1997). The two forms of
oxidative stress used in this study, hypoxia and H2O2 both involve the activity of reactive
oxygen species (ROS).
Hypoxia has been shown to generate reactive oxygen species from the mitochondria which
regulate the cytosolic redox state and are required for the stablization of the p53 protein
(Chandel et al., 2000). In this study, U87 cell line exhibited marked increases in p53 protein
over a 24 hour period when exposed to 0.5% oxygen. Not surprisingly, the mutant protein in
U373 cells did not show any increase in p53 expression, which remained extremely high.
Following p53 protein stabilization, the p53 dependent proteins p21 (Green et al., 2001;
Chandel et al., 2000), p27 (Gardner et al., 2000), Bax (Ruan et al., 1999; Kimura et al., 2001)
and Fas/FasL (Vogt et al., 1998) have been shown to be expressed which can then activate
cell cycle arrest (p21and p27) and/or apoptosis (Bax and Fas/FasL). Levels of p21 were
found to gradually increase over time in response to hypoxia in U87 cell line in this study.
No changes in p21 expression were observed in the P53 mutant U373 cell line. Bax remained
unchanged in both U87 and U373 cell lines. Levels of 90kDa MDM2 appeared to increase
after exposure to hypoxia in U87 cells but not in U373 cells. Levels increased after lhour and
then remained stable over the 24hour period. The 60kDa truncated MDM2 isoform remained
unchanged in response to 0.5% oxygen in both lines. Levels of 90kDa MDM2 have
previously been shown to be reduced in response to hypoxia in order to allow for the
accumulation of the p53 protein (Alarcon et al, 1999). It is possible that the increase in p53
protein stimulated an initial increase in full length MDM2 protein but post-translational
modifications and the involvement other proteins, such as pl4 , do not allow any
subsequent MDM2 transcription and/or negative association with the active p53 molecule.
This is supported by the continual increase in p53 over the 24 hour period. HIF-la.
expression was also found to increase after 2 hours exposure to hypoxia. Hypoxia has been
shown to activate very high levels HIF-la which are required help stabilize the p53 protein
(Carmeliet et al., 1998) (as discussed in 3.5.6). HIF-la expression was upregulated in both
wild-type and mutant P53 cell lines thus agreeing with earlier evidence suggesting this to be
an event upstream of the p53 protein (An et al., 1998).
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In various brain diseases, reactive oxygen intermediates (ROIs) which include H202,
superoxide anions and hydroxyl radicals are important mediators of physical and chemical
stresses. For example, ischaemic-reperfusion injured tissue has been shown to excrete large
amounts of H202 (Marx, 1987). NO, another reactive oxygen intermediate has also been
shown to increase levels of H202 and has been implicated around areas of tumour associated
hypoxia (Asahi et al., 1995). The addition of large amounts of H202 (ImM) to cells in vitro
has a similar effect to hypoxia in that it can increase levels of p53 protein and subsequent
levels of p21, GADD45 (Kitamura et al., 1999), Bax (Wang et al., 2001) and Bak (another
pro-apoptotic member of the Bcl-2 family)(Kitamura et al., 1999). Low levels of H202 have
been implicated in signal transduction in endothelial cells (Rao and Berk, 1992). The
addition of 1M H202 to the medium of the cell lines in this study resulted in an upregulation
of the p53 protein in the two P53 wild-type lines U87 and A172. No such increase was seen
in the P53 mutant lines, U373 and MOG-G-CCM. p21, MDM2 (60kDa or 90kDa forms) and
Bax were not seen to be upregulated in response to H202 in any of the lines.
The findings in this part of the study suggested that wild-type P53 was able to be upregulated
in two of the cell lines, U87 and A172, in response to stress, irrespective of any other genetic
alterations present. This response in monolayer culture to these types of stress raised the
possibility that p53 could be important for the regulation of cell death within and around
areas of endogenous cell death in glioblastoma. The central areas of glioma spheroids are
likely to be subjected to increases in free radical stress due to increases in acidosis, toxic
waste build up and lipid peroxidation of necrotic cell membranes (Mueller-Klieser et al.,
2000). In addition, levels of intraspheroidal oxygen become very low at large spheroid sizes
in central regions, thus p53 could potentially mediate a cell death response within these areas.
4.3.5. P53 status and levels of apoptosis in spheroid cultures
Quantitative analysis revealed that glioma spheroids derived from U87 cell line, which has a
P53 wild-type status, had significantly more apoptotic figures than the other 3 cell lines.
However, U373 which has mutant P53 contained more apoptotic figures than either MOG-G-
CCM (p53 mutant) or A172 cell line which was wild type for P53. Therefore, in comparing
levels of apoptosis between cell lines, no simple correlation existed with P53 status. In
addition, there was no correlation between P53 status and susceptibility to necrosis which
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occurred at a similar diameter in all four cell lines. These findings support many reports in
glioblastoma biopsy material where P53 wild-type tumours do not show higher apoptotic
indices than P53 mutant tumours. Some investigators have suggested that the reason for this
may be due to the fact that over expression of wild-type P53 often correlates with the
expression of pro-survival Bcl-2 thus allowing an escape from p53 mediated apoptosis in
wild-type tumour cell populations (Alderson et al., 1995). However, other studies report that
no such correlation exists (Tews, 1999). What is most likely is that a combination of genetic
alterations and expression patterns are likely to lead to the same functional effect (Rasheed et
al., 1999). For example, homozygous deletions in the CDKN2A locus in U87 and A172 cell
lines may result in a similar apoptotic deficit as P53 mutations in U373 and MOG-G-CCM
lines. Although this is the case, it is possible that the endogenous cell death observed within
perinecrotic tissue may arise via different pathways (p53 related or otherwise) in spheroids
derived from either P53 mutant or wild-type lines.
4.3.6. Perinecrotic expression of p53 related proteins
It was hypothesised that increases in p53 expression and other p53 related proteins may be
associated with areas of cell death in either pre- or post-necrotic spheroids. Although no
increases in p53 expression have been detected previously in vivo, it was possible that spatio-
temporal monitoring of glioma spheroid cultures may pin-point changes in protein expression
within glioma cell populations as areas of cell death form. However, as the spheroids became
larger, no increase in p53 protein was apparent in or around the developing area of central
necrosis for any of the cell lines examined. In the P53 mutant lines, p53 protein levels were
consistently high across the spheroid radius. This pattern was to be expected due to the
inability of the mutant protein to be identified and subsequently degraded. However, in the
wild-type cell lines, labelling was faint and peripherally located. There was no increase in
centrally located p53 expression at any time point in spheroid development. Peripheral
expression was similar to levels in small spheroids and in monolayer culture. Although wild
type p53 has a very short half life, it is surprising that expression of the wild type protein
should be decreased around areas of cell stress. A comparable pattern of expression was seen
in the biopsy sections where p53 labelling in both high and low p53 expression groups
appeared to be present within healthy cell populations with no increase in labelling around
areas of cell death. It would therefore appear that the regions of cell death present within
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glioma cell populations are dying as a result of mechanism not requiring accumulation of the
p53 protein. Many different cell types exhibit p53-independent apoptosis. It is possible that
endogenous cell death in glioblastoma in both P53 wild-type and mutant cells are activated
via similar p53-independent pathways rather than different pathways resulting from the
varying P53 status of the cells.
In the P53 wild-type lines, a similar reduction in perinecrotic p21 labelling was observed
within inner spheroid regions. Like p53, p21 labelling was present in cells around the
spheroid periphery, within the proliferating cell population, at a similar level that was
observed in the monolayer cultures. This was surprising as p21 is known to activate cell
cycle arrest in similar regions in other spheroid types as a result of cell-cell contact and
variations in growth factor availability. In Ml(Ha-ras oncogene transformed fibroblasts)
spheroids, the inner region of quiescence was characterised by the induction of p21 (LaRue
et al., 1998). Cellular quiescence is thought to work as a defence mechanism against likely
reductions in metabolites that eventually occur within these areas (Mueller-Klieser, 2000).
However, other members of the Cip/Kip family of CDK inhibitors may be responsible for
cell cycle arrest within the glioma spheroid cultures. p27 is not thought to be regulated by the
p53 pathway and can be induced by IFNs (interferons) and activated post translationally,
particularly in response to cell-cell contact and serum deprivation (Pagano et al., 1995;
Kuniyasu et al., 1997; Moro et al., 1998; Levenberg et al., 1999). In experiments performed
by St Croix et al. (1998), EMT6 cells were transfected with an exogenous E-cahedrin
expression vector which resulted in tighter cell adhesion in inner spheroid regions, similar to
those found in this study. This resulted in an increase in the CDK inhibitor p27 and
subsequent growth arrest. In addition, recent evidence has shown that p21 may be more
important in regulating cell cycle re-entry after hypoxic injury rather than activating hypoxia-
induced arrest (Green et al., 2001).
Perinecrotic upregulation of Bax was not seen in either the brain tumour spheroids or in
biopsy tissue. This, in addition to the lack of Bax upregulation in response to oxidative stress,
suggests that Bax is not important for the regulation of cell death in this system. Most cells
exhibiting high levels of Bax expression appeared within healthy proliferating cell
populations in spheroid culture and in human glioblastoma biopsy material. In some tumour
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cell lines high levels of endogenous Bax have been associated with good response to
chemotherapeutic agents (McPake et al., 1998). However, because Bax is thought to work as
a dimer with other Bcl-2 family members releasing pro-apoptotic factors into the cytoplasm,
it is likely that other associated proteins may be be more important for regulating cell death
in these cells. Some studies have shown that there is no relationship between Bax and the
pro-survival factors Bcl-2, Mcl-1 and Bcl-XL (Krajewski et al., 1997). However, others have
suggested that the anti-apoptotic protein Bcl-2 increases during the development of an initial
to recurrent glioblastoma (Strik et al., 1999). The heat shock binding protein Bag-1 has also
been implicated in providing a survival advantage to glioma cells in deprived
microenvironments (Roth et al., 2000). In addition, a novel member of the Bcl-2 family has
been discovered called Diva which can interfere with apoptotic signalling downstream from
cytochrome C release and upstream form Apaf-1 activation (Naumann et al., 2001).
Monitoring levels of Bid, which is transactivated by the p53 protein and is a known mediator
of the death receptor superfamily may also be of value, particularly as Fas receptors have
found to be expressed around areas of cell death in GBM (Yin, 2000; Tachibana et al., 1996).
4.3.7. Perinecrotic MDM2 expression
One of the most important findings in this study was the localisation of a 60kDa MDM2
isoform around areas of cell death both in the spheroid cultures and the glioblastoma biopsy
material. This occurred in spheroid cultures and in glioblastoma biopsies irrespective of P53
status or p53 protein distribution. This suggested that the accumulation of this protein was
distinct from the overexpression/upregulation of full length MDM2 commonly found in
primary glioblastoma cells exhibiting wild-type p53. Levels of centrally located, truncated
MDM2 appeared at a similar level as that found in monolayer cultures and small spheroids.
Therefore, a reduction in levels of this isoform was associated with outer proliferative
regions rather than a specific upregulation within perinecrotic tissue. This suggested that
60kDa MDM2 did not actively accumulate as a result of interspheroidal cell stress, such as
hypoxia, but may be associated with non-cycling cells. This was confirmed by the lack of a
60kDa MDM2 increase following exposure to oxidative stress. Nevertheless, the existence of
this isoform within perinecrotic cells, as compared to healthy proliferating cell populations,
could potentially have major implications in the susceptibility of these glioma cell
populations to stress. A variety of other MDM2 splice variants have previously been found in
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other cell types, including astrocytoma neoplasms (Lukas et al., 2001; Matsumoto et al.,
1998). Importantly, the existence of these splice variants have been shown to correlate with
malignancy. For example, glioblastomas have shown greater incidence of shortened MDM2
transcripts (69%) than astrocytomas (0%) (Matsumoto et al., 1998).
It has been suggested that truncated MDM2 isoforms can compete with full length MDM2
binding to various target molecules (Pochempally et al., 1999; Damian et al., 2000).
Certainly, the cellular distribution of the 60kDa MDM2 isoform showed that it appeared to
reside in the nucleus as well as the cytoplasm across the spheroid radius, where it would have
preferential access to active transcription factors such as p53, unlike the full length molecule
which was predominantly present in the cytoplasm within healthy cell populations. However,
nuclear and cytoplasmic extracts would have to be individually assessed to confirm this.
The high expression of the truncated MDM2 protein was initially thought to account for the
lack of p53 protein found around perinecrotic areas. However, the 60kDa isoform found in
this study is thought to be lacking in a C-terminal domain which contains the ubiquitin ligase
E3 which is responsible for mediating ubiquitination of the p53 molecule and/or self
ubiquitination of the MDM2 molecule (Figure 35). A RING finger domain also situated on
carboxyl terminal is responsible for coordinating this intrinsic E3 activity (Honda et al.,
2000). Removal of either the E3 domain or the RING finger domain can result in the loss of
ubiquitination capabilities. Therefore, the lack of the whole C-terminal domain would result
in an increase in the half life of the truncated MDM2 molecule because MDM2 mediated
degradation of p53/MDM2 complexes or MDM2 itself would not occur (Honda et al., 2000;
Fang et al., 2000). A similar 60kDa MDM2 has previously been identified in a variety of
breast cancer cell lines (Pochempally et al., 1998) (Figure 35). This isoform was found to
have a significantly longer half life than 90kDa MDM2 and was found in non-apoptotic
tumour cells. The MDM2 splice variants found in astrocytic tumours were found to be
lacking regions encoding for the N-terminal p53 binding domain and are different than the
60kDa isoform identified in this study.
Artificially induced, truncated MDM2 isoforms with a similar configuration to the 60kDa
isoform found in this study have been shown to bind to and inhibit transactivation of down
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stream targets of p53. In all of these experiments, the truncated transcripts encoded proteins
with intact N-terminal p53 binding domains and defective C-terminal regions. In experiments
performed by Yap et al (2000) and Chen et al (1996), MDM2 mutants (MDM2-A(222-437),
MDM2-A(340-491), MDM2-A(440-491)) were created by removing residues over the C-
terminus of the MDM2 protein removing either the critical ubiquitin ligase function of the
MDM2 and/or the RING finger E3 controlling domain (Figure 35). The antibody
combinations used, together with the size of the MDM2 protein found in this study suggests
that the endogenous form found in the glioma cell lines is likely to result in the loss of both
these domains. These three mutants were found to bind to and inhibit p53 induction of
endogenous p21 expression. There was little or no difference between the ability of these 3
mutants and wild-type, full length MDM2 in preventing Gi arrest by p53. It is possible
therefore, that in the glioma spheroid system, the lack of p21 expression situated within
spheroid central regions may be explained by the increase in truncated MDM2. Although the
interaction of Bax and other down stream target molecules with truncated MDM2 have not
been previously investigated, it is likely that a similar p53-independent inhibition may occur.
However, it is interesting to note that the transuppression of the pro-survival genes Bcl-2 and
MAP4 (microtubule associated protein 4) remain unaffected by the artificial addition of
truncated MDM2 (Miyashita et al., 1994). It is likely that the E3/degradation function of
MDM2 is required to prevent transuppression of these genes.
Using the same MDM2 mutants (MDM2-A(222-437), MDM2-A(340-491), MDM2-A(440-
491)), p53-dependent apoptosis was found to be significantly reduced in cell lines expressing
high levels of the truncated MDM2 isoforms, although they were not as effective as the full
length molecule. It is therefore likely that in spheroids derived from p53 wild-type cell lines
U87 and A172, p53 mediated cell death may be severely compromised by the presence of
high levels of 60kda MDM2. Similarly, in vivo, stressed glioblastoma cell populations that do
not harbour p53 mutations, but possess large quantities of the 60kDa MDM2 isoform may
have a decreased susceptibility to cell death compared to those without high level of this
protein. 80% of the biopsies examined in this study also exhibited high levels of endogenous
perinecrotic 60kDa MDM2.
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Because MDM2 associates with pathways other than the p53 pathway, accumulation of
60kDa MDM2 may be advantageous to both p53 wild-type and p53 mutant tumours. This is
reflected in the large quantities of 60kDa MDM2 found within perinecrotic tissue in both P53
wild-type and mutant tumours. Large quantities of intracellular truncated MDM2 may
influence levels of cell cycle regulatory molecules including the Rb (retinoblastoma gene
product) protein and E2F1. The MDM2 protein can interact physically and functionally with
the Rb protein and, as with p53, can inhibit pRB growth regulatory function and allow cell
cycle progression (Xiao et al., 1995). Because the MDM2 protein binds the Rb protein with
its N-terminus, the truncated molecule may be able to modulate cell cycle progression in a
similar way to the wild-type molecule. It is thought that E2F1 has a dual function in
regulating cell cycle progression and apoptosis which are partly under the control of p53 and
MDM2. Firstly, MDM2 has been found to associate with E2F1 and another transcription
factor, DPI at the activation domain of p53 (Martin et al., 1995). In doing this MDM2 can
positively augment proliferation through S-phase. Secondly, high levels of MDM2 can block
E2F1 mediated induction of apoptosis and also block the E2Fl-mediated accumulation of
p53 (Kowalik et al., 1998). Because the N-terminal binding domain on the 60kDa MDM2
isoform found in this study is thought to be intact, it is possible that a similar effect may
occur within glioma cell populations. The absence of a C-terminal domain suggests that E2F-
l/pl4ARF mediated degradation of 60kDa MDM2 will not occur. The resulting abnormal
activity of the Rb and E2F-1 pathways could therefore result in variations in the proliferative
and survival status of the cell. It is theoretically possible that under periods of stress, high
levels of truncated MDM2 could allow aid cell survival, inhibit apoptosis and decrease levels
of active p53.
4.3.8. Possible regulation of 60kDa MDM2
The mechanisms responsible for the activation and regulation of the 60kDa MDM2 isoform
remain unknown. If the isoform observed in these studies is identical to the similarly sized
molecule found by Pochempally et al. (1998), a post translational truncation event is likely to
have occurred. A caspase 3 analogue was found to be cleaving full length MDM2 in non-
apoptotic tumour cells in these studies. Further experiments would have to be performed
using specific caspase 3 inhibitors to examine whether this reduces levels of the 60kDa
MDM2 found in these spheroid cultures. Because of the fragment sizes found and the
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antibody specificities observed in this study, it is likely that the 60kDa MDM2 isoform found
here will have similar physiological functions to that found by Pochempally et al. The one
point that contradicts the likelihood of these being identical proteins, is the finding that the
P53 mutant lines in this study exhibit equally high levels of 60kDa MDM2 isoform as the
wild-type lines. If the 60kDa MDM2 had accumulated due to a post-translational truncation
event, full length MDM2 would have to be translated first. The T>55His273 mutation in U373
cell line has been shown to result in a reduction in the DNA binding ability of the mutant
protein to the MDM2 promoter and it is likely that the P55Vall59 mutation in the MOG-G-
CCM cell lines has a similar transcriptional deficit (Saintigny et al., 1999). Therefore, if a
post-translational truncation event is proven, it is unclear how such high levels of original
90kDa MDM2 isoform can arise in the P53 mutant cell lines. Perhaps a separate mechanism
for the transcription of full length MDM2 exists in the cell lines harbouring P53 mutations
and those without. No p53 independent transcription factors have yet been identified that can
actively transactivate the full length MDM2 promoter sequence in glioma cell lines.
However, Ras-driven Raf/MEK/MAP kinase pathway has been shown to regulate MDM2
activation in a p53-independent manner in colon cancer cells (Ries et al., 2000). In addition,
thyroid receptors (T3Rs) have been found to transactivate the MDM2 promoter sequence in
GH4C1 pituitary adenoma cells (Qi et al., 1999).
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Figure 35. Diagram of previously designed/identified full length and truncated MDM2
molecules. References: 1Honda et al., 1997; 2Pochempally et al., 2000; 3Chen et al., 1997;
4Strachan et al., 1996.
A separate mechanism for the production of high levels of 60kDa MDM2 could be the direct
transcription of truncated alternative mRNA transcripts. Rallapalli et al in 1999 found that
alternative splicing of MDM2 transcripts could result in proteins with a similar conformation
to those found in this study. An MDM2 isoform MDMX (80kDa), was found to be present in
a variety of mouse and human transformed cell lines (Figure 35). This protein has a
considerably weaker affinity for p53 than full length MDM2. Although MDMX can bind p53
and block its ability to activate to activate transcription and induce apoptosis, it can also bind
to full length MDM2 and increase p53 stability. MDMX is thought to be activated via a p53
independent mechanism as it is not induced by DNA damaging agents that are known to
induce full length MDM2. Another protein identified by this group called MDMX-S was also
identified in these experiments that, unlike MDMX was missing all three zinc-finger domains
and ubiquitin ligase E3 function. Although this protein is considerably smaller than the
60kDa protein found in this study, the interaction with p53 is likely be similar. Flowever,
post-translational modifications of this protein are likely to be very different due to
differences outwith the p53 binding domain (Figure 35). Post translational modifications by
DNA-PKs, for example, can significantly influence the activity of the MDM2 molecule
(Khosravi et al., 1999). MDMX-S is actively transcribed by the p53 protein. It is therefore
clear that different MDM2 isoforms can arise by post translation truncation events or direct
transcription of truncated MDM2, perhaps via a p53-independent mechanism. Interestingly,
U87 glioblastoma cells were tested in the Rallapalli study and were found to contain high
levels of MDMX and MDMX-S mRNA. Neither of these truncated proteins would be
recognised by the two MDM2 antibodies, SMP-14 and C-18 , used in this study.
Further research needs to be completed into the activation of the 60kDa MDM2 molecule
found in this study. Defining the amino acid composition of the protein using mass
spectrometry should confirm the status of this protein as a definite isoform of the full length
MDM2 molecule. In addition, an accurate structural analysis need to be performed in order
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to establish the importance of this protein in relation to cell death susceptibility within
glioblastoma cell populations. What is clear from previous studies is that a large amount of
an MDM2 isoform lacking a C-terminus is likely to significantly influence the interactions of
many pro-apoptotic and pro-survival proteins. It is also unknown why this truncated MDM2
becomes localised around and within areas of necrosis in glioblastoma biopsies and
spheroids. Perhaps the activation of pro-death pathways actively encourages the
accumulation of these abnormal isoforms, which do not occur in normal cells. Or perhaps
this 60kDa isoform is lost in the proliferating cell population due to some unknown
mechanism. It is however likely that the expression of abnormal MDM2 isoforms in
transformed cells may represent an important step in neoplastic transformation in cancer
cells. The results in this study suggest that the accumulation of some abnormal MDM2
isoforms may occur in tumours exhibiting both mutant and wild-type P53. This implies that
that 60kDa MDM2 isoform may increase tumourigenicity in pathways other than those
involving p53. Previously studies have shown that abnormal build up of full length MDM2 is
normally associated with primary glioblastomas exhibiting wild-type P53 (Kraus et al.,
1999., Rasheed et al., 1999).
4.3.9. MDM2 upregulation and activation of apoptosis
Because p53 accumulation and its downstream targets Bax and p21 appear not to be
important for the onset of cell cycle arrest/apoptosis in these experiments, the mechanisms
that activate the observed levels of endogenous cell death within these glioblastoma cell
populations remain unclear. Interestingly, recent research has highlighted the ability of
MDM2 to arrest cell cycle in normal human fibroblasts and promote apoptosis in p53
deficient human medullary thyroid carcinoma cells (Dilla et al., 2000). In addition, various
MDM2 overexpression experiments have shown that MDM2 can contribute to an apoptotic
response following DNA damage. Genotoxic aryl-hydrocarbons ( BPDE) for example, have
been shown to augment an MDM2 mediated apoptotic response (Hsing et al., 2000; Wu et
al., 1999). The mechanism by which MDM2 contributes to apoptosis in these experiments
has not yet been elucidated. However, it has been suggested that the E2F family of
transcription factors may be involved. E2F-1, as previously mentioned, is involved in both
cell cycle progression and apoptosis (Xiao et al., 1995). MDM2 is known to bind to Rb and
derepress E2F-1 activation. Theoretically, high levels of MDM2 (or perhaps truncated
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MDM2) could bind to Rb thus allowing E2F-1 overexpression and subsequent acceleration
of both cell cycle progression and apoptosis. These suppositions are supported by
experiments showing concurrent increases in E2F-1 and MDM2 expression in response to
BPDE (Hsing et al., 2000).
Although the above findings are generally associated with direct DNA damage, the
involvement of ARNT (HIF-ip)with AhRs (aryl-hydrocarbon receptors) implies similar
pathways could be activated in response to various types of free radical and oxidative stress
(Dipple, 1995; Hemminki, 1993). As a result, it is possible that the extremely high levels of
MDM2 observed in this system around central regions regardless of P53 status may
encourage suppression of p53 mediated apoptosis and induce an apoptotic response through
E2F-1. However, the involvement of p53 related proteins, other than those studied here,
cannot be ruled out. It is likely that a combination of factors, including intact p53
independent pathways may play a part in activating both apoptosis, necrosis and even some
of the other observed cell death morphologies found within glioma spheroid cultures.
4.3.10. Summary of p53 related findings
Given the absence of wild-type p53, Bax and p21 proteins around areas of cell death within
glioma spheroids and in biopsy material there is no evidence to suggest that the accumulation
of these proteins is important for the onset of cell cycle arrest in intermediate spheroid
regions, or the onset of necrosis and subsequent apoptosis within stressed glioblastoma cell
populations. This lack of p53 accumulation occurred even when the wild-type P53 cell lines
were known to activate p53 dependent pathways in response to both oxidative and free
radical stress, both of which were thought to occur in central spheroid regions. The only p53
related protein investigated in this study that was seen to be increased within perinecrotic
tissue was a 60kDa isoform of MDM2. A protein with a similar configuration has previously
been identified in a variety of breast cancer cell lines and is expressed in non-apoptotic cells
(Pochempally et al., 1998). This protein lacks a C-terminal domain and fails to mark the p53
protein for degradation Previous research has shown that the long half-lives of similar
proteins lacking C-terminal regions are likely to result in a decreased susceptibility to cell
death due to their capacity to inhibit both p53 transcriptional activity and post-translational
modification other cell cycle control checkpoints, such as Rb (Honda et al., 1997; Rallapalli
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et al., 1999). Therefore the presence of this isoform could significantly alter cell death
susceptibility when the cells in question are exposed to a variety of cell stresses.
It is clear that using the spheroid system to investigate the expression of the various cell
death related proteins examined in this study has been invaluable. The use of monolayer
cultures has elucidated certain protein-protein interactions and patterns of gene expression
when cells are under stress. However, monolayer cultures exposed to both hypoxia and free
radical stress cannot accurately reflect the changes in protein expression found endogenously
in vivo. It is thought that by understanding endogenous cell death in vivo we will be in a
stronger position to identify intact cell death pathways. These findings prove that growing
cells as three dimensional structures can significantly influence the expression of cell death
associated proteins under conditions of endogenous stress. The expression of p53, p21, Bax
and MDM2 (both 90kDa and 60kDa isoforms) was virtually identical in spheroid cultures
and within phenotypically similar areas in glioblastoma biopsy material. The benefits of
experimenting with the glioma spheroid system over archival glioblastoma tissue is that it
can be used a model for genetic manipulation studies to investigate the properties of various
genes and proteins in a more in v/vo-like environment. Individual zones across the spheroid








The evidence thus far has suggested that p53 and its downstream target proteins, Bax and p21
are not involved in the stimulation of apoptosis around the center of glioma spheroids.
Certainly, the P53 mutant status of the lines U373 and MOG-G-CCM suggests that p53-
mediated perinecrotic apoptosis is unlikely. In addition, the lack of perinecrotic p53
accumulation also implies p53-mediated cell death is unlikely in spheroids derived from the
P53 wild-type U87 and A172 cell lines. However, the examination of protein expression
immunohistochemically is insufficient to fully assess the functional capabilities of the p53
molecule in this system. Downregulation of p53 together in the presence of high levels
60kDa MDM2 do not necessarily imply that p53 is redundant in central regions. In fact,
because p53 is the known main regulator of MDM2, increases in 60kDa MDM2 suggest p53
may have some function within these cells. Perhaps the presence of 60kDa MDM2 masks the
true activity of perinecrotic p53 and the subsequent short half-life of the active p53 molecule
means that it may escape detection.
In order to investigate whether p53 has a regulatory role in determining susceptibility to
apoptosis and necrosis, P53 gene transfer technology is utilised. By modulating levels of
intracellular p53, variations in the central cell death response and levels of downstream
protein expression can be monitored. For example, if in P53 wild-type spheroids, decreases
in endogenous wild-type p53 result in a drop in perinecrotic apoptotic index, wild-type p53
may indeed be involved in the cell death response. This would in turn suggest a role for p53
in endogenous cell death in some glioblastomas harbouring wild-type P53. Modulation of
intracellular p53 levels would also confirm the importance of a wild-type P53 gene in the
normal regulation cell death in tumours harbouring mutant p53.
To fulfill the hypothesis that p53 has a regulatory role in determining cell death susceptibility
in glioblastoma, three P53 vectors were used, one wild-type P53 vector (p53wtEGFP), one
dominant negative vector (p53mtl35EGFP) and a control vector (p53mtl44EGFP)
(Vogelstein and Kinszer, 1992; Cormack et al., 1996). The wild-type vector encodes a wild-
type p53 protein that is capable of activating downstream target sequences such as Bax, p21
and MDM2. The dominant negative vector translates a p53 protein that can bind to and
inactivate any endogenous p53 wild-type activity. The control vector was used to assess the
168
effects of artificially increasing intracellular levels of a similarly sized, totally inactive p53
protein (possesses no wild-type or dominant negative activity). Therefore the aims of these
experiments were to establish whether increases in wild-type/dominant negative p53 (i)
influence levels of intraspheroidal cell death/growth (ii) alter the expression distribution of
Bax and p21 within glioma spheroids (iii) affect the expression and distribution of 60kDa and
90kDa MDM2.
To fulfill these aims, two cell lines, one P53 wild-type (U87) and one P53 mutant (U373)
were utilised. The cell line U87 has previously been transfected with vectors containing p53
inserts with no subsequent effect on cell viability (Komata et al., 2000; Badie et al., 1999). In
contrast, other researchers have observed that all U87 transfected cells die by apoptosis 3
days post-transfection (Cerrato et al., 2001; Li et al., 1997). P53 mutant cell lines including
U373 nearly always show 100% loss of cell viability by apoptosis following wild-type P53
transfection (Komata et al., 2000; Badie et al., 1999). However, it is thought that His273
mutants, such as U373, may harbour some wild-type p53 transactivation ability Signal et al.,
2000 ; Saintigny et al., 1999).
169
5.2. Results
5.2.1. Verification of p53WT and mutant vectors
To confirm the success of the transformation of the WTp53EGFP vector into chemically
competent E.Coli and subsequent plasmid preparation, a PCR was set up to amplify a
region(ex2.1-ex6.1) of the P53 gene. This region was successfully amplified (652bp) in both
the samples tested (Figure 36A).
A plasmid-only control vector was produced by removing the P53 gene from the
p53wtEGFP vector. The correct configuraton of the plasmid-only vector (poEGFP) was
proven by the presence of specific sized bands after the whole plasmid was digested with
Aval and Ncol restriction enzymes (see Table 6 for correct sized fragments, Figure 36B).
Sequencing confirmed the correct plasmid-only sequence over the ligation point after
removal of the WT P53 gene(Figure 36C).
Successful ligation and transformation of the mtl35insert into the EGFP vector
(p53mtl35EGFP) was confirmed by the amplification of a region of DNA from the CMV
promoter region (CMV1) into the P53 gene (630bp) using ten random transformed colony
lysates (Figure 36D). All ten colonies were positive, proving that the insert was correctly
orientated into the EGFP vector. Once the plasmid preparation had been performed,
sequencing over the mutation site (TGC—»TAC at codon 135) confirmed the presence of the
mutation (Figure 37A).
The amplification of the 518bp fragment between primer sequences 4.1-6.1 confirmed the
presence of a P53 sequence after the ligation of the mtl44insert (from the pCp53-scx3
Vogelstein vector) into the EGFP vector (p53mtl44EGFP) (Figure 37B). The presence of a
320bp fragment in two of the three cell lysates (instead of a 370bp fragment in the WT
sequence) following the Hhal digest confirmed the presence of the mutation at codon 144
(CAG->TAG) (Figure 37C). P53 gene sequencing of the 2 vectors absolutely confirmed the
presence of the mtl44 insert (Figure 37D).
Once the cell lines U87 and U373 had been transfected with the appropriate P53 EGFP











Figure 36. Vector conformation verification. A, gel showing PCR product between ex2.1-ex6.1
in p53wtEGFP (652bp). B, restriction digest ofpoEGFP and p53wtEGFP. l=p53wtEGFP digest
with Avail, 2=poEGFP digest with Avail, 3=p53wtEGFP digest with Ncol, 4=poEGFP digest
with Ncol. C, sequencing gel showing the ligation point of the poEGFP vector after the removal
of wtp53. D, amplification between CMV1 and ex4.2 of p53mtl35EGFP (630bp) using 10
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Figure 37. Vector conformation verification continued. A, sequencing gel showing the mutation
at codon 135 in p53mtl35EGFP compared to the wild-type sequence. B, gel showing the 518bp
PCR product from the p53mtl44EGFP vector (2 identical samples). C, Hhal restriction digest of
p53mtl44EGFP vector of PCR product from B. Samples 1 and 2 show the presence of the mtl44
vector. Samples 3 and 4 show the wild-type sequence. D, sequencing gel showing the mutation at
codon 144 in p53mtl44EGFP compared to the wild-type sequence.
strong green fluorescence (Figure 38A). Stable transfectants were not established for the
p53wtEGFP vector in U373 cell line because the cells died 3 days post-transfection (Figure
38B). Cells not successfully transfected with the EGFP vector died as a result of the toxic
effects of G418. Because the U373p53wtEGFP cells died after 3 days, these cells did not
form spheroids and were therefore eliminated from any further experimentation.
5.2.2. p53 protein expression in transfected monolayer and spheroid cultures
As expected, p53 expression was very high in the p53-transfected cell lines. U87
p53wtEGFP, p53mtl35EGFP and p53mtl44EGFP transfected cell lines showed strong p53
labelling (using both antibodies Bp53-12 and Pabl801) in over 80% of cells (Figure 39A).
Many of these cells had positively labelled cytoplasm as well as the expected nuclear staining
pattern. When the cells reached approximately 80% confluence the number of cells
exhibiting p53 positive nuclei dropped to around 60-70%. As expected, U87 poEGFP
(plasmid-only) cultures showed a similar level of p53 labelling as untransfected monolayer
U87 cultures (Figure 39A). Western blotting confirmed these findings where strong bands
were observed for U87 cells transfected with the three P53 vectors compared to a faint band
for the poEGFP U87 transfectant (Figure 39B).
Although levels of high confluency appeared to decrease the numbers of p53 positive cells in
monolayer, in spheroid cultures, 75-80% of cells expressed abnormally high levels of p53 in
the U87 spheroid culture for all of the constructs (Figures 40B-D). Levels of p53 labelling
were consistent across the radius of U87 spheroids transfected with the 3 vectors,
p53wtEGFP, p53mtl35EGFP and p53mtl44EGFP.
Although U373 cells contained a P53 mutation and therefore expressed abnormally high
levels of the mutant p53 protein, monolayer cultures transfected with the p53mtl35EGFP
and p53mtl44EGFP vectors nevertheless showed considerably darker staining than non-
transfected U373 cells (Figure 39A). A large amount of cytoplasmic labelling was observed
as well as nuclear staining. All U373 cells transfected with the p53wtEGFP vector died by
day five post-transfection and p53 immunohistochemistry was not performed. Western
blotting confirmed these findings (Figure 39B). P53mtl35EGFP and p53mtl44EGFP U373
transfectants showed darker bands than the U373 plasmid-only cells.
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Figure 38. Live U87 and U373 monolayer cultures following transfection with WTp53EGFP.
U87 cells remained healthy and formed small spheroids (A) and U373 cells dies 3 days post
transfection by apoptosis (B). Bars= 50pm
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Figure 39. p53 labelling in transfected U87 and U373 monolayer cultures. A, 1, transfected U87
plasmid-only monolayer culture showing basal levels of p53 expression. 2-4, p53 mutant and
WT U87 transfectants showing a strong 80% p53 labelling index. 5, U373 plasmid-only
monolayer culture showing basal levels of p53 expression. 6-7, p53 mutant U373 tranfectants
showing a slightly stronger p53 labelling index including evidence of cytoplasmic labelling. All
bars=100pm. B, p53 (53kDa) western blot confirming large increases in p53 expression in
p53mutant and WT transfectants.
Figure 40. p53 expression in spheroid cultures using transfected U87 and U373 cell lines. A,
U87poEGFP showing basal levels p53 expression. Strong p53 labelling across the radius in
spheroids derived from U87p53WTEGFP cells(B), U87p53mtl35EGFP cells (C),
U87p53mtl44EGFP cells (D). E, basal levels of p53 expression in U373poEGFP spheroids. p53
mutant U373 transfectants, U373p53mtl35EGFP (F) and U373mtl44EGFP (G), showing similar
labelling patterns when grown as spheroids. Note the absence of a decrease in perinecrotic p53
labelling in the p53 transfectants (F & G) as compared with the plasmid-only U373 spheroids (E)
(arrows). All bars=100pm.
In U373 spheroids, darker nuclei and more cytoplasmic p53 labelling was observed across
the spheroid radius compared to untransfected and plasmid-only groups (Figures 40F and G).
There was no significant difference in the distribution of the p53 protein between the U373
spheroids transfected with the two mutant P53 vectors. However, no decrease in p53
labelling was observed in the cells directly adjacent to the necrotic centre as in the plasmid-
only and untransfected spheroids (Figure 39E). No spheroid cultures were established for the
U373p53wtEGFP group as the cells did not survive long enough.
5.2.3. Bax, p21 and MDM2 expression in transfected monolayer and spheroid cultures
The transfection of U87 cell line with the three p53EGFP vectors did not have any significant
effect on the expression of Bax or p21 in monolayer culture. There was no variation in
intracellular Bax expression in response to the artificial induction of the wild-type and
mutant p53 proteins in the U87 cell line (Figure 41A). Notably, there was no increase in Bax
expression with the addition of the wild-type P53 vector and no reduction in Bax expression
with the addition of the dominant negative vector (p53mtl35EGFP). In the U373 cell line,
levels of Bax also remained the same in monolayer culture when the cells were transfected
with poEGFP, p53mtl35EGFP and p53mtl44EGFP vectors (Figure 41A).
In spheroid culture, levels of Bax were similar in U87 spheroids transfected with the three
p53EGFP vectors as compared to the plasmid-only cells and wild-type cells. In addition,
there was no difference in the distribution of these proteins across the radius of transfected
U87 spheroids as compared to untransfected cells (Figure 41B). Similarly, in U373
spheroids, the level and distribution of the Bax protein were not altered with the addition of
the p53mtl35EGFP and p53mtl44EGFP vectors (Figure 41B).
Levels of p21 in monolayer culture appeared unchanged with the addition of the wild-type
P53 and mutant P53 vectors. Western blotting experiments showed that in U87 cell line, the
band size and intensity was the same using the control vector poEGFP, and the p53wtEGFP,
p53mtl35EGFP and p53mtl44EGFP vectors (Figure 42A). Therefore, like Bax, the
dominant negative vector mtl35EGFP did not reduce intracellular levels of p21 and the wild-













Figure 41. Bax expression in transfeeted U87 and U373 monolayer and spheroid cultures. A,
western blot showing a similar level of Bax expression in both plasmid-only and transfected U87
and U373 monolayer cultures. B, 1-4, U87 transfected spheroid cultures showing no difference
in the distribution of Bax protein between plasmid-only (1), mtl35 (2), mtl44 (3) and wt p53 (4)
transfectants. B, 5-7, U373 transfected spheroid cultures showing no difference in the
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Figure 42. p21 expression in transfected U87 and U373 monolayer and spheroid cultures. A,
western blot showing no variation in p21(21kDa) expression between monolayer U87 cells
transfected with the p53 EGFP vectors (2-4) and the plasmid-only vector (1). The absence of p21
labelling in U373 cell lines was not altered with the addition of the two mutant p53 vectors,
p53mtl35 (6) and p53mtl44 (7). B, U87 spheroid cultures showing a decrease in p21 expression
in spheroids transfected with wtp53 (p53wtEGFP) at weeks 2 and 4 (2 & 4), compared to the
plasmid only spheroids at the same time point (1 & 3). All bars= 100pm.
poEGFP, p53mtl35EGFP and p53mtl44EGFP cells all showed a complete absence of p21
protein (Figure 42A).
In spheroid culture, U87 cells transfected with the poEGFP, p53mtl35EGFP and
p53mtl44EGFP vectors all showed similar labelling patterns. However, the p53wtEGFP
vector resulted in an unexpected decrease in p21 expression across the radius of the spheroids
compared to the plasmid-only and mutant spheroids (Figure 42B). This was mainly apparent
at weeks 1-2. At week 3 peripherally labelled cells were much less frequently observed than
in plasmid-only and mutant cultures. U373 spheroid did not show any variation in p21
expression with the addition of the two mutant P53 vectors.
Levels of 60kDa MDM2 appeared to be slightly decreased in monolayer cultures derived
from U87 cells transfected with the p53mtl35EGFP vector compared to the control poEGFP
and p53mtl44EGFP cells (Figure 43A). However, this was only apparent in the western
blotting experiments. No difference was observed in the in situ labelling of these cells. There
was no difference in 60kDa MDM2 expression between cells transfected with p53wtEGFP,
p53mtl44EGFP and poEGFP (Figure 43A). No variations were observed in 60kDa MDM2
labelling between p53mtl35EGFP, p53mtl44EGFP and poEGFP transfected U373 cells. In
U87 spheroid cultures, there was no difference in 60kDaMDM2 labelling between poEGFP,
p53wtEGFP, p53mtl35EGFP and p53mtl44EGFP vectors in terms of both intensity and
distribution (Figure 43B). Similarly, no variation in 60kDa MDM2 labelling was observed in
U373 spheroids transfected with poEGFP, p53mtl35EGFP and p53mtl44EGFP vectors
(Figure 43B).
Like the 60kDa MDM2 protein, the 90kDa MDM2 protein appeared to be slightly decreased
in monolayer cultures derived from U87 cells transfected with the p53mtl35EGFP vector
compared to poEGFP and p53mtl44EGFP cells (Figure 43A). Again, however, this appeared
only in the western blotting experiments. No difference in 90kDa MDM2 expression using
monolayer p53mtl35EGFP cells was detected immunohistochemically. Levels of 90kDa
MDM2 were increased in U87 monolayer cells transfected with the p53wtEGFP vector
(Figure 43A). Similarly, in U87p53wtEGFP spheroid cultures, there was an increase in















Figure 43. MDM2 expression in transfected U87 and U373 monolayer and spheroid cultures. A,
western blot showing 60kDa and 90kDa MDM2 expression in p53 transfected cells in monolayer
culture. B, 1 and 2, 60kDa MDM2 immunohistochemical labelling of central regions of
U87poEGFP(l) and U87p53wtEGFP(2) spheroid cultures. B, 3 and 4, MDM2 immunohisto¬
chemical labeling of peripheral regions of U373poEGFP(3) and U373p53mtl35EGFP(4)
spheroid cultures. All bars=lOOpm.
compared to control cultures (Figures 44A and B). The expression of this increased levels of
90kDa MDM2 was primarily cytoplasmically located. In the U373 cell line, no differences
were observed between poEGFP, p53mtl35EGFP and p53mtl44EGFP cells for the 90kDa
MDM2 protein in either the monolayer or spheroid cultures (Figures 43A).
5.2.4. The effects of p53 modulation on monolayer growth
Using the MTT proliferation assay, U87poEGFP, U87p53wtEGFP, U87p53mtl35EGFP and
U87p53mtl44EGFP all showed similar growth rates (Figure 45A). Similarly U373poEGFP,
U373p53mtl35EGFP and U373p53mtl44EGFP showed similar growth rates (Figure 45B).
Therefore the addition of the above P53 vectors did not have any effect of monolayer growth
in either of the two cell lines. Only transfecting U373 cell line with the p53wtEGFP vector
caused significant growth inhibition and subsequent death of the U373 cells.
5.2.5. The effects of p53 modulation on spheroid growth
After following the same protocol as with the wild-type spheroids (2.11.1), the radius
measurements taken over the 5 week period from spheroids transfected with the wild-type
and mutant p53 vectors showed that there was no statistical difference (p>0.05) between
transfected, control and non-transfected cells. This was similar for both U87 and U373
spheroids (Figures 45C and D).
5.2.6. P53 gene transfer and cell death in spheroid cultures
Apoptotic counts taken from U87poEGFP, U87p53wtEGFP, U87p53mtl35EGFP and
U87p53mtl44EGFP cell lines showed that the mean apoptotic index for spheroids containing
the wild-type insert were slightly higher than the 2 mutant transfectants and the plasmid only
spheroids over the 5 week period (Figure 45E). However, statistical analysis (using a split-
plot ANOVA) proved this not to be significant (p>0.05). Although not graphed, there was
also no significant difference in cell number between U87 spheroids transfected with P53
wild-type and mutant vectors. There was also no difference in the apoptotic indices between
transfected and non-transfected U373 spheroids over the 5 week period (Figure 45F). Similar
to the U87 transfected cultures, there was also no difference in cell number between
transfected and non-transfected U373 spheroids.
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There was no difference in the time of onset of central necrosis, in U87 and U373 cells
transfected with either the wild-type or mutant P53 EGFP vectors. Areas of necrosis began to
evolve over week 3 in all of the cultures. In addition, subsequent increases in the areas of
central necrosis did not vary between cells transfected with control vectors and those
transfected with wild-type and mutant P53 transcripts. In all of the transfectants derived from
both U87 and U373 cell lines, areas of central necrosis consisted of, on average, around 5%
of the spheroid radius at week 3 and this increased with spheroid diameter over the
subsequent 2 weeks.
5.2.7. HIF-la expression in transfected spheroid cultures
There was no variation in HIF-la expression in monolayer cultures transfected with
poEGFP, p53wtEGFP, p53mtl35EGFP and p53mtl44EGFP vectors for either U87 or U373
cell lines. In spheroid culture however, there was an increase in HIF-la expression outside
the perinecrotic zone in U87p53wtEGFP transfected cells (Figure 44D). In all other
transfected cells lines HIF-la expression was confined to central regions (Figure 44C).
Increased HIF-la expression in association with wild-type P53 transfection was confirmed
by western blotting experiments using spheroid culture whole cell lysates where HIF-la
expression was higher in U87p53wtEGFP cells than the other U87 transfectants after 3
weeks of spheroid culture.
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Figure 44. 90kDa MDM2 expression (using MDM2(C-18) antibody) in U87poEGFP spheroids
(A) and U87p53wtEGFP spheroids (B). HIF-1 □ expression was confined to central regions in
U87poEGFP spheroids (C) but was present throughout the spheroid mass in U87p53wtEGFP
cells (D). All bars=100pm.
Figure 45. Graphs showing the growth characteristics of transfected U87 and U373 monolayer
and spheroid cultures. A, MTT assay results using transfected U87 cells. B, MTT assay results
using transfected U373 cells. C, spheroid radius over time for transfected U87 cells. D, spheroid
radius over time for transfected U373 cells. D, number of observed apoptotic figures per
spheroid over time for transfected U87 cells. E, number of observed apoptotic figures per



















5.3.1. Summary of results
Levels of spheroid growth and cell death were found not to differ between U87 cells
(possesses endogenous wild-type P53) transfected with plasmid-only (PO), wild-type P53
(WTp53), dominant-negative P53 (Mtl35p53) and control P53 (Mtl44p53). Peripheral
expression of p21 appeared to be reduced in spheroids derived from cells containing the
wild-type P53 transcript. In the same spheroids, increases in HIF-la and 90kDa MDM2 were
observed whereas levels of 60kDa MDM2 and Bax remained unaffected. In the U373 cell
line (possesses endogenous mutant P53) transfection with wild-type P53 resulted in cell
death by apoptosis in all of the cultures by 3 days post transfection. The addition of
dominant-negative P53 (Mtl35p53) and control P53 (Mtl44p53) did not have any effect on
U373 spheroid growth or death. In addition, these two vectors failed to influence levels of
endogenous Bax, p21 and MDM2 (60kDa and 90kDa) expression in U373 spheroid culture.
5.3.2. p53 expression in monolayer and spheroid cultures
U87 and U373 monolayer cultures were stably transfected with each of the P53 vectors
preceding spheroid formation. Although over 90% of cells appeared EGFP positive in live
culture conditions, only 75-80% of cells in U87 (p53wild-type) appeared to be strongly p53
positive at high confluency levels. It has previously been shown that cell-cell contact can
discourage the activity of the transfected vector which governs both the activity of the neor
cassette and p53 protein production (Sasaki et al., 1992). However, in spheroid cultures, the
p53 labelling index was very high, even within spheroid central regions where cell-cell
contact was maximal. It was more difficult to monitor exogenous p53 expression in U373
cultures due to the presence of large amounts of mutant protein. EGFP was present in nearly
100% of live monolayer U373 cultures and p53 immunoblots showed considerably stronger
bands in the transfected lines compared to the plasmid only controls. P53
immunohistochemical labelling was also noticeably stronger in U373 spheroid cultures, even
including spheroid central regions where p53 labelling was low in the plasmid-only controls.
These findings confirmed that when the two cell lines were grown as spheroids there were
consistently high levels of exogenous p53 across the spheroid radius.
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5.3.3. Monolayer and spheroid growth following P53 gene transfer
U87 monolayer cultures transfected with the 4 vectors (p53mtl35EGFP, p53mtl44EGFP,
p53wtEGFP and poEGFP) showed similar growth curves once stable transfectants were
obtained. The addition of wild-type P53 (p53wtEGFP) to this cell line failed to reduce cell
numbers over a five day period. Similar results have been found using this cell line by other
investigators (Cerrato et al., 2001; Shinoura et al., 2001; Badie et al., 1999). Other
researchers have observed a rapid drop in U87 monolayer viability following transfection
with similar P53 containing vectors, but this was not found in this study (Li et al., 1997;
Komata et al., 2000). As has been suggested previously, cell lines with similar names have
been found to possess different genotypic alterations, possibly due to the transformation of
the lines in culture and/or mix up of cell line samples (Van Meir et al., 1997).
Similar growth results were observed when the U87p53wtEGFP transfectants were grown as
spheroid cultures. There was no decrease in size in spheroids derived from cells transfected
with p53wtEGFP compared to the control lines. Therefore growing U87p53wtEGFP cells as
3-dimensional structures did not stimulate any reduction in spheroid growth as a result of
exogenous wild-type P53.
Transcripts encoding P53 with a p53135Val mutation express a highly stable p53 protein
with a conformation-dependent loss of wild-type activity and the ability to eliminate any
endogenous p53 wild-type activity (and often p63 and p73 activity) in a dominant negative
manner (Shaulian et al., 1992; Unger et al., 1993; Di Como et al., 1999; Strano et al., 2000;
Strano et al., 2002). The addition of the p53135Val dominant negative vector failed to alter
U87 monolayer growth in this study. In addition, when U87p53mtl35 cells were grown as
spheroids, no increase in spheroid size was observed compared to control spheroids over the
5 week period. Studies have shown that induction of p53135Val and other dominant negative
p53 proteins to wild-type p53 cultures can result in an increase in the transformation ability
of various cell lines by increasing proliferative potential (Slingerland and Benchimol, 1991;
Signal et al., 2000). Core domain mutants such as p53135Val have been shown to be able to
transactivate the c-myc promoter (Frazier et al., 1998), the proliferating cell nuclear antigen
promoter (Deb et al., 1992), the human heat shock protein 70 promoter (Tsutsumi-Ishii et al.,
1995) and the human epidermal growth factor receptor promoter (Ludes-Meyers et al., 1996).
188
However, aberrations in proliferative pathways in the U87 cell line may render it
unsusceptible to further transformation. Other studies have shown that the introduction of
dominant negative p53 proteins to cell lines can block differentiation (Shaulsky et al., 1991).
However, the morphology and GFAP positivity of cells situated within the so-called 'region
of differentiation' appeared unchanged in the presence of p53135Val compared to control
cultures. The size of this region also remained consistent between spheroids derived from the
various transfected clones.
The addition of wild-type p53 to the P53 mutant U373 cell line resulted in loss of the entire
cell population 3 days following transfection. This is consistant with a central role for loss of
p53 function in the transformation of this cell line. P53 mutations are often early
transformation events vital for the survival of tumour cells and are common in secondary
glioblastomas (Rasheed et al., 1999). Subsequent alterations often occur that add
transformation potential to the cells, although this is rarely sufficient to prevent death
following addition of exogenous wild-type p53. Similar findings have been found using the
U373 cell line by other researchers (Badie et al., 1999; Komata et al., 2000; Shinoura et al.,
2001). Badie et al observed that U373 cells undergo massive apoptosis and die within
48hours of treatment with adenoviral P53 (Adp53). There has been some suggestion that
p53273His mutants retain wild-type configuration and can activate CAT p53 reporter
sequences. As a result, it was thought that this mutant is capable of activating, at least
partially, some downstream targets of the p53 protein. However, in terms of monolayer and
spheroid overall growth, the addition of the dominant negative P53 vector had no positive
effect on U373 cell numbers compared to the plasmid-only and p53mtl44EGFP controls
suggesting that the p53273His mutant molecule has little capacity for overall growth
inhibition.
5.3.4. Intraspheroidal cell death following P53 gene transfer
The addition of exogenous wild-type P53 to the U87 cell line failed to increase the basal
level of apoptotic cells present in monolayer culture. In some glioma cell lines, such as the
C6 rat glioma cell line, cell cycle arrest/apoptosis does occur directly as a result of P53
transfection (Timiryasova et al., 1999). However, it has been shown that adding exogenous
wild-type p53 to other cell lines that already possess a wild-type P53 gene increases p53
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pathway activation following cellular insults, rather than stimulating an apoptotic response
directly as a result of increasing levels of exogenous protein (Badie et al., 1999). This was of
particular interest when studying glioblastoma cell populations, where areas of extreme cell
stress occur within densely populated regions of tissue distinct from the tumour vasculature.
The cell line A172, for example, contains wild-type P53 and demonstrates minimal apoptosis
after infection with Adp53; however, apoptosis increases following treatment with increasing
doses of irradiation compared to non-transfected A172 cells (Badie et al., 1999). This
suggested that some P53 wild-type tumours may be sensitive to wild-type P53 gene transfer
only when exposed to stress. However, when central regions of cell stress were observed in
U87 spheroids, no increases in apoptotic or necrotic cell death were observed between
spheroids derived from U87p53wt vectors and U87mtl44 and U87plasmid-only vectors.
Onset and subsequent growth of the area of necrosis occurred at the same time point and
perinecrotic apoptotic indices remained similar between the different transfected clones. The
differing responses of Adp53A172 (Badie et al., 1999) and p53WTU87EGFP cells (in this
study) to stress were initially thought to be a result of exposure to different types of stress
(A172 was exposed to p53 inducing irradiation in studies by Badie et al, and intraspheroidal
U87 cells were likely to be exposed to a combination of hypoxia, metabolite depletion and
waste product build up). However, U87 cells have previously shown a intrinsic resistance to
increasing doses of irradiation following infection with Adp53 (Badie et al., 1999).
Although there will be variations between gene transfer techniques, particularly in terms of
transfection efficiency, it is clear that different P53 wild-type lines have variable responses to
wild-type P53 gene transfer. For example, C6 cells die directly following Adp53 infection,
A172 cells infected with Adp53 die following irradiation and U87 cells transfected with
WTp53 vectors are resistant to high levels of wild-type p53 protein and both irradiation and
perinecrotic stress in spheroid cultures. Other studies have even shown that using a 9L (a rat
P53 wild-type cell line) brain tumour model in vivo, exogenous wild-type p53 expression
conferred an additional survival advantage when exposed to radiation compared to non-
transfected 9L cells (Bampoe et al., 2000). Conversely, the addition of rW(recombinant
vaccina virus)-WTp53 to monolayer 9L cells results in total growth inhibition and
subsequent apoptosis (Timiryasova et al., 1999). The combination of these findings between
different cell lines and different brain tumour models accentuates the need for studies
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examining a variety of wild-type P53 lines using 3 dimensional systems to assess the efficacy
of P53 wild-type gene transfer methods and the susceptibility to endogenous cell death
within in vivo glioblastoma cell populations.
Dominant/negative gene transfer into U87 cells failed to reduce the observed basal levels of
apoptosis observed in monolayer culture and/or the increases apoptotic observed around
perinecrotic areas in spheroid culture. It has previously been shown that transfection of P53
wild-type cell lines with dominant negative P53 can increase resistance to chemotherapeutic
agents. For example, the transfection of human ovarian carcinoma cells (A2780 cell line)
possessing wild-type P53 with p53135Val results in a resistance to the chemotherapeutic
reagent CCNU (N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea) (Aquilina et al., 2000).
However, this is unlikely to occur in U87 cell line due to the resistance of the U87 cells to
radiation following Adp53 infection and the lack of resistance of U87 cells to perinecrotic
cell death following dominant negative transfection.
As previously described, 100% of U373 successfully transfected cells died apoptotically 3
days post transfection therefore U373p53wtEGFP cells did not form spheroid cultures.
Nearly all studies examining wild-type P53 gene transfer on P53 mutant lines result in a
significant reduction in survival of the cells. Commonly used P53 mutant glioma lines
include U373, GB-1, T98G, U251-MG and LG. All of these lines die a week post
transfection following Adp53 infection (Shinoura et al., 2000; Komata et al., 2000; Shinoura
et al., 2001; Badie et al., 1999; Hong et al., 2000). These findings suggested that there were
no other genetic alterations present that were sufficient to allow survival of these lines.
U373p53mtl35EGFP and U373p53mtl44EGFP cells did form spheroids, although there was
no difference in the onset of central necrosis and/or the surrounding perinecrotic apoptotic
index. This implies that there is no evidence to suggest that inhibiting residual mutant P53
function has any effect on spheroid growth and/or death.
5.3.5. P53 gene transfer and Bax expression in glioma spheroid culture
Wild-type P53 gene transfer into U87 cells did not affect levels of Bax protein in monolayer
or spheroid cultures. These findings are consistent with those of Badie et al (1999) and
Shinoura (2001), where there was no change in the high levels of endogenous Bax with the
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addition of Adp53 and/or Adp53 combined with irradiation in this line. In addition, no
increase in Bax expression was observed within perinecrotic tissue in response to exogenous
wild-type p53 expression. These results confirmed the findings in the hypoxia experiments
where an upregulation of wild-type p53 was not followed by an increase in Bax. Therefore it
is clear that in the U87 cell line, there is no p53 dependent stimulation of Bax, even under
conditions of extreme metabolic stress.
To further confirm that there was no relationship between Bax and p53 in this cell line, the
consistently high levels of endogenous Bax present in U87 cells were not affected by the
addition of the dominant negative p53135Val vector. If p53 were responsible for influencing
endogenous levels of Bax, the p53mtl35 protein would bind to and nullify further
transcription of Bax mRNA (Signal and Rotter, 2000). These observations were consistent
over a long period of time incorporating many subsequent generations using stable
p53135Val transfectants. Therefore, in addition to previous evidence in this study showing
that endogenous Bax expression is present within perinecrotic tissue in the absence of wild-
type P53, these further experiments have shown that endogenous expression of Bax in U87
cell line is almost certainly p53 independent. Although the mechanisms behind p53-
independent activation of Bax require elucidation, other investigators have recorded both
high levels of endogenous Bax and an upregulation of Bax following exposure to
chemotherapeutic agents in tumour cell populations that do not express wild-type p53
(Strobel et al., 1996).
Although wild-type p53 was unable to upregulate levels of Bax in U87 cell line, it is
interesting to note that when increasing amounts of exogenous Bax are added to these cells
there is no stimulation of apoptosis or necrosis (Naumann and Weller, 1998). These findings
appear to be cell line specific (Vogelbaum et al., 1999; Shinoura, 2001). Adenoviral
transfection of Bax into the P53 wild-type cell line A172 results in necrotic cell death
(Shinoura et al., 1999). A high level of Bcl-XL (a pro-survival member of the Bcl-2 family)
was found to prevent Bax-induced apoptosis in this cell line. When levels of Bax were
further increased, the necrotic mode of death was replaced by an apoptotic mode of death.
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Levels of Bax were not measured in U373 cells following the induction of p53wtEFGP
because the cells died before spheroids could be grown. However, other studies have shown
that transfection of U373 cells with Adp53 does result in an upregulation of Bax protein and
subsequent cell death by apoptosis, as was seen in this study (Shinoura et al., 2001; Badie et
al., 1999). High levels of endogenous Bax in U373 cell line were not effected by the
expression of the dominant negative P53 vector. Therefore, it is possible that endogenous
Bax, like that found in U87 cells, may accumulate independently of p53.
The inactivity of endogenous Bax in U373, may occur as a result of equally high endogenous
levels of pro-survival proteins such as Bcl-2 and Bcl-XL. When exogenous p53 is added to
the cell, levels of Bax increase thus allowing Bax homodimerisation on the mitochondrial
membrane and subsequent cytochrome C release (Hengartner, 2000). U373 cells and other
P53 mutant lines such as U251 appear to be more sensitive to adenoviral induction of Bax
than P53 wild-type lines such as U87 and A172 (Naumann and Weller, 1998; Shinoura et al.
1999; Yin et al., 1997).
The presence of active and inactive forms of Bax and other pro-apoptotic Bcl-2 family
members in tumour cells has also been hypothesized. High levels of endogenous Bax, Bid
and Bad proteins found in tumours with increasing grade with or without corresponding
decreases in pro-survival family members. This suggests that basal levels of these so-called
pro-apoptotic proteins may have little or no pro-apoptotic function (Kurabayashi et al., 2001;
Korsmeyer et al., 1999).
The findings involving the ability of p53 to activate Bax in the 3 lines U87, U373 and A172
appear to reflect levels of cell death both in the spheroid system and in experiments
performed by others. P53 gene transfer did not result in increasing levels of Bax and no
apoptosis occurred in U87 cell line. Apoptosis arises in response to p53 and subsequent Bax
expression gene transfer in U373 cells. A172 appears to fall into an intermediate group were
increasing levels of Adp53 result in apoptosis only when exposed to an element of cell stress
(eg irradiation) and/or very high levels of Bax accumulation (Shinoura et al., 1999).
5.3.6. P53 gene transfer and p21 expression in glioma spheroid culture
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p21 expression in large U87 untransfected spheroid cultures was localized around the
spheroid periphery. Surprisingly, the addition of wild-type p53 to the U87 cell line resulted in
a dramatic decrease in this p21 expression, whereas no decrease in p21 expression was seen
in monolayer U87 cultures as a result of exogenous wild-type p53. There can be no simple
explanation for these findings. The cells in both monolayer and spheroid cultures are situated
within close proximity to the medium. The only difference that is apparent is that more cells
are proliferating within the spheroid periphery and the cells are more closely associated.
Even the levels of peripheral 60kDa MDM2 in U87 cell line were similar to monolayer levels
thus transactivation of the p21 promoter was not inhibited by the presence of abnormal levels
of this protein on the spheroid periphery. It is clear that whatever is causing this phenomena
is specific to cells growing in 3-dimensional culture. Therefore, the cell-cell interactions that
occur in spheroid culture and in vivo may significantly influence the expression and
interaction of p53 related proteins. Gene transfer studies using monolayer cultures may not
accurately reflect the likely response of glioblastoma cell populations in vivo to various gene
transfer strategies.
Due to the P53 null status of the U373 cell lines, levels of p21 in U373 were not altered using
the dominant/negative p53 vector. p21 levels remained extremely low/non-existent in both
monolayer and spheroid cultures.
5.3.7. P53 gene transfer and MDM2 expression in glioma spheroid culture
Increases in wild-type p53 expression due to hypoxia and transfection with the p53wtEGFP
vector resulted in a slight increase in full length 90kDa MDM2 in monolayer U87 cultures. In
addition, when the dominant negative p53mtl35EGFP vector was transfected into U87 cells
a reduction in 90kDa MDM2 was seen compared to the control cells, U87poEGFP and
U87p53mtl44EGFP. These findings suggested that the levels 90kDa MDM2 found in this
cell line are under control of the p53 protein. This was further supported by the finding that
higher levels of 90kDa MDM2 and p53 co-exist around the spheroid periphery in
untransfected U87 spheroid cultures. Full length 90kDa MDM2 is known to be upregulated
by p53, and is often seen to be upregulated concurrently with p53, as a means of controlling
p53 levels within the cell (Kubbutat et al., 1997). Most of the 90kDa MDM2 expression was
cytoplasmically located, suggesting that it had translocated from the nucleus. Cytoplasmic
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localization of MDM2 occurs when p53 is being shuttled by full length MDM2 into the
cytoplasm following ubiquitination (Honda et al., 1997). This allows degradation of the
MDM2/p53 complex by the proteosome. Because of the high level of exogenous wild-type
p53 in U87p53wtEGFP cells, full length MDM2 is likely to be active in this role. P53
labelling was also seen to be present in the cytoplasm of some cells. Because a homozygous
deletion has been identified in the CDKN2A locus endcoding the pl4ARF protein in the U87
cell line, P14ARF inhibitory activity in regulating this translocation is likely to be
compromised.
In contrast, 60kDa MDM2 did not appear to be regulated by wild-type p53. The addition of
p53wtEGFP to U87 cells did not increase levels of 60kDa MDM2 either in monolayer or in
spheroid culture compared to the control lines. Levels of this protein did appear to be slightly
reduced using the dominant negative P53 vector in the western blotting experiments but this
was not confirmed when examining monolayer cultures in situ or in the spheroid cultures.
Possibilities for the p53 independent induction of 60kDa MDM2 are discussed in 4.3.7. The
absence of a corresponding increase in 60kDa MDM2 with increasing 90kDa MDM2
expression suggests transcriptional activation of a truncated mRNA splice variant, rather then
post translational caspase cleavage of the full length molecule. Although the relative stability
of a 30kDa MDM2 C-terminal fragment is not known, the absence of such a fragment on the
various western blotting experiments performed is again indicative of a direct transcriptional
event.
Similar levels of endogenous 90kDa MDM2 were found in untransfected U373 cells as in
untransfected U87 cells. Considering that the regulation of full length MDM2 appears to be
under control of the p53 in the U87 cell line, these findings are surprising. Siantigny et al
(2000) demonstrated that p53273His mutants are capable of activating the MDM2 promoter
sequence on average at 30% of the activity of the wild-type protein. Therefore it was initially
suggested that this 90kDa isoform may be produced as a result of some residual
transactivation activity of the p53 transcription factor. However, the dominant mutant
p53135Val when transfected into U373 cells failed to inhibit production of full length
MDM2. Similar levels of full length MDM2 were observed in both monolayer and spheroid
cultures between control and dominant negative p53 U373 cells. Therefore it appeared that
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both 90kDa and 60kDa MDM2 were activated independently of p53 in this cell line. The
question was raised as to whether the dominant negative p53135Val mutant could effectively
bind to and inhibit the p53273His molecule. It was assumed that heteromerization would
occur due to the wild-type configuration of the both molecules. In addition, the
oligomerization regions (residues 319-360) of the two molecules are known to be fully
functional in these two mutants. However, further investigation may be required to confirm
this.
It is possible that intrinsic MDM2 gene amplification may have occurred in this line.
However, this finding would be unusual as CDKN2A mutations and MDM2 amplification are
rarely found in glioblastomas or glioma cell lines harbouring P53 mutations (Fulci et al.,
1998; Rasheedet al., 1999; Ishii et al., 1999).
5.3.8. P53 gene transfer and HIF-la expression in glioma spheroid culture
The addition of the dominant negative vector p53mtl35Val to either U87 or U373 cell lines
failed to have an effect on the expression of HIF-la either in monolayer or spheroid culture.
This was not surprising as p53 is thought to play a role downstream of HIF-la.
Dephosphorylated HIF-la is known to bind to the p53 protein to activate p53 dependent
apoptosis (Suzuki et al., 2001). The phoshorylation status of HIF-la was not monitored in
this study. Therefore it was not possible to determine whether the HIF-la found in this study
was of the type that associates with p53 and promotes apoptosis or whether is was the
phosphorylated form that associates with HIF-ip (ARNT) to promote VEGF expression and
neovascularisation (Suzuki et al., 2001). In this study, HIF-la expression was largely used as
a marker of the oxygenation/metabolic status of the central core of the spheroid cultures for
the characterization part of the study (3.4.5).
When wild-type P53 was added to U87 cells, a definite increase in HIF-la was observed
within spheroid cultures that was not apparent in monolayer culture. HIF-la was observed
across the spheroid radius, not localized within pre or perinecrotic tissue as in the
untransfected/control groups. Although HIF-1« is thought to have an upstream effect
stabilizing p53, there is no evidence in the literature to suggest that p53 has a regulative role
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in modulating levels of HIF-la. Certainly, p53 is known to repress phosphorylated HIF-lcx
mediated transcription of genes such as VEGF and PDEGF (platelet derived endothelial
growth factor) (Blagosklonny et al., 2001; Dachs and Tozer, 2000). Perhaps high levels of
exogenous p53 can, under some circumstances, be involved in a positive feed back loop
resulting in an increase in pro-apoptotic dephosphorylated HLF-la.. However, in some cells
possessing wild-type p53, HIF-la mediated accumulation of p53 may be largely redundant,
such as in U87 cell line, where the addition of wild-type p53 does not increase
intraspheroidal apoptotic index. These findings may be more relevant to wild-type and
mutant P53 cells lines that have altered cell viability following p53 gene transfer.
5.3.9. Summary of P53 modulation experiments
The aim of these experiments was to examine whether altering endogenous levels of
intracellular p53 has an effect on tumour cell death susceptibility in P53 wild-type U87
spheroids and in P53 mutant U373 spheroids. Contrary to some reports, U87 monolayer
culture viability was not affected by increasing or decreasing intracellular wild-type p53
levels (Cerrato et al., 2001; Li et al., 1997). Similarly, when U87 cells were metabolically
stressed within large glioma spheroid cultures, the modulation of intracellular wild-type p53
did not effect the onset of central death or apoptotic index. This occurred irrespective of
alterations in p21, HIF-la and full length MDM2 expression. These findings show that it is
highly unlikely that p53 plays a direct role in the activation of endogenous cell death in U87
spheroids. The implications of these findings for wild-type P53 glioblastoma populations are
limited, due to the fact that only one cell line (U87) was used in this study. P53 gene transfer
experiments done by others show (Timiryasova et al., 199; Badie et al., 1999) that this
response is likely to vary between cell lines, thus a wide variety of cell lines need to be tested
in order to fully investigate the importance of p53 in endogenous cell death within 3-
dimensional cell populations harbouring a wild-type P53 gene. However what is clear, is that
when situated within metabolically deprived environments, some P53 wild-type tumour cells
do not activate p53 mediated pathways resulting in an apoptotic phenotype, even following
the addition of large amounts of exogenous wild-type p53. This could have implications for
therapeutic targeting of specific p53 related pathways in tumours with a similar genetic
background.
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The addition of exogenous wild-type p53 to p53 mutant U373 cells resulted in apoptotic cell
death in the entire cell population 3 days following transfection. This is often seen to occur
P53 mutant cell populations derived from most cancer types (Komata et al., 2000; Badie et
al., 1999). This confirms that the P53 mutation is likely to be the single most important
transformation event in this line. Because the dominant negative vector failed to have an
effect on either cell death or the transcription of downstream genes, the mutant p53His 273
protein is likely to possess very little residual pro-apoptotic activity. This is contrary to
findings using artificial luciferase promoter sequences suggesting that p53His 273 mutants
can activate the WAF1 (p21) and MDM2 promoter sequences at up to 30% of wild-type p53
(Saintigny et al., 1999). However, these latter observations utilising the dominant negative
P53 vector should be taken with care as the binding affinity of the mutant p53135Val protein
to the p53273His protein has not been fully elucidated in this study. However, all of above
results support the conclusion that endogenous cell death observed in U373 spheroids is
unlikely to occur via a p53 related mechanism.
The origins of the 60kDa MDM2 isoform could be further elucidated using the P53 gene
transfer studies. In experiments using the U87 cell line, 60kDa MDM2 was unaffected by
increases in p53 expression and subsequent 90kDa MDM2 upregulation. Therefore it is
likely that 60kDa MDM2 arises independently of p53 and is not derived from the 90kDa
MDM2 molecule. This was further supported by the presence of equally high levels of
60kDa MDM2 in the P53 mutant U373 line. More importantly, because a lack of p53
mediated apoptosis was demonstrated within the transfected spheroid cultures, the presence
of the 60kDa MDM2 isoform may be largely redundant in its inhibition of p53 dependent
transcription. Therefore as previously suggested, 60kDa MDM2 may be involved in other
pro-apoptotic or even cell survival pathways, perhaps involving E2F-1 and Rb. This would
explain the selection for high levels of 60kDa MDM2 expression in glioma cell lines
exhibiting both P53 mutant and wild-type genotypes in the absence of a p53 mediated
apoptotic response.
One of the most important conclusions of this part of the study was that successful
production of spheroids derived from transfected cell lines was demonstrated. This is means
that future studies investigating protein function through genetic modification will be
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possible. One particular line of interest may be to create inserts encoding truncated MDM2
sense and anti-sense transcripts. The effect of modulating levels of 60kDa MDM2 on cell
death susceptibility/ tumourgenicity within glioma spheroids could then be assessed.
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5.4. General conclusions and further work
The killing of tumour cells in vivo is the single most important factor in reducing tumour
volume. Many researchers have devised potential therapeutic strategies based on their
efficacy using monolayer culture systems using permanent cell lines. However, the
homogeneity and morphology of these systems often does not reflect the in vivo scenario.
Avoiding the expense and time consuming nature of animal experimentation, the spheroid
system has been shown in these experiments to possess many of the features present within
in vivo glioblastoma, particularly those relating to cell death.
One of the first conclusions of this study was that large glioma spheroid cultures appeared
highly representative of glioblastoma mutiforme in terms of patterns of cell death,
differentiation and proliferation. These compared favourably with cross sections of
glioblastoma biopsy material spanning from blood vessels to nutritionally compromised
tissue distinct from the vasculature. The formation of central areas of necrosis and
subsequent onset of apoptosis in spheroid cultures resulted in morphologies very similar to
the small foci of necrosis surrounded by pseudopallisading layers of tumour cells seen in
vivo. The observed predictable onset of necrosis in spheroids derived from the four cell lines
examined allowed the cultures to be examined at a particular time point and any changes
could be monitored that were associated with individual cell lines and also following
alterations to the genotype of the lines.
Many current studies involve targeting pro-death genes, such as P53, depending on the
genotype of the representative cell lines in question. However, in this study, regions of
endogenous intra-spheroidal cell death were monitored in order to assess the activity of
specific proteins/pathways that may be important for glioma cell death susceptibility. In the
P53 wild-type cell lines U87 and A172, the p53 protein and its downstream targets p21 and
Bax were found not to be important for the onset of endogenous cell cycle arrest or cell death
in 3-dimensional spheroid cultures. This appeared to be the case even when p53
accumulation was found to be associated with monolayer exposure to oxidative and free
radical stresses. In addition, when U87 cells were transfected with vectors encoding a variety
of P53 wild-type and mutant transcripts, no effect on cell death susceptibility was observed.
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Therefore, even when levels of wild-type p53 were extremely high in this cell line,
subsequent increases in cell death were not observed.
High levels of perinecrotic apoptosis in the P53 mutant lines U373 and MOG-G-CCM lines
suggested that p53 was not responsible for endogenous cell death in these lines. The addition
of wild-type p53 to U373 cells resulted in the death of the whole monolayer population 3
days post transfection, whereas addition of the dominant negative transcript had no effect on
endogenous Bax expression or on cell death. This confirmed that the p53273His mutant
possessed little or no pro-apoptotic function. Therefore apoptosis in spheroids derived from
this line must arise via a p53 independent mechanism.
These experiments using spheroid cultures suggest that p53 accumulation is not important for
the onset of endogenous cell death not only in P53 mutant tumours, but also in some tumours
harbouring a wild-type P53 gene. It is possible that growing cell lines as 3-dimensional
cultures may be the best way of testing the potential of targeting p53 related pathways, even
when p53 accumulation and subsequent cell death is seen using monolayer culture systems.
Further experimental analysis utilizing a variety of P53 wild-type cell lines grown as 3-
dimensional cultures should hopefully further elucidate these findings.
The presence of high levels of a perinecrotic 60kDa MDM2 isoform could have significant
implications in cell death susceptibility in tumours harbouring both wild-type and mutant
p53. Although the P53 gene in both the P53 wild-type cell line U87 and the P53 mutant line
U373 appeared to be essentially redundant within perinecrotic tissue, high levels of truncated
MDM2 could associate with Rb allowing E2F family mediated cell cycle progression and
resistance to cell death depending on the RB status of the tumours in question. These
interactions may theoretically protect centrally located cells against very low p02 levels and
even allow E2F-1 mediated apoptosis to occur depending on specific, as yet unidentified,
pathophysiological stimuli. Other p53 independent pro-apoptotic molecules may also be
involved. Further work examining the relationship between 60kDaMDM2 and Rb/E2F
family members is therefore required. A series of experiments examining the effect of
increasing levels of 60kDa MDM2 in cell lines exhibiting low levels of 60kDa MDM2 in
response to various types of stress may implicate a pro-survival/pro-death role for such high
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levels of this novel protein. In addition, the 60kDa MDM2 isoform needs to be
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The development of necrosis and apoptosis in glioma: experimental findings using
spheroid culture systems
Cell death in gliomas may occur either by apoptosis, or,
in the case of high grade tumours, by necrosis, but
questions remain as to the pathogenesis and relation¬
ship between these processes. The development of cell
death was investigated in multicellular glioma spheroid
cultures. Spheroids model the development of cell death
due to diffusion gradients in a three-dimensional system
without confounding influences of immune response,
pressure gradients, etc. Spheroid cultures were estab¬
lished from four malignant glioma cell lines: U87,
U373, MOG-G-CCM and A172; harvested from culture
at weekly intervals and stained with Haematoxylin and
Eosin (H&E), TdT-mediated dUTP-X nick end labelling
(TUNEL) and by immunohistochemislry for vimentin,
Glial Fibrillary Acidic Protein (GFAP) and Ki67.
Annexin V flow cytometry and counts of apoptotic
cells on H & E stained sections were performed to assess
levels of apoptosis. Modes of cell death were also
characterized by electron microscopy. Spatially separate
zones of proliferation, differentiation and central cell
death developed with increasing spheroid diameter.
Central cell death developed at a predictable radius
(300-400 |_im) for each cell line. Ultrastructural exami¬
nation showed this to be necrotic in type. Apoptosis
was most reliably assayed by morphological counts
using H & E. Basal levels of apoptosis were low
(<0.5%), but increased with increasing spheroid dia¬
meter (>2% in U87). In particular, levels of apoptosis
rose following development of central necrosis and
apoptoses were most abundant in the peri-necrotic
zone. There were quantitative differences in the levels of
apoptosis and necrosis between glioma cell lines. The
predictable onset of necrosis in the spheroids will allow
us to investigate the pathogenesis of necrosis and events
in prenecrotic cells. There is a relationship between the
development of necrosis and apoptosis in this model
and these processes can be separately assayed. Further
in vitro and genetic studies will enable us to study these
events and interactions in greater detail than is possible
using other cell culture and in vivo systems.
Keywords: Glioma, spheroid, apoptosis, necrosis, TUNEL labelling, Annexin V
Introduction
The growth rate of tumours is dependent both on the
rate of proliferation and on the rate of cell loss [41]. Cell
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loss due to the death of cells may occur due to either
apoptosis or necrosis. Apoptosis is a process that often
requires new gene transcription and the triggering of
complex regulatory pathways [49]. In contrast, necrosis
is sudden and accidental cell death brought on by a large
stimulus sufficient to kill the cell and generate an
inflammatory response. Necrotic cell death, sometimes
referred to as oncotic necrosis, is characterized by
membrane damage and energy depletion. Necrosis is
generally regarded as an unregulated process which, in
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contrast to apoptosis, is not under genetic control |46].
However, necrosis is a poorly understood process and
it is possible that there are regulatory mechanisms
involved, perhaps separate from those involved in
apoptosis [10].
Both apoptosis and necrosis are observed in glioma.
Apoptotic bodies are observed in both high and low
grade gliomas and apoptotic index generally increases
with tumour grade. It tends therefore to be associated
with more aggressive behaviour, although it has not
been found to be of independent prognostic significance
[13,31,38], In the diffuse astrocytoma group of tumours,
necrosis is associated with high grade tumours |2| and
is a diagnostic feature to allow the categorization of
an astrocytoma as glioblastoma multiforme [23], In
glioblastoma, (here is emerging evidence that two distinct
types of necrosis exist [22]. The first of these has an
inl'arct-like pattern and is thought to be ischemic in
origin. The second type observed is that of smaller areas
of necrosis surrounded by pseudopallisading layers of
tumour cells. It has been suggested that such areas may
have evolved from small clusters of apoplotic cells [22].
Differences between these two types of necrosis have also
been found in the perinecrotic tumour cells. Expression of
Fas (CD95). a member of the TNF receptor super-
family which mediates some apoptotic signalling path¬
ways. has been found particularly in cells around areas of
ischaemic necrosis, whilst cells with apoptotic features
are found particularly around pseudopallisaded necrosis
[43], These findings suggest that a relationship may exist
between apoptosis and necrosis in glioma, although the
relationship between the two is uncertain.
in contrast, there is some evidence to suggest that
apoptosis and necrosis are independently regulated.
Levels of apoplosis appear to vary according to tumour
type [40]. Some CNS tumours, such as oligodendro¬
gliomas and medulloblastomas, have higher apoptotic
indices but do not necessarily contain areas of necrosis
[38], Levels of apoptosis and variations between tumour
types are likely to be determined in part by the expres¬
sion of various oncogenes [6,19]. In some systems,
susceptibility to necrosis is inversely proportional to
apoptosis [3], In astrocytomas, it is unclear whether
apoptosis and necrosis develop in parallel, or whether
they are independently determined. It may be important
to distinguish between these processes and their
associated mechanisms when considering pro-apoptotic
therapies.
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A number of in vitro and in vivo models have been
developed to study the characteristics of glial tumour
cell growth [7,8,16,39]. Monolayer and cell suspension
systems are of great value when assessing detailed cell
function and studying regulation of apoptosis, but they
do not reconstruct the cellular microenvironments
present within a tumour cell mass and there are no
simulated nutrient gradients. In addition, many in vitro
models are limited in the study of cell death in that they
do not model necrosis. The spheroid system for cell
culture is a three-dimensional (3-D) model which creates
areas of proliferation, differentiation and cell death
within a tumour cell mass [26,42,44]. These areas can
be studied individually when the spheroid becomes larger
and a nutrient gradient forms across the radius of the
spheroid. Brain tumour spheroids have been used to test
the response of tumour cells to various therapeutic
stimuli within the 3-D tumour cell mass and the invad¬
ing cell population [5,37]. Many studies have reported
the presence of a central area of necrosis within the glial
cell spheroids and some groups have examined responses
of these oxygen deprived cells [34,35], However, the
exact mechanisms resulting in this area of cell death
remain unclear.
The aim of this study was to develop the spheroid
model to study the pathogenesis of cell death in glioma.
Multicellular tumour spheroids were derived from four
different human glioma cell lines, U87. U373, MOG-G-
CCM and A172, which have different molecular genetic
alterations [2()|. It was hypothesized that this model
would allow spatial separation of zones of proliferation,
differentiation and cell death. The study objectives
were: (I) to determine how cell death occurs in glioma
spheroids: is it necrotic or apoptotic? (II) lo determine the
time course of development of central cell death and
how levels of apoptosis vary with lime and size (III) to
establish the best means of quantifying both apoptosis
and necrosis in this model, with the aim of comparing ceil
lines with different genetic backgrounds (IV) to determine




Four human glioma cell lines derived from anaplastic
astrocytoma or glioblastoma multiforme (GBM) were
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used in this study: A172, MOG-G-CCM, U373, and U87.
All cell lines were supplied by the European Collection
of Cell Cultures, CAMR, Salisbury, UK. They were grown
in monolayer in Dulbecco's Modified Eagles Medium
(DMEM) supplemented with 10% foetal calf serum (PCS),
penicillin and streptomycin (all from GibcoBRL, Life
Technologies, Paisley, Scotland).
Spheroid formation
Once the monolayer cultures became confluent the cells
were trypsinized and seeded into spinner culture flasks
at a density 3 x 10ft cells/100 ml of medium (DMEM
with 10% PCS), and spun at 180 r.p.m. for 5 weeks
(previously described in Bell et al. 1999 [6]). Approxi¬
mately 200 spheroids from each cell line were removed
from culture at weekly intervals, 50% of these were used
for flow cytometry and 50% for paraffin embedding
following fixation. 5 pm sections were then cut for
H & E (haematoxylin and eosin) staining, immunohisto-
chemistry and TUNEL labelling. 30-40 spheroids were
also removed at these time points for EM processing.
Immunohistochemistry
All immunohistochemistry was performed using
the standard immunoperoxidase protocol. The three
antibodies used were Glial Fibrillary Acidic Protein
(GFAP) (DAKO Ltd, Cambridgeshire, UK, dilution
1: 1000), Ki67 (Novocastra Ltd, Vector Laboratories
Ltd, Peterborough, UK, dilution 1 : 200) and Vimentin
(DAKO Ltd, dilution 1 :200). The slides to be stained
with Vimentin and Ki67 were first microwaved in a
citrate buffer for 15 min. The secondary antibodies
used were swine antirabbit (DAKO Ltd) for GFAP and
goat antimouse (Vector Laboratories Ltd) for Ki67 and
Vimentin. The avidin-biotinylated enzyme complex
used was a vector elite kit (Vector Ltd). The stain was
visualized using diaminobenzidine tablets (Sigma-Aldrich
Company Ltd, Poole, Dorset, UK), then the sections were
counterstained with haematoxylin and examined using
light microscopy.
TUNEL labelling
TUNEL (TdT-mediated dlJTP-X nick end labelling) labels
DNA strand breaks which occur during early apoptosis
[28]. Spheroid sections were dewaxed. rehydrated as
€ 2001 Blackwell Science Ltd. Neuropathology and Applied Neurolno
above and incubated with proteinase K for 20 min at a
concentration of 20 pg/ml in 10 dim/HCI, pll 7.6. After
washing in PBS, the sections were incubated in TUNEL
reaction mixture (TdT-mediated dUTP-X nick end label¬
ling). This was followed by the addition of a secondary
detection system that contained a biotinylated antibody
to enable visualization of the fluorescent markers for
light microscopy (instructions as described for in-situ
Cell detection kit, AP from Boehringer Mannheim
Roche Diagnostics Ltd. Leines, East Sussex). Once
the substrate was added (5-Bromo-4-Chloro-3-Indolyl
Phosphate/Nitro Blue Tetrazolium Tablets (BCIP/NBT)
from Sigma) the sections were washed, dehydrated,
counterstained and mounted as above.
Light microscopy
The sections were examined using light microscopy and
the regional staining patterns of TUNEL, Ki67, GFAP
and vimentin staining were recorded photographically.
The slides stained with H & E were used to measure the
radius of the spheroids for each cell line at each given
time point using a graticule. The 10 largest spheroids
were measured on each slide and the average taken.
These sections were also used to establish the time point
for each cell line when a central area of cell death first
appears. The number of cells per spheroid were also
counted to determine spheroid packing density. This was
done using a specially designed graticule (Graticules
Division, Pyser-SGI Ltd, Edenbridge, IJK), to count indi¬
vidual segments of each spheroid examined. A segment
representing 10% of the area of each spheroid was
counted and the 10 largest spheroids (as above) from
each slide were chosen. Morphological apoptotic counts
were also recorded using H & E stained sections in the
technique mentioned in the previous sentence. An
apoptotic index was determined for each cell line as a
percentage of total cell counts per spheroid (Al).
Electron microscopy (EM)
Spheroids derived from the four cell lines at each time
point were fixed for 2 h at 4"C in 3% glutaraldehyde
in 0.1 m Sodium Cacodylate/HCl buffer pH 7.2-7.4.
They were then washed 3 times in double distilled
water for 20 min and fixed for 45 min in 1% osmium
tetroxide. Following dehydration to 100% ethanol, the
spheroids were submerged in propylene oxide for 30 min
i. 27. 291-304
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then left overnight in Emix resin (Taab Laboratories,
Aldermaston, Berks, UK) at room temperature. Once the
spheroids had polymerized (20 h at 70°C), 90 nm
sections were cut with a glass knife on a Reichert
0MU2 microtome and mounted on 300 mesh copper
grids. The sections were then stained by the Uranyl
Acetate/Lead Citrate method and examined using a
Jeol 100 CXI1 transmission electron microscope with
an operating voltage of 60 KV. Photographs were
taken using Kodak 4489 film and developed using a
Ilford P & 0 Universal developer (Ilford Imaging UK Ltd,
Mobberley, Cheshire, UK) on Ilford Multigrade glossy
photographic paper. Spheroids derived from each cell line
at each time point were assessed and photographed.
The ultrastructural types of cell death observed in week
three spheroids were morphologically and quantatively
assessed in a single spheroid for each of the cell lines.
Flow cytometry
At weekly intervals, the spheroids were disaggregated
following centrifugation (3000 g for 5 min) in
universal tubes using trypsin (0.5 g trypsin and 0.2 g
EDTA in 250 ml PBS) in a water bath at 37°C for 5 min.
To avoid membrane damage, cycles of resuspension
were used to break down spheroids from weeks 4-5.
10 mis of DMEM (containing 10% ECS, as above) was
then added to each tube to inhibit the action of the
trypsin. The cells were then centril'uged again, the
supernalent removed and the cells suspended in 100 pi
of Annexin V/propidium iodide solution (Boehringer
Mannheim - see instructions for methods) for 15 min
at room temperature. 400 pi of PBS was then added
and the resulting cell suspensions were analysed using
a Coulter EPICS XL flow cytometer (Beckman Coulter Ltd,
High Wycombe, Buckinghamshire, UK) with EPICS
XL-MCL System II software (Beckman Coulter Ltd.
High Wycombe, Buckinghamshire, UK). This identified
apoptotic and necrotic cells on the basis of side scatter
and fluorescence associated with Fluorescein-labelled
Annexin V and propidium iodide [12]. In the early stages
of apoptosis, phosphatidyl serine residues flip to the
external side of the cell membrane. These can be labelled
with the Annexin V probe. The cell membranes of
necrotic cells become permeabilized early on. allowing
the entry of both the Annexin V probe and propidium
iodide. The combination of high Annexin V labelling with
low propidium iodide labelling indicates an apoptotic cell,
whilst high labelling for both Annexin and Propidium
iodide indicates a necrotic cell.
Statistics
A split plot analysis of variance (anova) was used to
assess in situ cell counts and apoptotic index results.
To analyse the former, a null hypothesis was set up
where 'the total number of cells per spheroid remains the
same between cell lines over time'. After finding that
Mauchly's test of sphericity was significant, the F-ratio
was obtained using the new degrees of freedom calcu¬
lated using the Huynh-Fel Epsilon value. In order to
analyse the distribution of apoptotic index over time,
a null hypothesis was set up where 'the apoptotic index
of each spheroid remains the same between cell lines
over lime'. After finding that Mauchly's test of spheri¬
city was significant, again the F-ratio was obtained
using the new degrees of freedom calculated by using the
Huynh-Fel Epsilon value.
Results
Phenotypic characterization of the spheroid
system
Positive GFAP staining in all 4 cell fines (MOG-G-CCM.
U87, U373, A172) in monolayer culture confirmed their
glial nature. In spheroid cultures the staining pattern
varied from weeks 1-5. At week one, GFAP positive cells
were diffusely scattered across the radius of the spheroid
(Figure la). As the spheroids became larger at week 2,
GFAP labelling was observed in the centre of the
spheroids (Figure lc). By week four GFAP positive cells
were found in a ring around the centre of the spheroid
Figure 1. Light micrographs showing various immunohistochemical staining patterns in IJ87 cell lines over weeks 1-5. (a). Week 1
spheroids showing random GFAP labelling across the radius, (c), Central GFAP staining pattern at week 2. (e), Ring of GFAP positivity around
the spheroid centre at week 4. (b). Random distribution of Ki67 labelling across the radius at week 1. (d), Localization of Ki67 around
the spheroid periphery at week 2. (f). Week 4 spheroids show no Ki67 labelling centrally, but a very high peripheral index, (g). Central TUNEL
positivity in week 4 spheroids, note the absence of TUNEL labelling in some apoptotic cells (arrow) and positively labelled central necrotic
tissue, (h). H & E showing central areas of necrosis (right) surrounded by apoptotic figures (left) at week 4. All bars= 100 gm.
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(Figure le), with loss of staining in the spheroid centre
and no labelling of the outer proliferating cells. This
pattern was the same in all four cell lines examined.
The antibody against human vimentin demonstrated
a similar pattern to GFAP although the staining was
much fainter. At week one the Ki67 antibody labelled
cells randomly across the radius of the spheroids in a
similar pattern to GFAP with a nuclear pattern of
staining (Figure lb). However, by week 2 Ki67 was
confined to the perimeter of the spheroids and no positive
cells were observed in the centre (Figure Id & f). This
proliferative rim was approximately 100 pm wide and
was consistent in all of the cells lines examined.
Ultrastructural examination of individual spheroids
revealed that the cells formed intermediate junctions and
became closely packed together as the spheroids became
larger (Figure 3a). This was particularly apparent
within the viable rim at weeks 3-4. The cells around
the periphery of the spheroid became polarized with the
nucleus basally situated towards the spheroid centre
(Figure 3b).
Glioma spheroid growth kinetics
The four cell lines showed similar growth rates when
grown as spheroids (Figure 2a). At the end of the first
week, the spheroids had a radius of approximately
50 pm. This increased over 4 weeks until the radius
of the spheroids reached approximately 500 pm. On
average, A172 spheroids were slightly larger than the
other three cell lines but this was not statistically
significant. Between weeks 1 and 3 the cell counts
remained low (below or around 2000 cells/spheroid).
This was followed by a huge increase in cell number
from weeks 3-4 (Figure 2b). By week 5 the cell numbers
had levelled at approximately 10 000 cells per spheroid
(Figure 2b). There were differences in cell number over
time between cell lines. Al 72 spheroids contained the
largest number of cells over the 5-week period compared
to the other three cell lines (P< 0.001) with a maximum
cell number of 14 000 cells at week 5. This was due to
reduced cell loss in the A172 cell line. There was no
significant difference (P> 0.05) in cell numbers between
U87, MOG-G-CCM and U3 73 cell lines. Cell packing
density dropped over weeks 1-3 in each cell fine as the
cells became more loosely packed within the spheroid
mass (as observed under EM), but increased from
weeks 4-6 as the cells became very tightly packed
around the spheroid periphery (Figure 2c). There
was a slight increase in packing density in week 5
spheroids derived from the A172 cell line compared
to the other cell lines at week 5. This was due to the
lack of cell death in the spheroid centre (Figure 2d).
As packing density was relatively similar between cell
lines, it was not thought to influence the onset of
cell death in this model.
The qualitative distribution of cell death in
glioma spheroids
Central cell death developed over week 3 in all four cell
lines (Figure 2e), although the extent of necrosis varied
considerably between lines (Figure 2d). Thus necrosis
could be accurately predicted at a certain time point and
size for each cell line. By week 5 the areas of necrosis were
very large in 3 of the 4 cell lines, U87, MOG-G-CCM and
U373 (Figure 2d). A1 72 exhibited a different pattern of
necrosis, where the percentage of the radius that was
necrotic over weeks 3-4 did not increase above 10%
(Figure 2d).
Using week 3 spheroids it was possible to identify three
morphological types of cell death using electron micro¬
scopy. The first type was characterised by large swollen
cells, dilation of organelles and break up of the cell
membrane, features typical of necrosis (Figure 3c). The
second type was characteristic of apoptosis: electron
dense cells (resulting from cell shrinkage), condensation
of chromatin, nuclear fragmentation and a convoluted
cell membrane (Figure 3d). A distinct pattern of cell
death emerged with necrotic cells in the spheroid centre
surrounded by apoptotic cells (Figure )g & h). This
pattern was present in all of the cell lines examined.
Figure 2. Graphs showing the growth characteristics of U373. U87. MOG-G-CCM and Al 72 cell lines when grown as spheroids, (a). Length
of spheroid radius over time for each cell line.(b). Number of cells per spheroid for each cell line over time. (c). Packing density for each
spheroid derived from each cell line over time (number of cells per mm2), (d), Extent of necrosis in each cell line over time, i.e. the
percentage of the radius consisting of necrotic cells, (e). Graph showing the percentage of spheroids (derived from all four cell lines)
containing areas of necrosis over weeks 1-5. (f), Number of observed apoptotic figures per spheroid over time for each cell line. n = 10
for each point on the above graphs. Error bars tire shown.
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Figure 3. Electron micrographs showing the ultrastructural changes that occur when glioma cell lines are grown as spheroids,
(a), An intermediate junction formed between adjacent cells in A172 cell line (x 51 000). (b), Cell showing evidence of nuclear
polarization and autophagic activity (MOG-G-CCM). (c). A necrotic cell (Al 72). (d), An apoptotic cell (11373). (e). Vacuolar cell death
(1187). (f). The autophagic phenotype (MOG-G-CCM). (b). ( c), (d). (e) & (f): x 16000.
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A third type of cell death observed was termed
'vacuolar cell death'. Here, the cells contained huge
vacuoles, which often appeared to arise from the dila¬
tion and fusion of organelles. The cytoplasm was very
electron dense and the cell membrane appeared to be
intact, although in some instances a slight 'blebbing'
effect was observed (Figure 3e). In addition, an auto¬
phagic pattern of cell injury was identified (Figure 3f).
This phenotype was present in all of the cell lines to
some extent, but was particularly prevalent in the
MOG-G-CCM cell line. These cells contained lysosomal
vacuoles, often containing myelin whorls or fragments
of organelles. In addition, these cells were often slightly
more electron dense than normal cells, although it is
unclear whether this is due to cell shrinkage. In the
MOG-G-CCM cell line, some cells in the proliferative zone
exhibited this phenotype.
TUNEL labelling was present in the centre of week 3-5
spheroids in all of the cell lines (Figure 1 g). These were
cells which had been ultrastructurally shown to have
a necrotic pattern of cell death. Scattered cells within the
viable rim and zone of differentiation were also observed,
although there was a sharp decline in TUNEL labelling
from the centre of the spheroid to the periphery. Close
examination using high-power light microscopy revealed
that many apoptotic cells around the spheroid centre
were not TUNEL positive. For this reason, the TUNEL
results were not quantitively assessed.
Quantitative distribution of apoptosis and necrosis
in glioma spheroids
Ultra structural examination by means of electron
microscopy meant that week 3 spheroids could be
quantitatively assessed using the cell death classification
criteria described below (Table 1). A172 demonstrated
the largest proportion of necrotic cells, and U87 demon¬
strated the greatest proportion of apoptotic cells. The
vacuolar morphology was observed most frequently in
U87, and autophagic cells were observed most frequently
in MOG-G-CCM cell fine.
Morphological counts of apoptotic cells using H & E
stained sections showed thai at weeks 1-2 the apoptotic
index was nearly zero for all of the cell fines studied. This
index increased at week 3, when the central core of
cells had begun to necrose. By week 5, the apoptotic
index ranged from 0.6% in A172 cell fine to 2.75% in
U87 cell line (Figure 2f). Statistical analysis revealed
that U87 had a significantly higher apoptotic index over¬
time than the other 3 cell lines (P<0.001) and A172
had a significantly lower apoptotic index lhan U373
and U87 cell lines (PcO.OOl). These results supported
the above quantities observed using electron microscopy
(Table 1).
To further quantify apoptosis and necrosis in glioma
spheroids, Annexin V How cytometry was employed.
Although this method confirmed an increase in the
proportion of non-viable cells present in spheroids over
time, it could not distinguish between apoptosis and
necrosis in many of the cells derived from larger
spheroids. It is possible that the trypsinization process
required for disaggregation was too aggressive, causing
semi-permeablization of the cell membranes of some
non-necrotic cells that allowed the entry of propidium
iodide. Monolayer experiments using the same tech¬
niques showed valid apoptotic cell populations, suggest¬
ing that the high trypsin concentrations required for
spheroid disaggregation might be the reason for the lack
of an apoptotic cell population in these experiments.
Morphologically, viable and non-viable cells in spheroid

















Cell membrane breaks rare
MOG 11 21 4 4
U87 52 35 5 18
U373 37 46 2 8
A172 fi 67 2 0
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cell populations were distinguished by their laser scatter
characteristics. Two distinct populations with different
forward- and side-scatter were observed in disaggre¬
gated spheroid cell populations. The Annexin V labelling
in the total cell populations was approximately 2% for
week 2 spheroids derived from each cell line. For week 4
spheroids, 6% Annexin V labelling was observed for week
4 spheroids derived from the cell lines MOG, U87 and
U373 and 3% Annexin V labelling for week 4 Al 72
spheroids.
Discussion
The development of cell death in a multicellular tumour
spheroid model of human glioma was studied. The study
demonstrated that:
1. the spheroids show spatially distinct regions of
proliferation, differentiation and cell death;
2. the central area of cell death is necrotic in nature:
3. central necrosis develops at a predictable radius for
each cell line:
4. apoptosis occurs mainly in peri-necrotic cells:
5. apoptosis increases with spheroid radius, particularly
after necrosis has developed: and
6. there are differences between the cell lines with
respect to susceptibility to apoptosis and necrosis, and
in the relative proportions of each.
Glioma spheroid characterization
Certain criteria were initially established to justify the
use of this system to study specific interactions usually
only found in vivo. Spheroid cultures derived from
glioma cell lines contained regionally distinct areas of
proliferation, differentiation and cell death. GFAP stain¬
ing confirmed the glial nature of the cell lines. Expres¬
sion of GFAP was observed in an intermediate zone
between the spheroid centre and the spheroid periphery.
The outer proliferative zone did not express GFAP. This
is consistent with reports that GFAP is rarely expressed
in cycling cells in human glioma in situ [15]. GFAP
expression was lost from the spheroid centre as an area of
cell death developed. GFAP is generally expressed when
cells leave the cell cycle, become larger and extend their
processes [14], It is not clear whether the expression of
GFAP in this model is due to a stress response [27] or a
reflection of differentiation. The layer of GFAP positive
cells was termed the area of 'differentiation'.
Ultrastructural study of the spheroids over time
showed distinct cellular morphologies. The peripheral
cells showed evidence of polarization, characterized by
a basally located nucleus and the cytoplasm contained
many microvilli which extended into the medium. Inter¬
mediate junctions were observed between cells as the
spheroids became larger, similar to those found in vivo
[9], It was probable that together with the entangling of
the cell processes, these junctions held the cells within
the spheroids tightly together.
The spheroids derived from the four cell lines showed
similar growth characteristics. All four cell lines showed
identical patterns of proliferation. Ki67 positivity was
restricted to an outer zone of 100 pm in width, thus
implying that the cell lines required similar metabolic
requirements in which to stimulate proliferation around
the nutrient-rich periphery of the spheroids. Within the
proliferative zone, virtually all cells were Ki67 positive.
Because the diameter of the proliferative zone was
limited to 100 pm, the ratio of the proliferative zone to
total volume decreased as the volume of the spheroid
increased. The consequent decline in growth fraction
would itself therefore contribute to the slowing of over¬
all growth at high volumes in spheroids, as in solid
tumours [45]. The diameter of the proliferative zone
itself may well be a reflection and measure of the ability
of tumour cells to proliferate under conditions of increas¬
ing stress. Thus, together with the cell death response,
ability to proliferate under stress may be another way
by which the tumour cell response to stress determines
the growth characteristics of the tumour.
When examining the behaviour of the spheroids over¬
all, it is clear that when grown in a 3-D environment, the
cells become more closely associated and behave differ¬
ently to monolayer cultures. There is evidence to suggest
that cells grown in 3-D culture produce different growth
factors than in monolayer cultures [32], In monolayer
culture, the cellular morphologies of the four cell lines
are very different (H S Bell, unpublished data), but in 3-D
culture, they exhibit very similar behaviour patterns.
Although onset and extent of cell death differs between
cell lines in 3-D cult ure, the number of observed apoptotic
ligures and nonviable cells in spheroid culture is not
reflected in monolayer culture (HS Bell, unpublished
data), thus confirming the need for such a 3-D system to
study these processes. In addition, the spheroid system
allows the study of cellular interactions within pure glial
tissue. Cell death in this system is not a result of any
< 2001 Blackwell Science Ltd. Neuropathology and Applied Neurobiology. 27. 291-304
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immunological or inflammatory response such as those
found in vivo.
Development of cell death in glioma
The pathogenesis of cell death in glioma remains unclear.
The predictable onset of cell death in this model has
allowed us to examine the earliest structural changes
present in the central regions of brain tumour spheroids
as they become larger and the centre becomes nutrient
depleted. These can be directly compared to similar
situations in vivo. Ultrastructural examination of the
spheroids at 3 weeks, when the centres are metabolic-
ally stressed, revealed (he presence of both apoptotic
and necrotic cells in a particular pattern. In all four
cell lines cell death in the centre of the spheroids was
necrotic in type. Apoptotic cells surrounded this area and
decreased in number towards the spheroid periphery. The
cells within the central area of cell death were labelled
with the TIJNEL reaction, despite the fact that death
in this area was proven ultrastructuraily to be necrotic.
The TUNEL method has previously been shown to lack
specificity, in that it may label necrotic as well as
apoptotic cells [17,18], In our system too, TUNEL lacked
the ability to discriminate between different cell death
patterns. It may also label very actively transcribing
nuclei [25],
it was hypothesized that the area of central cell death
might arise by apoptosis rather than necrosis. Sublethal
injury may induce apoptosis in a variety of settings
including hypoxic states in vivo [4,36] and in cell lines
grown in monolayer culture [30], In the case of the
spheroid model, the slowly increasing stress associated
with increasing diameter might initially be expected to
produce a sublethal insult. However, we found no
evidence to support this contention, the central area of
cell death appears necrotic at the earliest lime point,
although admixed cells with apoptotic morphology
were seen. There is emerging evidence that apoptosis
and necrosis are not entirely distinct processes, but may
coexist, with the energy status of the cell determining
whether apoptosis or necrosis occurs [29,33]. Thus, an
initially apoptotic process might become necrotic. Such
a pattern has been documented in human and experi¬
mental myocardial infarction 11,21,48], A very early
apoptotic phase preceding necrosis cannot be entirely
excluded in our model, but certainly completion of cell
death for most of the central cells is necrotic in type,
< 2001 Blackwell Science Ltd, Neuropathology anil Applied Neurobic
indicating that central energy depletion rapidly becomes
too severe to allow an apoptotic mode of death.
Although variations existed between cell lines, nearly
all the apoptotic cells observed within the spheroids
were surrounding the central area of necrosis. This could
be a result of sublethal injury to these cells as the radius
of the spheroid became larger. However, this seems
unlikely as apoptosis was not stimulated to any great
extent when the central regions of prenecrotic spheroids
were subjected to a similar stress. It is likely that
necrotic tissue in the centre of the spheroids may have
stimulated an apoplolic response in surrounding cells,
suggesting the presence of a relationship between the
two processes. Products of phospholipase degradation of
membranes and reactive oxygen intermediates released
during necrosis [28] are possible candidate pro-apoplotic
agents. This is supported by the increase in the number of
apoptotic figures observed elsewhere within the tumour
cell mass from weeks 3—5, after areas of necrosis have
formed. Whereas the apoptotic index was nearly zero
from weeks 1-2, the index rose rapidly following the
onset of necrosis.
Ultrastructural examination revealed two other cell
injury morphologies. In one process, termed 'vacuolar
cell death', the cell cytoplasm contained huge vacuoles,
which often appeared to arise from the dilation and
fusion of organelles. The cytoplasm was very electron
dense and the cell membrane appeared to be intact,
although in some instances a slight 'blebbing' effect was
observed. Some of the features appeared intermediate
between classical apoptotic and necrotic morphologies,
consequently it was difficult to classify this form of cell
death. Vacuolar cell death patterns were mostly asso¬
ciated with the U8 7 cell line and were observed mainly
in the centre of the spheroid admixed with necrotic cells.
Another phenotype that was particularly prevalent in
the MOG-G-CCM cell line was characterized by the
presence of abundant myelin-like membrane whorls
within the cytoplasm. It was unclear whether this
autophagic pattern was an injury response which
would eventually lead to the death of the cells con¬
cerned, as many of the cells around the periphery of
the spheroids derived from MOG-G-CCM cell line also
expressed this autophagic pattern as well as cells
towards the centre. Varying cell death morphologies, in
addition to classical apoptosis and necrosis, have been
observed in other systems. These include vacuolar and
autophagic patterns of cell death in developing neurones
27. 291-304
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[101. The significance of the varying morphological
patterns which we have observed in the spheroid model
suggests that there may be other mechanisms and/or
intermediate phenotypes involved in cell death in glioma
besides those of necrosis and apoptosis.
Quantitative comparison of cell death between
cell lines
The group of tumours classed as GBM vary in terms of
both histological appearance and genetic background.
Differences in the molecular genetics of gliomas range
from p53 mutations resulting in the accumulations of
other mutations in secondary GBM. to EGFR ampli¬
fication having a central role in the development of
de novo tumours [11]. These differences result in equally
aggressive and morphologically similar cancers [24],
Therefore, the development of cell death in spheroids
derived from cell lines with differing genetic backgrounds
was compared in this study [20,47].
Differences in the susceptibility to cell death between
cell lines started to become apparent at week 3. Although
central cell death appeared in all of the cell lines at this
time point, the spheroids varied in size. For example, the
A172 cell line had an average radius of nearly 400 |im
whereas U87 cell line had a average radius nearer
300 pm. These measurements are crucial as the spheroid
radius is the limiting factor for the passage of metabolites
from the spheroid periphery to the centre.
Apoptotic index over time was measured using 3
techniques: morphological counts using Ff & E stained
sections. TUNEL labelling and Annexin V flow cyto¬
metry. Using H & E stained sections, significant differ¬
ences in apoptotic index between cell lines were observed.
Between weeks 1 and 2 the apoptotic index in all of the
cell lines was nearly zero but by week 3, U87 spheroids
had significantly more apoptotic ligures than the other
three cell lines. U373 and MOG-G-CCM cell lines had
intermediate levels of apoptosis. A172 had the least
number of apoptotic figures over time and this was
confirmed by the ultrastructural data at week 3. Annexin
V flow cytometery reflected these results in terms of cell
viability i.e. U87, MOG-G-CCM and U373 lines had
significantly larger non-viable cell populations over time
compared to the A172 cell line. However, it could not
distinguish accurately between apoptotic and necrotic
cell populations due to membrane damage during
trypsin disaggregation. As TUNEL was not accurate in
labelling all of the observed apoptotic figures present and
often labelled necrotic cells as well as apoptotic cells, H &
E stained sections of paraffin embedded spheroids proved
to be the best method of quantifying cell death in glioma
spheroids.
The extent of central necrosis varied between cell
lines over time. At week 3, Al72 cell line had a relative
excess of necrotic cells compared to apoptotic cells and
other cell death morphologies. However, as the spheroids
became larger, this small number of necrotic cells
(<10% of the radius) did not increase in size as was
observed with the spheroids derived from the other cell
lines (> 50%), nor was there any observed increase in
apoptotic index. Therefore, A172 showed an overall
decrease in susceptibility to cell death compared to the
cell lines U373, MOG-G-CCM and U87, and this was
reflected in terms of apoptotic index and the extent of
necrosis. This reinforced the earlier evidence suggesting
that necrosis may play a role in the stimulation of
apoptosis in this model. It certainly implies that inducible
apoptosis in the glioma spheroid system does not occur
independently of necrosis. When these results were
compared to the genotypic characterizations made by
Van Meir et al. [27], there was little correlation between
the extent of apoplosis and relevant mutations present in
these cell lines. However, further analysis is required to
include all four cell lines and other genes involved in the
regulation of cell death pathways.
In conclusion, we have investigated the development
of cell death in a glioma multicellular tumour spheroid
model. We have shown that the central area of cell death
which develops is necrotic in type and the predictable
nature of its onset will enable the study of putative
regulatory events in prenecrotic cells. Apoptosis tends
to increase with necrosis in this model and comparisons
between cell lines suggest that there is a relationship
between the susceptibility to necrosis and to apoptosis.
The low levels of apoptosis observed at weeks 1 and 2,
when the spheroids are small and relatively unstressed,
suggests (hat the effect of the dysregulated cell cycle of
these tumour cells alone is a small contributor to levels of
apoptosis. In contrast, most of the apoptosis observed
appears to be that which is induced, either by stresses
caused by increasing diffusion gradients or by break¬
down products of necrotic cells. Differences observed
in the susceptibility and patterns of cell death in the
different cell lines, however, are likely to reflect the
interaction between the molecular genetic status of
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a cell line with the environment, giving rise to the
particular cell death response to increasing stress. The
ability to distinctly quantify apoptosis and necrosis using
the spheroid model will prove to be a valuable tool to
study the interactions in the regulation of both apoptosis
and necrosis in gliomas.
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